WO2021067859A1 - 5-fluoronicotinamide derivatives and uses thereof - Google Patents

5-fluoronicotinamide derivatives and uses thereof Download PDF

Info

Publication number
WO2021067859A1
WO2021067859A1 PCT/US2020/054134 US2020054134W WO2021067859A1 WO 2021067859 A1 WO2021067859 A1 WO 2021067859A1 US 2020054134 W US2020054134 W US 2020054134W WO 2021067859 A1 WO2021067859 A1 WO 2021067859A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
heterocyclyl
alkyl
heteroaryl
aryl
Prior art date
Application number
PCT/US2020/054134
Other languages
French (fr)
Inventor
Mohammad A. MANDEGAR
Snahel PATEL
Ulhas Bhatt
Pingyu Ding
Martin Holan
John Lee
Yihong Li
Julio Medina
Alok NERURKAR
Frederick SEIDL
David Sperandio
Tien WIDJAJA
Xiaodong Wang
Original Assignee
Tenaya Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tenaya Therapeutics, Inc. filed Critical Tenaya Therapeutics, Inc.
Priority to CA3156303A priority Critical patent/CA3156303A1/en
Priority to JP2022520444A priority patent/JP2022550576A/en
Priority to EP20870779.4A priority patent/EP4037670A4/en
Publication of WO2021067859A1 publication Critical patent/WO2021067859A1/en
Priority to US17/712,780 priority patent/US20230123856A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • Histone deacetylase are a class of enzymes with deacetylase activity with a broad range of genomic and non-genomic substrates. There are eleven zinc-dependent HDAC enzymes classified based on sequence identity and catalytic activity.
  • Histone deacetylase inhibitors have been described and used in various therapeutic applications, including oncology, neurodegeneration, autoimmune disease, chemotherapy-induced peripheral neuropathy and cardiac indications.
  • many HDAC inhibitors are non-specific (i.e., they inhibit the activity of more than one HDAC with more or less the same affinity).
  • pan-HDAC inhibitors e.g., SAHA and Panabinostat
  • HDAC inhibitors that selectively target a particular HDAC, such as HDAC6.
  • the present disclosure provides small molecules and compositions as well as therapeutic compositions and uses of specific small molecule compounds.
  • the present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; X is O, NR 4 , or CR 4 R 4' ; Y is a bond, CR 2 R 3 or S(O) 2 ; R 1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH 2 )–carbocyclyl, –(CH 2 )–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R 1 and R 2 taken together with the carbon atom to which they are attached form a
  • the present disclosure provides a compound of Formula (Ia) or pharmaceutically acceptable salt thereof: wherein: n, X, and Y are as defined above for Formula (I); and Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are independently selected from N and CR 5 ; wherein R 5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • the present disclosure provides a compound of Formula (Ib) or pharmaceutically acceptable salt thereof: wherein: n, X, and Y are as defined above for Formula (I); and R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • the present disclosure provides a compound of Formula (Ic) or pharmaceutically acceptable salt thereof: wherein: n, X, and Y are as defined above for Formula (I); and R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • the present disclosure provides a compound of Formula (II) or pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; X is NR 4 or CR 4 R 4' ; R 1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH 2 )–aryl, and –(CH 2 )–heteroaryl, or R 2 and R 3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R 4 and R 4' are independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(
  • the present disclosure provides a compound of Formula (IIa) or pharmaceutically acceptable salt thereof: wherein: n, R 2 , R 3 , and R 4 are as defined above in Formula (II); Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are independently selected from N and CR 5 ; wherein R 5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O- aryl, -O-heteroaryl, –SO2–alkyl, and –CN.
  • the present disclosure provides a compound of Formula (IIb) or pharmaceutically acceptable salt thereof: wherein: n, R 2 , R 3 , and R 4 are as defined above in Formula (II); R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • the present disclosure provides a compound of Formula (IIc) or pharmaceutically acceptable salt thereof: wherein: n, R 2 , R 3 , and R 4 are as defined above in Formula (II); R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN.
  • the present disclosure provides a compound of Formula (III) or pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; Y is a bond or CR 2 R 3 ; R 1 is selected from the group consisting of H, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH 2 )–carbocyclyl, –(CH 2 )–heterocyclyl, – (CH 2 )–aryl, and –(CH 2 )–heteroaryl; or R 1 and R 2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl
  • the present disclosure provides a compound of Formula (IV) or pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; p is 0, 1, 2, 3, or 4; q is each independently 0, 1, or 2; X is O, S(O) 2 , NR 12 , or CHR 12 ; R 11 is each independently H, F, alkyl, or oxo; or two adjacent R 11 taken together with the carbon atoms to which they are attached form an aryl, heteroaryl, or heterocyclyl ring; or two non-adjacent R 11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring; R 12 is selected from the group consisting of alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH 2 )–carbocyclyl, –(CH 2 )–heterocyclyl, –(CH 2 )–aryl, and –(CH 2
  • the present disclosure provides therapeutic methods comprising use of the compounds disclosed herein (i.e., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (II), Formula (IIa), Formula (IIb), Formula (IIc), Formula (III), and Formula (IV)) in treating patients suffering from aberrant cell proliferative disorders, ⁇ -amyloid protein aggregation, polyglutamine protein aggregation, neurodegeneration, stroke, psychiatric disorders, depression, autoimmune disease, chemotherapy-induced neuropathy, Charcot-Marie-Tooth disease, idiopathic pulmonary fibrosis, erectile dysfunction, hypertension, muscular dystrophy, and/or cardiac diseases or disorders.
  • the compounds disclosed herein i.e., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (II), Formula (IIa), Formula (IIb), Formula (IIc), Formula (III), and Formula (IV)
  • aberrant cell proliferative disorders i.
  • Proliferative disorders include, but are not limited to, malignant gliomas, breast cancer, basal cell carcinoma, medulloblastomas, neuroectodermal tumors, and ependymomas.
  • Cardiac diseases or disorders that can be treated with the compounds of the present disclosure include, but art not limited to, coronary heart disease, cardiomyopathy, endocarditis, congenital cardiovascular defects, congestive heart failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, myocardial infarction, congestive heart failure, long QT syndrome, atrial arrhythmia, ventricular arrhythmia, diastolic heart failure, systolic heart failure, cardiac valve disease, cardiac valve calcification, left ventricular non- compaction, ventricular septal defect, and ischemia.
  • salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc.
  • acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • Alkyl or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C 1 -C 12 alkyl, an alkyl comprising up to 10 carbon atoms is a C 1 -C 10 alkyl, an alkyl comprising up to 6 carbon atoms is a C 1 -C 6 alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl.
  • a C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and C1 alkyl (i.e., methyl).
  • a C1-C6 alkyl includes all moieties described above for C1-C5 alkyls but also includes C6 alkyls.
  • a C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and C 1 -C 6 alkyls, but also includes C 7 , C 8 , C 9 and C 10 alkyls.
  • a C 1 -C 12 alkyl includes all the foregoing moieties, but also includes C 11 and C 12 alkyls.
  • Non-limiting examples of C1-C12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t- butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl.
  • an alkyl group can be optionally substituted.
  • Alkylene or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms.
  • C 1 -C 12 alkylene include methylene, ethylene, propylene, n-butylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted.
  • alkenyl or “alkenyl group” refers to a straight or branched hydrocarbon chain having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included.
  • An alkenyl group comprising up to 12 carbon atoms is a C2-C12 alkenyl
  • an alkenyl comprising up to 10 carbon atoms is a C2-C10 alkenyl
  • an alkenyl group comprising up to 6 carbon atoms is a C2-C6 alkenyl
  • an alkenyl comprising up to 5 carbon atoms is a C 2 -C 5 alkenyl.
  • a C 2 -C 5 alkenyl includes C 5 alkenyls, C 4 alkenyls, C 3 alkenyls, and C 2 alkenyls.
  • a C 2 -C 6 alkenyl includes all moieties described above for C 2 -C 5 alkenyls but also includes C6 alkenyls.
  • a C2-C10 alkenyl includes all moieties described above for C 2 -C 5 alkenyls and C 2 -C 6 alkenyls, but also includes C 7 , C 8 , C 9 and C 10 alkenyls.
  • a C 2 - C 12 alkenyl includes all the foregoing moieties, but also includes C 11 and C 12 alkenyls.
  • Non- limiting examples of C2-C12 alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso- propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3- pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2- heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4- octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonen
  • alkyl group can be optionally substituted.
  • alkenylene or “alkenylene chain” refers to an unsaturated, straight or branched divalent hydrocarbon chain radical having one or more olefins and from two to twelve carbon atoms.
  • C 2 -C 12 alkenylene include ethenylene, propenylene, n-butenylene, and the like.
  • the alkenylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond.
  • alkenylene chain can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.
  • Alkynyl or “alkynyl group” refers to a straight or branched hydrocarbon chain having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included.
  • An alkynyl group comprising up to 12 carbon atoms is a C2-C12 alkynyl
  • an alkynyl comprising up to 10 carbon atoms is a C2-C10 alkynyl
  • an alkynyl group comprising up to 6 carbon atoms is a C2-C6 alkynyl
  • an alkynyl comprising up to 5 carbon atoms is a C 2 -C 5 alkynyl.
  • a C 2 -C 5 alkynyl includes C 5 alkynyls, C 4 alkynyls, C 3 alkynyls, and C 2 alkynyls.
  • a C 2 -C 6 alkynyl includes all moieties described above for C 2 -C 5 alkynyls but also includes C6 alkynyls.
  • a C2-C10 alkynyl includes all moieties described above for C 2 -C 5 alkynyls and C 2 -C 6 alkynyls, but also includes C 7 , C 8 , C 9 and C 10 alkynyls.
  • a C 2 - C 12 alkynyl includes all the foregoing moieties, but also includes C 11 and C 12 alkynyls.
  • Non- limiting examples of C2-C12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
  • Alkynylene or “alkynylene chain” refers to an unsaturated, straight or branched divalent hydrocarbon chain radical having one or more alkynes and from two to twelve carbon atoms.
  • Non- limiting examples of C 2 -C 12 alkynylene include ethynylene, propynylene, n-butynylene, and the like.
  • alkynylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond.
  • the points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through any two carbons within the chain having a suitable valency.
  • an alkynylene chain can be optionally substituted.
  • Alkoxy refers to a group of the formula -OR a where R a is an alkyl, alkenyl or alknyl as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.
  • Aryl refers to a hydrocarbon ring system comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring, and which is attached to the rest of the molecule by a single bond.
  • the aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems.
  • Aryls include, but are not limited to, aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the “aryl” can be optionally substituted.
  • Carbocyclyl refers to a rings structure, wherein the atoms which form the ring are each carbon, and which is attached to the rest of the molecule by a single bond.
  • Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring.
  • Carbocyclic rings include aryls and cycloalkyl, cycloalkenyl, and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted.
  • Carbocyclylalkyl refers to a radical of the formula -R b -R d where R b is an alkylene, alkenylene, or alkynylene group as defined above and R d is a carbocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a carbocyclylalkyl group can be optionally substituted.
  • Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon consisting solely of carbon and hydrogen atoms, which can include fused or bridged ring systems, having from three to twenty carbon atoms (e.g., having from three to ten carbon atoms) and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
  • Cycloalkenyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkenyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like.
  • Polycyclic cycloalkenyls include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted.
  • Cycloalkynyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkynyl include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted.
  • Haloalkyl refers to an alkyl, as defined above, that is substituted by one or more halo radicals, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.
  • Heterocyclyl refers to a stable saturated, unsaturated, or aromatic 3- to 20-membered ring which consists of two to nineteen carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and which is attached to the rest of the molecule by a single bond.
  • Heterocyclycl or heterocyclic rings include heteroaryls, heterocyclylalkyls, heterocyclylalkenyls, and hetercyclylalkynyls.
  • the heterocyclyl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl can be partially or fully saturated.
  • heterocyclyl examples include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholin
  • heteroaryl refers to a 5- to 20-membered ring system comprising hydrogen atoms, one to nineteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, at least one aromatic ring, and which is attached to the rest of the molecule by a single bond.
  • the heteroaryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl can be optionally oxidized; the nitrogen atom can be optionally quaternized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furany
  • Heterocyclylalkyl refers to a radical of the formula -Rb-Re where Rb is an alkylene, alkenylene, or alkynylene group as defined above and Re is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkyl group can be optionally substituted.
  • substituted means any of the groups described herein (e.g., alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, heterocyclyl, and/or heteroaryl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamine
  • “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple- bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • a higher-order bond e.g., a double- or triple- bond
  • nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • R g and R h are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
  • “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N- heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group.
  • a point of attachment bond denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond.
  • “ ” indicates that the chemical entity “XY” is bonded to another chemical entity via the point of attachment bond.
  • the specific point of attachment to the non-depicted chemical entity can be specified by inference.
  • Histone deacetylases are a class of enzymes with deacetylase activity with a broad range of genomic and non-genomic substrates. There are eleven Zinc-dependent HDAC enzymes classified based on sequence identity and catalytic activity (Haberland et al., 2009).
  • Histone deacetylase inhibitors have been described as a therapeutic agents in oncology (Yoon and Eom, 2016), neurodegeneration (Butler et al., 2010) autoimmune disease (Choi et al., 2018), chemotherapy-induced peripheral neuropathy (Krukowski et al., 2017) and cardiac indications (Zhang et al., 2002).
  • oncology Yoon and Eom, 2016
  • neurodegeneration butler et al., 2010
  • autoimmune disease Choi et al., 2018
  • chemotherapy-induced peripheral neuropathy Krukowski et al., 2017
  • cardiac indications Zhang et al., 2002.
  • pan-HDAC inhibitors Given the role of nuclear HDACs on regulating gene transcription, inhibition of these class of targets is known to have pleiotropic effects in various cell types; most notably resulting in cell toxicities. Therefore, limiting the toxicity of pan-HDAC inhibitors has been a major obstacle in wide-spread utilization for this
  • pan-HDAC inhibitors e.g. SAHA and Panabinostat
  • pan-HDAC inhibitors e.g. SAHA, TSA and Givinostat
  • TAC transverse aortic constriction
  • hypertension in Dahl salt-sensitive rats Jeong et al., 2018
  • myocardial infarction Nagata et al., 2019
  • HDAC6-selective inhibitors have been used to ameliorate the effects of pressure overload in rodent models (Demos- Davies et al., 2014) and provide protection against proteotoxicity in a transgenic cardiomyopathy mouse model (McLendon et al., 2014).
  • HDAC6 belongs to the class IIb enzyme and contains two catalytic domains, a ubiquitin binding domain and a cytoplasmic retention domain (Haberland et al., 2009). HDAC6 is predominately a cytoplasmic enzyme and its best-characterized substrates include tubulin, HSP90 and cortactin (Brindisi et al., 2019).
  • HDAC6-selective inhibitors are known to have reduced cytotoxicity due to the cytoplasmic nature of HDAC6 substrates and reduced effects on nuclear targets (including H3K9 and c-MYC) and on global transcription (Nebbioso et al., 2017).
  • Hydroxamic acids are zinc chelators and have been used extensively in the development of pan- and HDAC-selective inhibitors.
  • hydroxamic-acid based HDAC inhibitors either lack the desired selectivity or show poor bioavailability with a poor pharmacokinetic profile (Butler et al., 2010; Santo et al., 2012).
  • the present disclosure provide hydroxamic acid compounds that, in some embodiments, selectively inhibit HDAC6.
  • n is 0 or 1;
  • X is O, NR 4 , or CR 4 R 4' ;
  • Y is a bond, CR 2 R 3 or S(O) 2 ;
  • R 1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl;
  • R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or
  • R 1 and R 2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R 2 and R 3 taken
  • the present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; X is O, NR 4 , or CR 4 R 4' ; Y is a bond, CR 2 R 3 or S(O) 2 ; R 1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH 2 )–carbocyclyl, –(CH 2 )–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R 1 and R 2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a carbo
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof is provided: wherein: n is 0 or 1; X is NR 4 or CR 4 R 4' ; Y is CR 2 R 3 or S(O)2; R 1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl, or R 2 and R 3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl, each of which is optionally substituted; and R 4 and R 4' are independently selected from the group consisting of H, alkyl, carbo
  • n is 1. In some embodiments, n is 0. [0050] In some embodiments of Formula (I), X is NR 4 or CR 4 R 4' . In some embodiments, X is NR 4 or O. In some embodiments, X is NR 4 . In some embodiments, X is CR 4 R 4' . In some embodiments, X is O. [0051] In some embodiments of Formula (I), X is NR 4 , and R 4 is H. [0052] In some embodiments of Formula (I), Y is a bond or CR 2 R 3 . In some embodiments, Y is S(O) 2 or CR 2 R 3 .
  • Y is a bond. In some embodiments, Y is CR 2 R 3 . In some embodiments,Y is S(O) 2 . [0053] In some embodiments of Formula (I), X is NR 4 and Y is CR 2 R 3 . In some embodiments, X is NR 4 and Y is S(O) 2 . In some embodiments, X is NR 4 and Y is a bond. In some embodiments, X is CR 4 R 4' and Y is CR 2 R 3 . In some embodiments, X is CR 4 R 4' and Y is a bond. In some embodiments, X is O and Y is CR 2 R 3 .
  • R 1 is selected from the group consisting of amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R 1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl.
  • R 1 is selected from the group consisting of H, cyclopropyl, phenyl, 6-membered heterocyclyl, 8-10 membered fused bicyclic heterocyclyl and 11-13 membered fused tricyclic heterocyclyl, wherein each heterocyclyl contains 1-3 heteroatoms selected from the group consisting of N, O, and S(O) w (wherein w is 0, 1, or 2).
  • each cyclopropyl, phenyl, and heterocyclyl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, oxo, hydroxy, alkoxy, –OCH 3 , –CO 2 CH 3 , –C(O)NH(OH),–CH 3 , morpholine, and –C(O)N-cyclopropyl.
  • R 1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. In some embodiments, R 1 is pyridinyl.
  • R 1 is phenyl. In some embodiments, R 1 is H. In some embodiments, R 1 is cyclopropyl. In some embodiments, R 1 is selected from the group consisting of pyridinyl, hydrogen, cyclopropyl, and phenyl. [0055] In some embodiments of Formula (I), X is NR 4 , Y is CR 2 R 3 , and R 1 is aryl or heteroaryl. In some embodiments, X is NR 4 , Y is CR 2 R 3 , and R 1 is aryl. In some embodiments, X is NR 4 , Y is CR 2 R 3 , and R 1 is heteroaryl. In some embodiments, n is 0.
  • n is 1.
  • X is NR 4 , Y is a bond, and R 1 is H.
  • X is CR 4 R 4' , Y is a bond, and R 1 is H.
  • X is O, Y is CR 2 R 3 , and R 1 is H.
  • n is 0.
  • n is 1.
  • R 1 and R 2 taken together with the carbon atom to which they are attached form a C 3-12 carbocyclyl.
  • the C 3-12 carbocyclyl is a propyl ring.
  • the C 3-12 carbocyclyl is a cyclobutyl ring. In another embodiment, the C 3-12 carbocyclyl is an indane ring. In some embodiments of Formula (I), R 1 and R 2 taken together with the carbon atom to which they are attached form a C 3-12 heterocyclyl. In some embodiments, the C 3-12 heterocyclyl is an oxetanyl ring.
  • R 2 and R 3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH 2 )–(4- to 6-membered heterocyclyl).
  • R 3 is C 1-6 alkyl optionally substituted with alkoxy.
  • R 3 is C1-6 alkyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, or cyclohexyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form an azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, or tetrahydropyranyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form an oxetanyl, cyclopropyl, cyclobutyl, cyclopentyl, pyrrolidinyl, and piperidinyl, each of which is optionally substituted with one or more substituents selected from the group consisting of fluoro, -OCH 3 , -CH 3 and oxo.
  • R 2 is H and R 3 is C3-6 cycloalkyl.
  • R 2 is H and R 3 is cyclopropyl.
  • R 2 and R 3 are C1-6 alkyl.
  • R 2 and R 3 are methyl.
  • R 1 is C3-6 cycloalkyl or aryl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl.
  • R 1 is aryl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl.
  • R 1 is aryl, R 2 is H, and R 3 is C 3-6 cycloalkyl or C 1-5 alkyl.
  • R 1 is aryl, R 2 is H, and R 3 is C3-6 cycloalkyl.
  • R 1 is C3-6 cycloalkyl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl.
  • R 1 is C3-6 cycloalkyl
  • R 2 is H
  • R 3 is C 3-6 cycloalkyl or C 1-5 alkyl.
  • R 1 is C 3-6 cycloalkyl
  • R 2 is H
  • R 3 is C 3-6 cycloalkyl.
  • the aryl is phenyl and C 3-6 cycloalkyl is cyclopropyl.
  • R 4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH 2 )–carbocyclyl, and –(CH 2 )–heterocyclyl.
  • R 4 is H or alkyl. In some embodiments, R 4 is H. In some embodiments, R 4 is –(CH2)–heterocyclyl. In some embodiments, R 4 is –(CH2)–oxetane. In some embodiments, R 4 is alkyl. In some embodiments, the alkyl is C 1-5 alkyl. In some embodiments, R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is isopropyl. In some embodiments, R 4 is –C(O)(CH3). [0062] In some embodiments of Formula (I), R 4 and R 4' are each H. In some embodiments, R 4 and R 4' are each alkyl.
  • R 4 and R 4' are each methyl. In some embodiments, R 4 and R 4' taken together with the carbon atom to which they are attached form a C 3-6 cycloalkyl. In some embodiments, R 4 and R 4' taken together with the carbon atom to which they are attached form a cyclopropyl. [0063] In some embodiments, the compound of Formula (I) is selected from the group consisting of:
  • the present disclosure provides a compound of Formula (Ia) or pharmaceutically acceptable salt thereof: wherein: n, X, and Y are as defined above for Formula (I); and Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are independently selected from N and CR 5 ; wherein R 5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN.
  • Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are CR 5 .
  • Z 1 is N and Z 2 , Z 3 , Z 4 and Z 5 are CR 5 .
  • Z 2 is N and Z 1 , Z 3 , Z 4 and Z 5 are CR 5 .
  • Z 3 is N and Z 1 , Z 2 , Z 4 and Z 5 are CR 5 .
  • one of Z 1 , Z 2 , Z 3 , Z 4 and Z 5 is N.
  • two of Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are N.
  • Z 1 and Z 5 are each N.
  • R 5 is independently selected from H, halogen, alkyl, alkoxy, and haloalkyl. In some embodiments, R 5 is independently selected from H and halogen. In some embodiments, R 5 is independently selected from H and fluoro.
  • the present disclosure provides a compound of Formula (Ib) or pharmaceutically acceptable salt thereof: wherein: n, X, and Y are as defined above for Formula (I); and R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and -O-haloalkyl.
  • R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H and halogen. In some embodiments, R 6 and R 10 are halogen and R 7 R 8 , and R 9 are H. In some embodiments, R 6 and R 10 are fluoro and R 7 R 8 , and R 9 are H.
  • the present disclosure provides a compound of Formula (Ic) or pharmaceutically acceptable salt thereof: wherein: n, X, and Y are as defined above for Formula (I); and R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H, halogen, alkyl, hydroxyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and - O-haloalkyl.
  • R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H and halogen. In some embodiments, R 6 is halogen and R 7 R 8 , and R 9 are H. In some embodiments, R 6 is fluoro and R 7 R 8 , and R 9 are H. [0072] In some embodiments of Formulas (I)-(Ic), each optionally substituted alkyl is independently an optionally substituted C 1-6 alkyl.
  • the C 1-6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert- butyl, amyl, and isoamyl.
  • the C1-6 alkyl is Me or Et.
  • the C1-6 alkyl is a C1-6 haloalkyl.
  • the C1-6 haloalkyl is selected from the group consisting of –CF 3 , –CHF 2 , –CH 2 F, and –CHBr 2 .
  • the C 1-6 haloalkyl is CF 3 .
  • each optionally substituted carbocyclyl is independently an optionally substituted C 3-12 cycloalkyl.
  • the carbocyclyl is a C 3-6 cycloalkyl.
  • the cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • each optionally substituted heterocyclyl is independently an optionally substituted 3-12 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S.
  • each optionally substituted heterocyclyl is independently an optionally substituted 3-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S.
  • the heterocycloalkyl is an optionally substituted 5-membered or 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N, O, and S.
  • the heterocyclyl is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl.
  • each optionally substituted aryl is independently a C6-12 aryl.
  • the C6-12 aryl is an optionally substituted phenyl.
  • each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S.
  • each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1 heteroatom independently selected from N, O, and S. In further embodiments, each optionally substituted heteroaryl is an optionally substituted 5-membered or 6-membered heteroaryl having 1 heteroatom independently from N, O, and S.
  • each heteroaryl is independently selected from the group consisting of tetrazole, oxadiazole, thiadiazole, imidazole, pyrazole, thiazole, or oxazole, each of which is optionally substituted.
  • the heteroaryl is tetrazole. In some embodiments, the heteroaryl is oxadiazole.
  • the present disclosure provides a compound of Formula (II) or pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; X is NR 4 or CR 4 R 4' ; R 1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH 2 )–aryl, and –(CH 2 )–heteroaryl, or R 2 and R 3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R 4 and R 4' are independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(
  • n is 1. In some embodiments, n is 0. [0079] In some embodiments of Formula (II), X is NR 4 . In some embodiments, X is CR 4 R 4' . [0080] In some embodiments of Formula (II), R 1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R 1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. In some embodiments, R 1 is pyridinyl. In some embodiments, R 1 is phenyl.
  • X is NR 4 and R 1 is aryl or heteroaryl. In some embodiments, X is NR 4 and R 1 is aryl. In some embodiments, X is NR 4 and R 1 is heteroaryl. In some embodiments, X is NR 4 and R 1 is carbocyclyl. In some embodiments, X is NR 4 and R 1 is heterocycloalkyl. In some embodiments, n is 0. In some embodiments, n is 1. [0082] In some embodiments of Formula (II), R 1 and R 2 taken together with the carbon atom to which they are attached form a C 3-12 carbocyclyl.
  • the C 3-12 carbocyclyl is a propyl ring. In some embodiments, the C 3-12 carbocyclyl is a cyclobutyl ring. In another embodiment, the C 3-12 carbocyclyl is an indane ring. [0083] In some embodiments of Formula (II), R 2 and R 3 are independently selected from the group consisting of H, F, C 1-6 alkyl, C 3-6 cycloalkyl, –(CH 2 )–C 3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl).
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, or cyclohexyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, or tetrahydropyranyl.
  • R 2 is H and R 3 is C3-6 cycloalkyl.
  • R 2 is H and R 3 is cyclopropyl.
  • R 2 and R 3 are C 1-6 alkyl. In some embodiments, R 2 and R 3 are methyl.
  • R 1 is C3-6 cycloalkyl or aryl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl.
  • R 1 is aryl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl.
  • R 1 is aryl, R 2 is H, and R 3 is C 3-6 cycloalkyl or C 1-5 alkyl.
  • R 1 is aryl, R 2 is H, and R 3 is C3-6 cycloalkyl.
  • R 1 is C3-6 cycloalkyl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl. In some embodiments, R 1 is C3-6 cycloalkyl, R 2 is H, and R 3 is C 3-6 cycloalkyl or C 1-5 alkyl. In some embodiments, R 1 is C 3-6 cycloalkyl, R 2 is H, and R 3 is C 3-6 cycloalkyl. In some embodiments, the aryl is phenyl and C 3-6 cycloalkyl is cyclopropyl.
  • R 4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH 2 )–carbocyclyl, and –(CH 2 )–heterocyclyl.
  • R 4 is H or alkyl.
  • R 4 is H.
  • R 4 is –(CH2)–heterocyclyl.
  • R 4 is –(CH2)–oxetane.
  • R 4 is alkyl.
  • the alkyl is C 1-5 alkyl.
  • R 4 is methyl.
  • R 4 is ethyl.
  • R 4 is isopropyl.
  • R 4 and R 4' are each H.
  • R 4 and R 4' are each alkyl.
  • R 4 and R 4' are each methyl.
  • R 4 and R 4' taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl.
  • R 4 and R 4' taken together with the carbon atom to which they are attached form a cyclopropyl.
  • each optionally substituted alkyl is independently an optionally substituted C1-6 alkyl.
  • the C1-6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, amyl, and isoamyl.
  • the C 1-6 alkyl is Me or Et.
  • the C 1-6 alkyl is a C1-6 haloalkyl.
  • the C1-6 haloalkyl is selected from the group consisting of –CF3, –CHF2, –CH2F, and –CHBr2.
  • the C1-6 haloalkyl is CF3.
  • each optionally substituted carbocyclyl is independently an optionally substituted C 3-12 cycloalkyl.
  • the carbocyclyl is a C 3-6 cycloalkyl.
  • the cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • each optionally substituted heterocyclyl is independently an optionally substituted 3-12 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S.
  • each optionally substituted heterocyclyl is independently an optionally substituted 3-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S.
  • the heterocycloalkyl is an optionally substituted 5-membered or 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N, O, and S.
  • the heterocyclyl is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl.
  • each optionally substituted aryl is independently a C6-12 aryl.
  • the C6-12 aryl is an optionally substituted phenyl.
  • each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S.
  • each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1 heteroatom independently selected from N, O, and S. In further embodiments, each optionally substituted heteroaryl is an optionally substituted 5-membered or 6-membered heteroaryl having 1 heteroatom independently from N, O, and S.
  • each heteroaryl is independently selected from the group consisting of tetrazole, oxadiazole, thiadiazole, imidazole, pyrazole, thiazole, or oxazole, each of which is optionally substituted.
  • the heteroaryl is tetrazole.
  • the heteroaryl is oxadiazole.
  • the present disclosure provides a compound selected from the group consisting of:
  • the present disclosure provides a compound of Formula (IIa) or pharmaceutically acceptable salt thereof: wherein: n, R 2 , R 3 , and R 4 are as defined above in Formula (II); and Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are independently selected from N and CR 5 ; wherein R 5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are CR 5 .
  • Z 1 is N and Z 2 , Z 3 , Z 4 and Z 5 are CR 5 .
  • Z 2 is N and Z 1 , Z 3 , Z 4 and Z 5 are CR 5 .
  • Z 3 is N and Z 1 , Z 2 , Z 4 and Z 5 are CR 5 .
  • one of Z 1 , Z 2 , Z 3 , Z 4 and Z 5 is N.
  • two of Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are N.
  • Z 1 and Z 5 are each N.
  • R 5 is independently selected from H, halogen, alkyl, alkoxy, and haloalkyl. In some embodiments, R 5 is independently selected from H and halogen. In some embodiments, R 5 is independently selected from H and fluoro.
  • the present disclosure provides a compound of Formula (IIb) or pharmaceutically acceptable salt thereof: wherein: n, R 2 , R 3 , and R 4 are as defined above in Formula (II); and R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN.
  • R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN.
  • R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and -O-haloalkyl.
  • R 6 , R 7 R 8 , R 9 , and R 10 are independently selected from the group consisting of H and halogen. In some embodiments, R 6 and R 10 are halogen and R 7 R 8 , and R 9 are H. In some embodiments, R 6 and R 10 are fluoro and R 7 R 8 , and R 9 are H.
  • the present disclosure provides a compound of Formula (IIc) or pharmaceutically acceptable salt thereof: wherein: n, R 2 , R 3 , and R 4 are as defined above in Formula (II); and R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN.
  • R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO 2 H, –CO 2 –alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and -O-haloalkyl.
  • R 6 , R 7 R 8 , and R 9 are independently selected from the group consisting of H and halogen. In some embodiments, R 6 is halogen and R 7 R 8 , and R 9 are H. In some embodiments, R 6 is fluoro and R 7 R 8 , and R 9 are H.
  • the present disclosure provides a compound of Formula (III) or pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; Y is a bond or CR 2 R 3 ; R 1 is selected from the group consisting of H, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH 2 )–carbocyclyl, –(CH 2 )–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R 1 and R 2 when present taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbo
  • n is 1. In some embodiments, n is 0. [00103] In some embodiments of Formula (III), Y is a bond or CR 2 R 3 . In some embodiments, Y is S(O)2 or CR 2 R 3 . In some embodiments, Y is a bond. In some embodiments, Y is CR 2 R 3 . In some embodiments,some embodiments, Y is S(O)2. [00104] In some embodiments of Formula (III), R 1 is selected from the group consisting of amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl.
  • R 1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R 1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. In some embodiments, R 1 is pyridinyl. In some embodiments, R 1 is phenyl. [00105] In some embodiments of Formula (III), Y is CR 2 R 3 and R 1 is aryl or heteroaryl. In some embodiments, Y is CR 2 R 3 and R 1 is aryl. In some embodiments, Y is CR 2 R 3 and R 1 is heteroaryl.
  • n is 0. In some embodiments, n is 1.
  • R 1 and R 2 taken together with the carbon atom to which they are attached form a C 3-12 carbocyclyl. In some embodiments, the C 3-12 carbocyclyl is a propyl ring. In some embodiments, the C 3-12 carbocyclyl is a cyclobutyl ring.
  • the C 3-12 carbocyclyl is an indane ring.
  • R 2 and R 3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl).
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a C 3-6 cycloalkyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, or cyclohexyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl. In some embodiments, R 2 and R 3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, or tetrahydropyranyl.
  • R 2 is H and R 3 is C3-6 cycloalkyl.
  • R 2 is H and R 3 is cyclopropyl.
  • R 2 and R 3 are C1-6 alkyl.
  • R 2 and R 3 are methyl.
  • R 1 is C3-6 cycloalkyl or aryl, R 2 is H, and R 3 is C3- 6 cycloalkyl or aryl.
  • R 1 is aryl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl.
  • R 1 is aryl, R 2 is H, and R 3 is C 3-6 cycloalkyl or C 1-5 alkyl.
  • R 1 is aryl, R 2 is H, and R 3 is C3-6 cycloalkyl.
  • R 1 is C3-6 cycloalkyl, R 2 is H, and R 3 is C3-6 cycloalkyl or aryl. In some embodiments, R 1 is C3-6 cycloalkyl, R 2 is H, and R 3 is C 3-6 cycloalkyl or C 1-5 alkyl. In some embodiments, R 1 is C 3-6 cycloalkyl, R 2 is H, and R 3 is C 3-6 cycloalkyl. In some embodiments, the aryl is phenyl and C 3-6 cycloalkyl is cyclopropyl. [00111] In some embodiments of Formula (III), each optionally substituted alkyl is independently an optionally substituted C 1-6 alkyl.
  • the C 1-6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, amyl, and isoamyl.
  • the C1-6 alkyl is Me or Et.
  • the C1-6 alkyl is a C 1-6 haloalkyl.
  • the C 1-6 haloalkyl is selected from the group consisting of –CF3, –CHF2, –CH2F, and –CHBr2.
  • the C1-6 haloalkyl is CF3.
  • each optionally substituted carbocyclyl is independently an optionally substituted C 3-12 cycloalkyl.
  • the carbocyclyl is a C3-6 cycloalkyl.
  • the cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • each optionally substituted heterocyclyl is independently an optionally substituted 3-12 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S.
  • each optionally substituted heterocyclyl is independently an optionally substituted 3-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S.
  • the heterocycloalkyl is an optionally substituted 5-membered or 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N, O, and S.
  • the heterocyclyl is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl.
  • each optionally substituted aryl is independently a C6-12 aryl.
  • each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 3 heteroatoms independently selected from N, O, and S. In still some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 2 heteroatoms independently selected from N, O, and S.
  • each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1 heteroatom independently selected from N, O, and S. In further embodiments, each optionally substituted heteroaryl is an optionally substituted 5-membered or 6-membered heteroaryl having 1 heteroatom independently from N, O, and S. In some embodiments, each heteroaryl is independently selected from the group consisting of tetrazole, oxadiazole, thiadiazole, imidazole, pyrazole, thiazole, or oxazole, each of which is optionally substituted. In some embodiments, the heteroaryl is tetrazole. In some embodiments, the heteroaryl is oxadiazole.
  • the compounds of Formula (III) are selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
  • Compounds of Formula (IV) [00117] In some embodiments, the present disclosure provides a compound of Formula (IV) or a pharmaceutically acceptable salt thereof: wherein: n is 0 or 1; p is 0, 1, 2, 3, or 4; q is each independently 0, 1, or 2; X is O, S(O)2, NR 12 , or CHR 12 ; R 11 is each independently H, F, alkyl, or oxo; or two adjacent R 11 taken together with the carbon atoms to which they are attached form an aryl, heteroaryl, or heterocyclyl ring; or two non-adjacent R 11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring; R 12 is selected from the group consisting of alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH 2
  • n is 1. In some embodiments, n is 0. [00119] In some embodiments of Formula (IV), q is 2. In some embodiments of Formula (IV), q is 1. In some embodiments, q is 0. [00120] In some embodiments of Formula (IV), X is S(O) 2 , NR 12 , or CHR 12 . In some embodiments, X is NR 12 or CHR 12 . In some embodiments, X is O. In some embodiments, X is S(O)2. In some embodiments, X is NR 12 . In some embodiments, X is CHR 12 .
  • R 11 is oxo, alkyl, or -O-alkyl. In some embodiments, R 11 is oxo or alkyl. In some embodiments, R 11 is oxo.
  • two adjacent R 11 taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring. In some embodiments, two adjacent R 11 taken together with the carbon atoms to which they are attached form an aryl ring. In some embodiments, the aryl ring is a phenyl ring.
  • two adjacent R 11 taken together with the carbon atoms to which they are attached form a heteroaryl ring or a heterocyclyl ring.
  • the heteroaryl ring or a heterocyclyl ring is a pyridinyl ring or a pyrimidinyl ring.
  • the heteroaryl ring is a pyridinyl ring.
  • two non-adjacent R 11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring (i.e., a bridged ring).
  • R 12 is H, alkyl, or aryl. In some embodiments, R 12 is H, Me, or Ph. In some embodiments, R 12 is Me. In some embodiments, R 12 is H. In some embodiments, R 12 is Ph. [00125] In some embodiments of Formula (I), R 11 and R 12 taken together with the carbon and/or nitrogen atoms to which they are attached form an aryl, heteroaryl ring, or heterocyclyl ring. In some embodiments, aryl is phenyl. In some embodiments, heteroaryl is a 5- to 6-membered heteroaryl.
  • heterocyclyl is a 3- to 8-membered heterocyclyl having 1, 2, or 3 heteroatoms selected from the group of N, S, and O. In some embodiments, the heterocyclyl ring is or . [00126] In some embodiments of Formula (IV), p is 1, 2, or, 3, or 4. In some embodiments, p is 1, 2, or 3. In some embodiments, 2, 3, or 4. In some embodiments, p is 4. In some embodiments, p is 3. In some embodiments, p is 2. In some embodiments, p is 1. In some embodiments, p is 0.
  • p is 0 or 1. In a specific embodiment, m is p. In another specific embodiment, p is 1. In yet another specific embodiment, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. [00132] In some embodiments, the present disclosure provides a compound of Table 1. Table 1. Examples of Compounds of the Present Disclosure.
  • compositions comprising one or more compounds disclosed herein, or a pharmaceutically acceptable solvate, hydrate, tautomer, N-oxide, or salt thereof, and a pharmaceutically acceptable excipient or adjuvant.
  • the pharmaceutically acceptable excipients and adjuvants are added to the composition or formulation for a variety of purposes.
  • a pharmaceutical compositions comprising one or more compounds disclosed herein, or a pharmaceutically acceptable solvate, hydrate, tautomer, N-oxide, or salt thereof, further comprise a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent.
  • suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone.
  • EXAMPLES [00134] The invention is further illustrated by the following examples. The examples below are non-limiting and merely representative of various aspects of the invention. Solid and dotted wedges within the structures herein disclosed illustrate relative stereochemistry, with absolute stereochemistry depicted only when specifically stated or delineated.
  • Prepacked silica gel cartridges e.g. RediSep ® R f and eluents such as gradients of 0-100% ethyl acetate in hexanes or 0-100% of 10% MeOH in CH2Cl2
  • Purification methods as described herein may provide compounds of the present disclosure which possess a sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present disclosure which is sufficiently basic, a trifluoroacetate or formate salt, or, in the case of a compound of the present disclosure which is sufficiently acidic, an ammonium salt.
  • a salt of this type can either be transformed into its free base or free acid form, respectively, by various methods known to a person skilled in the art, or be used as salts in subsequent biological assays. It is to be understood that the specific form of a compound of the present disclosure as isolated and as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity. [00139] All commercially available starting materials and reagents were used as is. 1 H Nuclear magnetic resonance (NMR) spectroscopy was carried out using a Bruker Avance III instrument operating at 400MHz using the stated solvent at around room temperature unless otherwise stated. In all cases, NMR data were consistent with the proposed structures.
  • NMR Nuclear magnetic resonance
  • Characteristic chemical shifts ( ⁇ ) are given in parts-per-million using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet; br, broad.
  • Preparative HPLC purification was performed by reverse phase HPLC using Agilent Technologies 1200 Infinity Series or an equivalent HPLC system such as Teledyne ISCO CombiFlash R f .
  • Chemical names were generated using the ChemDraw naming software (Version 17.0.0.206) by PerkinElmer Informatics, Inc.
  • Step 2 5-Fluoro-6-methy-N-hydroxynicotinamide
  • methyl 5- fluoronicotinate (20 mg) from above Step 1 was converted to the title compound as a white solid, 8 mg (40%).
  • Step 2 Methyl 6-amino-5-fluoronicotinate hydrochloride
  • Step 2 Methyl 6-amino-5-fluoronicotinate hydrochloride
  • Tert-butyl-(3-fluoro-5-(hydroxycarbamoy)pyridine-2-yl)carbamate obtained from above Step 1 was treated with 4 N HCl in methanol (5 ml) at ambient temperature for 18 h. Solvent was evaporated and a white solid was obtained, 150 mg (65%) as the title compound.
  • Step 3 6-Amino-5-fluoro-N-hydroxynicotinamide
  • methyl 6- amino-5-fluoronicotinate hydrochloride from above Step 2 which was first treated with saturated NaHCO 3 and extracted with ethyl acetate/MeOH was then converted to the title compound.
  • reaction mixture was sparged with a CO balloon for 1 minute, sealed and heated at 65 °C under CO atmosphere. After 17 h, full consumption of the starting material was observed by TLC. The mixture was washed with water, extracted with ethyl acetate, and concentrated. The resulting residue was purified by chromatography (Silica gel, ethyl acetate/hexane, 0-5%) to afford the title compound as a white solid, 91.7 mg (18%).
  • Step 2 5-Fluoro-N-hydroxy-6-methoxynicotinamide
  • methyl 6- methoxy-5-fluoronicotinate 31 mg, 0.17 mmol
  • Step 1 was converted to the title compound as a tan solid, 24.4 mg (79%).
  • [00189] Analysis of 5-fluoro-N-hydroxy-6-methoxynicotinamide: [00190] 1 H NMR (400 MHz, METHANOL-d4) ⁇ 8.35 (s, 1 H) 7.80 (dd, J 10.76, 1.47 Hz, 1 H) 4.05 (s, 3 H).
  • Step 1 Methyl 6-(bromomethyl)-5-fluoronicotinate
  • NBS 328 mg, 1.84 mmol
  • AIBN 38 mg, 231 mmol
  • the reaction mixture was stirred and heated at 75 o C for 48 h. After cooled, the reaction mixture was evaporated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 0:1) to afford the title compound as a white solid, 131 mg (46%).
  • Step 2 Methyl 5-fluoro-6-(((1-phenylcyclopropyl)amino)methyl)nicotinate
  • Methyl 6-(bromomethyl)-5-fluoronicotinate from above Step 2 80 mg, 0.323 mmol
  • 1-phenylcyclopropan-1-amine hydrochloride 54.8 mg, 0.323 mmol
  • K2CO3 89.1 mg, 0.323 mmol
  • Step 3 5-Fluoro-N-hydroxy-6-(((1-phenylcycloproyl)amino)methyl)nicotinamide [00200] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-(((1-phenylcyclopropyl)amino)methyl)nicotinate from above Step 2 was converted to the title compound.
  • Step 2 6-((2,3-Dihydro-1H-inden-2-yl)amino)-5-fluoro-N-hydroxynicotinamide [00210] Following the same experimental procedure as described in Example 1, methyl 6- ((2.3-dihydro-1H-inden-2-yl)amino-5-fluoronicotinate from above Step 1 was converted to the title compound.
  • Step 2 5-Fluoro-N-hydroxy-6-((1-phenylcyclopropyl)amino)nicotinamide [00220] Following the same experimental procedure as describe in Example 1, methyl 5- fluoro-6-((1-phenylcyclopropyl)amino)nicotinate from above Step 1 was converted to the title compound as a solid.
  • Step 2 5-Fluoro-N-hydroxy-6-(4-(2-methoxyphenyl)piperazin-1-yl)nicotinamide [00230] Following the same experimental procedure as describe in Example 1, methyl 5- fluoro-6-(4-(2-methyoxyphenyl)piperazin-1-yl)nicotinate from above Step 1 was converted to the title compound.
  • Step 2 (R)-5-Fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide [00240] Following the same experimental procedure as described in Example 1, methyl (R)-5-fluoro-6-((1-phenylethyl)amino)nicotinate from above Step 1 was converted to the title compound.
  • Step 2 (S)-5-Fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide [00250] Following the same experimental procedure as described in Example 1, methyl (S)-5-fluoro-6-((1-phenylethyl)amino)nicotinate from above Step 1 was converted to the title compound.
  • Step 1 (S,E)-N-(Cyclopropylmethylene)-2methylpropane-sulfinamide
  • (S,E)-N-(Cyclopropylmethylene)-2methylpropane-sulfinamide To a solution of cyclopropylcarboxaldehyde (5.33 mL, 71.3 mmol) in THF (150 mL) was added (S )-(-)2-methyl-2-propanesulfonamide (8.65 g. 71.3 mmol), and tetraisopropyl orthotitanate (41.8 mL, 143 mmol). The mixture was stirred at ambient temperature for 18 h. After the completion of reaction, the mixture was poured into brine and the slurry was filtered through Celite.
  • Step 2 (S)-N-((S)-Cyclopropyl(phenyl)methyl)-2-methylpropane-2-sulfonamide
  • Step 2 To a solution of (S,E)-N-(cyclopropylmethylene)-2methylpropane-sulfinamide from above Step 1 (12.4 g, 71.6 mmol) in THF (25 mL) was added phenyl magnesium bromide (1.0 N, 71.6 mL) dropwise at ambient temperature.
  • Step 3 (S)-Cyclopropyl(phenyl)methanamine hydrochloride [00262] (S)-N-((S)-Cyclopropyl(phenyl)methyl)-2-methylpropane-2-sulfonamide was converted to the title compound by treating with 4 N HCl in methanol from 0 o C to ambient temperature for 18 h. Ethyl acetate was added to the mixture and a white solid was formed as the title compound (85%).
  • Step 5 (S )-6-((Cyclopropyl(phenyl)methyl)amino-5-fluoro-N- hydroxynicotinamide [00266] Following the same experimental procedure as described in Example 1, methyl (S )-6-((cyclopropyl(phenyl)methyl)amino)-5-fluoronicotinate from above Step 4 was converted to the title compound.
  • Step 2 5-Fluoro-N-hydroxy-6-(phenylsulfonamido)nicotinamide
  • Step 2 Methyl 5-fluoro-6-((2-phenylpropan-2-yl)amino)nicotinate
  • Step 2 Methyl 5-fluoro-6-((2-phenylpropan-2-yl)amino)nicotinate
  • Step 2 Methyl 5-fluoro-6-((2-phenylpropan-2-yl)amino)nicotinate
  • Step 1 5-Bromo-3-fluoro-N-(2-phenylpropan-2-yl)pyridine-2-amine from above Step 1 was mixed with palladium acetate (0.8 mg, 0.0003 mmol), Xantphos (3.9 mg, 0.007 mmol), methanol and triethylamine (0.5 mL). The mixture was sparged with CO for 1 min, stirred and heated at 65 o C under CO atmosphere.
  • Step 3 5-Fluoro-N-hydroxy-6-((4-phenylpropan-2-yl)amino)nicotinamide
  • Step 3 5-Fluoro-N-hydroxy-6-((4-phenylpropan-2-yl)amino)nicotinamide
  • Step 2 6-(3,4-Dihydroisoquinolin-2(1H)-yl-5-fluoro-N-hydroxynicotinamide: [00326] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-bromonicotinate and 1,2,3,4-tetrahydroisoquinoline was converted to the title compound.
  • Step 2 6-((Methyl(1-phenylcyclopropyl)amino)methyl-5-fluoro-N- hydroxynicotinamide [00350] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-((methyl(1-phenylcyclopropyl)amino)methyl)nicotinate was converted to the title compound.
  • Step 2 5-chloro-N-hydroxy-6-morpholinonicotinamide
  • Step 2 (5-bromo-3-fluoropyridin-2-yl)methanol
  • Methyl 5-bromo-3-fluoropyridine-2-carboxylate (1.2 g, 5.13 mmol) was dissolved in dry methanol (30 mL), sodium borohydride (813 mg, 15.4 mmol) was slowly added in an ice bath.
  • Step 3 5-bromo-2-(bromomethyl)-3-fluoropyridine
  • 5-bromo-3-fluoropyridin-2-yl)methanol (0.25 g, 1.21 mmol
  • triphenyl phosphine (0.51 g, 1.94 mmol) dichloromethane
  • a solution of CBr4 (0.644 g, 1.94 mmol) in DCM (5 mL) at 0° C dropwise, and allowed to stir at room temperature overnight.
  • the reaction mixture was quenched with sat. NaHCO3, and extracted with dichloromethane twice.
  • Step 4 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-2-methyl-1H- benzo[d]imidazole [00431] To a solution of 2-methyl-1H-1,3-benzodiazole (153 mg, 1.16 mmol) in dry DMF (3 mL) was added 60% NaH (46 mg, 1.16 mmol) at 0 o C, then the mixture was stirred at 0 o C for 20 min. A solution of 5-bromo-2-(bromomethyl)-3-fluoropyridine (240 mg, 1.0 mmol) in dry DMF (2 mL) was dropwise added.
  • Step 5 methyl 5-fluoro-6-((2-methyl-1H-benzo[d]imidazol-1-yl)methyl)nicotinate
  • step 2 The title compound was synthesized by following the same experimental procedure as described in Example 17 (step 2) employing 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-2- methyl-1H-benzo[d]imidazole instead.
  • LC-MS m/z [M+H] + 300.1.
  • Step 6 5-fluoro-N-hydroxy-6-((2-methyl-1H-benzo[d]imidazol-1- yl)methyl)nicotinamide
  • the title compound was synthesized by following the same experimental procedure as described in Example 17 employing methyl 5-fluoro-6-((2-methyl-1H-benzo[d]imidazol-1- yl)methyl)nicotinate instead.
  • Step 2 5-bromo-3-fluoro-N-(1-(pyridin-2-yl)cyclopropyl)pyridin-2-amine
  • 1-(pyridin-2-yl)cyclopropan-1-amine 171 mg, 1.27 mmol
  • DMSO 3 mL
  • DIPEA 1.1 mL, 6.4 mmol, 5 equiv
  • 5-bromo-2,3-difluoropyridine (0.26 mL, 1.9 mmol, 1.5 equiv).
  • the biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic.
  • Step 3 methyl 5-fluoro-6-((1-(pyridin-2-yl)cyclopropyl)amino)nicotinate
  • 5-bromo-3-fluoro-N-(1-(pyridin-2-yl)cyclopropyl)pyridin-2- amine 85.0 mg, 0.28 mmol
  • palladium diacetate 1.2 mg, 5 ⁇ mol, 0.02 equiv
  • Xantphos 6.4 mg, 11 ⁇ mol, 0.04 equiv.
  • triethylamine (2 mL) and methanol (0.5 mL) were added, yielding a dark yellow heterogeneous suspension.
  • Step 4 5-fluoro-N-hydroxy-6-((1-(pyridin-2-yl)cyclopropyl)amino)nicotinamide
  • methyl 5-fluoro-6-((1-(pyridin-2- yl)cyclopropyl)amino)nicotinate 28.3 mg, 0.098 mmol
  • methanol 1 mL
  • THF 1 mL
  • 50% aqueous hydroxylamine (0.18 mL, 3.0 mmol, 30 equiv) was added all at once.
  • This biphasic mixture was filtered directly through water-wetted celite, washed once with water (50 mL) and once with ethyl acetate (50 mL). The filtrate was collected and the layers separated. The aqueous layer was extracted twice more with ethyl acetate (50 mL). The combined organic layers were washed twice with water (50 mL) and once with brine (25 mL), then dried over MgSO 4 , filtered and concentrated by rotary evaporation. The crude product was purified by column chromatography (Silica gel, 0 – 50% ethyl acetate in hexanes) to afford the title compound as a pale yellow oil, 1.66 g (49%).
  • Step 2 5-bromo-N-(1-(2,6-difluorophenyl)cyclopropyl)-3-fluoropyridin-2-amine
  • 1-(2,6-difluorophenyl)cyclopropan-1-amine 304 mg, 1.80 mmol
  • DMSO 3 mL
  • DIPEA 1.57 mL, 9.0 mmol, 5 equiv
  • 5-bromo-2,3-difluoropyridine (0.29 mL, 2.2 mmol, 1.2 equiv).
  • the biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic. The following day, LCMS analysis of the dark brown mixture reveals full conversion of the amine partner. The reaction was worked up by pouring into water (50 mL) and extracting three times with EtOAc (30 mL each). The combined organic layers were washed twice with water and once with brine, then dried over MgSO4, filtered and concentrated by rotary evaporation.
  • Step 3 methyl 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5-fluoronicotinate
  • 5-bromo-N-(1-(2,6-difluorophenyl)cyclopropyl)-3- fluoropyridin-2-amine 110 mg, 0.32 mmol
  • palladium diacetate 1.4 mg, 6 ⁇ mol, 0.02 equiv
  • Xantphos 7.4 mg, 13 ⁇ mol, 0.04 equiv.
  • Step 4 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5-fluoro-N- hydroxynicotinamide
  • methyl 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5- fluoronicotinate 30.5 mg, 0.095 mmol
  • methanol 1 mL
  • THF 1 mL
  • the colorless homogeneous solution was cooled to 0 °C in an ice bath. Then, 50% aqueous hydroxylamine (0.17 mL, 2.8 mmol, 30 equiv) was added all at once.
  • This biphasic mixture was filtered directly through water-wetted celite, washed once with water (50 mL) and once with ethyl acetate (50 mL). The filtrate was collected and the layers separated. The aqueous layer was extracted twice more with ethyl acetate (50 mL). The combined organic layers were washed twice with water (50 mL) and once with brine (25 mL), then dried over MgSO 4 , filtered and concentrated by rotary evaporation. The crude product was purified by column chromatography (Silica gel, 0 – 10% methanol in DCM with 1% NH 4 OH) to afford the title compound as an orange oil, 822 mg (31%).
  • Step 2 5-bromo-3-fluoro-N-(1-(pyridin-3-yl)cyclopropyl)pyridin-2-amine
  • Step 2 5-bromo-3-fluoro-N-(1-(pyridin-3-yl)cyclopropyl)pyridin-2-amine
  • 1-(pyridin-3-yl)cyclopropan-1-amine 134 mg, 1.0 mmol
  • DMSO 3 mL
  • DIPEA 0.87 mL, 5 mmol, 5 equiv
  • 5-bromo-2,3-difluoropyridine 0.20 mL, 1.5 mmol, 1.5 equiv.
  • the biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon).
  • Step 3 methyl 5-fluoro-6-((1-(pyridin-3-yl)cyclopropyl)amino)nicotinate
  • 5-bromo-3-fluoro-N-(1-(pyridin-3-yl)cyclopropyl)pyridin-2- amine 44.6 mg, 0.15 mmol
  • palladium diacetate 0.6 mg, 3 ⁇ mol, 0.02 equiv
  • Xantphos 3.3 mg, 6 ⁇ mol, 0.04 equiv).
  • Step 4 5-fluoro-N-hydroxy-6-((1-(pyridin-3-yl)cyclopropyl)amino)nicotinamide
  • methyl 5-fluoro-6-((1-(pyridin-3- yl)cyclopropyl)amino)nicotinate 35.8 mg, 0.13 mmol
  • methanol 1 mL
  • THF 1 mL
  • 50% aqueous hydroxylamine (0.23 mL, 3.7 mmol, 30 equiv) was added all at once.
  • Methylmagnesium bromide (1.4 M in 3:1 toluene : THF, 8.9 mL, 12.5 mmol, 2.5 equiv) was added dropwise with vigorous stirring over 5 minutes. The resulting brown opaque solution was heated to 70 °C overnight under N2 atmosphere (balloon). The following day, LCMS analysis indicated complete conversion. The black heterogeneous mixture was worked up by cooling to 0 °C in an ice bath, then adding 1M HCl (20 mL) (caution: exothermic, gas evolution). The lower brown aqueous layer was separated from the top clear toluene layer.
  • aqueous layer was basified (pH > 10) using 1M NaOH (30 mL), then extracted three times with EtOAc (30 mL each). The combined organic layers were washed with water, then brine, then dried over MgSO4 and filtered and concentrated by rotary evaporation to provide the title compound as a brown oil, 485 mg (71%), which was taken forward without further purification.
  • LC-MS m/z [M+H] + 137.1.
  • Step 2 5-bromo-3-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)pyridin-2-amine
  • 2-(pyridin-2-yl)propan-2-amine 144 mg, 1.06 mmol
  • DMSO 2 mL
  • DIPEA 0.92 mL, 5.3 mmol, 5 equiv
  • 5-bromo-2,3-difluoropyridine 0.21 mL, 1.6 mmol, 1.5 equiv.
  • the biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic.
  • Step 3 methyl 5-fluoro-6-((2-(pyridin-2-yl)propan-2-yl)amino)nicotinate
  • To a vial was added the oil 5-bromo-3-fluoro-N-(2-(pyridin-2-yl)propan-2- yl)pyridin-2-amine (63.4 mg, 0.20 mmol), followed by palladium diacetate (1 mg, 4 ⁇ mol, 0.02 equiv) and Xantphos (4.7 mg, 8 ⁇ mol, 0.04 equiv). Then, triethylamine (2 mL) and methanol (0.5 mL) were added, yielding a pale yellow heterogeneous suspension.
  • Step 4 5-fluoro-N-hydroxy-6-((2-(pyridin-2-yl)propan-2-yl)amino)nicotinamide
  • methyl 5-fluoro-6-((2-(pyridin-2-yl)propan-2- yl)amino)nicotinate 44.1 mg, 0.15 mmol
  • methanol 1 mL
  • THF 1 mL
  • 50% aqueous hydroxylamine (0.28 mL, 4.5 mmol, 30 equiv
  • the biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic. The following day, LCMS analysis of the dark orange mixture reveals full conversion of the amine partner. The reaction was worked up by pouring into water (50 mL) and extracting three times with EtOAc (30 mL each). The combined organic layers were washed twice with water and once with brine, then dried over MgSO 4 , filtered and concentrated by rotary evaporation.
  • Step 2 5-bromo-3-fluoro-N-methyl-N-(1-phenylcyclopropyl)pyridin-2-amine
  • Step 2 5-bromo-3-fluoro-N-methyl-N-(1-phenylcyclopropyl)pyridin-2-amine
  • Step 3 methyl 5-fluoro-6-(methyl(1-phenylcyclopropyl)amino)nicotinate
  • 5-bromo-3-fluoro-N-methyl-N-(1-phenylcyclopropyl)pyridin- 2-amine 69.5 mg, 0.22 mmol
  • palladium diacetate 1 mg, 4 ⁇ mol, 0.02 equiv
  • Xantphos 5.0 mg, 9 ⁇ mol, 0.04 equiv.
  • triethylamine (2 mL) and methanol (0.5 mL) were added, yielding an orange heterogeneous suspension.
  • Step 4 methyl 5-fluoro-6-(methyl(1-phenylcyclopropyl)amino)nicotinate
  • methyl 5-fluoro-6-((1-(pyridin-2- yl)cyclopropyl)amino)nicotinate 32.6 mg, 0.11 mmol
  • methanol 1 mL
  • THF 1 mL
  • 50% aqueous hydroxylamine (0.20 mL, 3.3 mmol, 30 equiv) was added all at once.
  • Step 2 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-5- carboxylic acid
  • methyl 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-1H- pyrrolo[2,3-b]pyridine-5-carboxylate 230 mg, 0.63 mmol
  • LiOH.H2O 53 mg, 2.1 mmol
  • THF-MeOH-H 2 O v/v/v 1:1:1, 6 mL
  • Step 3 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-cyclopropyl-1H-pyrrolo[2,3- b]pyridine-5-carboxamide
  • reaction mixture was stirred at 110 °C overnight. After completion of reaction, the mixture was cooled, diluted with water and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over MgSO 4 , filtered and concentrated. The product was purified by column chromatography using a Hex:EtOAc gradient 0-100% to afford the title compound as a yellow solid, 71 mg (44%).
  • Examples 62-74 [00587] In the following examples (62-74), the compounds were synthesized by following the same experimental procedure as described in Example 30 with the listed amine and 5-bromo- 2-(bromomethyl)-3-fluoropyridine as the starting materials for step 4.
  • Example 81 Biochemical Assay The compounds disclosed herein were tested for potency against HDAC6 and selectivity against HDAC1 in a biochemical assay.
  • a biochemical assay was adopted using a luminescent HDAC-Glo I/II assay (Promega) and measured the relative activity of HDAC6 and HDAC1 recombinant proteins.
  • Compounds were first incubated in the presence of HDAC6 or HDAC1 separately, followed by addition of the luminescent substrate. The data was acquired using a plate reader and the biochemical IC 50 were calculated from the data accordingly. Data is tabulated in Table 2. From these studies, it was determined that the compounds of the present disclosure are selective inhibitors of HDAC6 over HDAC1, providing selectivity ratios from about 5 to about 30,0000. Table 2. Evaluation of HDAC6 Activity and Selectivity for Disclosed Compounds.
  • Embodiments 1 A compound of Formula (I), or pharmaceutically acceptable salt thereof: wherein n is 0 or 1; X is O, NR 4 , or CR 4 R 4' ; Y is a bond, CR 2 R 3 or S(O)2; R 1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R 2 and R 3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH 2 )–aryl, and –(CH 2 )–heteroaryl; or R 1 and R 2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a
  • R 2 and R 3 are independently selected from the group consisting of H, F, C 1-6 alkyl, C 3-6 cycloalkyl, –(CH 2 )–C 3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH 2 )–(4- to 6-membered heterocyclyl). 13.
  • the compound of any one of embodiments 1-10, wherein R 2 and R 3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl.
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl.
  • R 1 is C3-6 cycloalkyl or aryl
  • R 2 is H
  • R 3 is C 3-6 cycloalkyl or aryl.
  • R 4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)– heterocyclyl. 22.
  • R 4 is H. 23.
  • Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are independently selected from N and CR 5 ; wherein R 5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and –CN.
  • R 5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO 2 –alkyl, and
  • the compound of any one of embodiments 32-41, wherein R 2 is H and R 3 is cyclopropyl. 48. The compound of any one of embodiments 32-41, wherein R 2 and R 3 are C 1-6 alkyl. 49. The compound of any one of embodiments 32-41, wherein R 2 and R 3 are methyl. 50. The compound of any one of embodiments 32-49, wherein R 4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH 2 )–carbocyclyl, and –(CH 2 )– heterocyclyl. 51. The compound of any one of embodiments 32-50, wherein R 4 is H. 52.
  • R 1 is phenyl.
  • R 2 and R 3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl).
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl.
  • R 1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. 130.
  • the compound of any one of embodiments 123-124 or 126-127, wherein R 1 and R 2 taken together with the carbon atom to which they are attached form a C 3-12 carbocyclyl.
  • a compound of Formula (IV), or pharmaceutically acceptable salt thereof wherein: n is 0 or 1; p is 0, 1, 2, 3, or 4; q is each independently 0, 1, or 2; X is O, S(O)2, NR 12 , or CHR 12 ; R 11 is each independently H, F, alkyl, or oxo; or two adjacent R 11 taken together with the carbon atoms to which they are attached form an aryl, heteroaryl, or heterocyclyl ring; or two non-adjacent R 11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring; R 12 is selected from the group consisting of alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl,
  • the compound of embodiment 161, wherein the heteroaryl ring is a pyridinyl ring. 163.
  • the compound of embodiment 161, wherein the heterocyclyl ring is: . 164.
  • a composition comprising a compound of any one of embodiments 1-171 and a pharmaceutically acceptable excipient.
  • a method of improving sarcomere quality or preventing sarcomere damage in cardiomyocytes comprising contacting a cardiomyocyte with an effective amount of the compound of any one of embodiments 1-171 or the composition of embodiment 172, wherein the method induces an improvement in sarcomere quality.
  • the method of embodiment 173, wherein the improvement in sarcomere quality is measured using an artificial intelligence algorithm. 175.
  • the heart disease is dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), left ventricular non-compaction (LVNC), arrhythmogenic right ventricular cardiomyopathy (ARVC), or arrhythmogenic right ventricular dysplasia (ARVD).
  • DCM dilated cardiomyopathy
  • HCM hypertrophic cardiomyopathy
  • RCM restrictive cardiomyopathy
  • LVNC left ventricular non-compaction
  • ARVC arrhythmogenic right ventricular cardiomyopathy
  • ARVD arrhythmogenic right ventricular dysplasia
  • the method of embodiment 178, wherein the heart disease is myocardial infarction.
  • the method causes at least one of the following effects in cardiomyocytes: increased tubulin acetylation, increased contractility, reduced sarcomere damage,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided herein is a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, Y, X, and n are defined herein. Also provided herein are compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of heart disease.

Description

5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of priority to U.S Provisional Application Serial No. 62/910,278, filed October 3, 2019, the contents of which are hereby incorporated by reference in their entirety for all purposes. BACKGROUND [0002] Histone deacetylase (HDAC) are a class of enzymes with deacetylase activity with a broad range of genomic and non-genomic substrates. There are eleven zinc-dependent HDAC enzymes classified based on sequence identity and catalytic activity. [0003] Histone deacetylase inhibitors have been described and used in various therapeutic applications, including oncology, neurodegeneration, autoimmune disease, chemotherapy-induced peripheral neuropathy and cardiac indications. However, many HDAC inhibitors are non-specific (i.e., they inhibit the activity of more than one HDAC with more or less the same affinity). When administered to humans, these so-called pan-HDAC inhibitors (e.g., SAHA and Panabinostat) exhibit significant adverse effects such as fatigue, nausea, diarrhea and thrombocytopenia. Thus, there is a need for HDAC inhibitors that selectively target a particular HDAC, such as HDAC6. SUMMARY [0004] The present disclosure is directed to compounds that selectively inhibit HDAC6 activity and uses thereof in treating various diseases and disorders. For example, the present disclosure provides small molecules and compositions as well as therapeutic compositions and uses of specific small molecule compounds. [0005] In one aspect, the present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof:
Figure imgf000002_0001
wherein: n is 0 or 1; X is O, NR4, or CR4R4'; Y is a bond, CR2R3 or S(O)2; R1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are each independently selected from the group consisting of H, alkyl, –CO2–alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, –C(O)NH(OH), –CH3, morpholine, and –C(O)N-cyclopropyl . [0006] In some embodiments, the present disclosure provides a compound of Formula (Ia) or pharmaceutically acceptable salt thereof:
Figure imgf000003_0001
wherein: n, X, and Y are as defined above for Formula (I); and Z1, Z2, Z3, Z4 and Z5 are independently selected from N and CR5; wherein R5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0007] In some embodiments, the present disclosure provides a compound of Formula (Ib) or pharmaceutically acceptable salt thereof:
Figure imgf000004_0001
wherein: n, X, and Y are as defined above for Formula (I); and R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0008] In some embodiments, the present disclosure provides a compound of Formula (Ic) or pharmaceutically acceptable salt thereof:
Figure imgf000004_0002
wherein: n, X, and Y are as defined above for Formula (I); and R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0009] In another aspect, the present disclosure provides a compound of Formula (II) or pharmaceutically acceptable salt thereof:
Figure imgf000005_0001
wherein: n is 0 or 1; X is NR4 or CR4R4'; R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl, or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and – (CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. [0010] In some embodiments, the present disclosure provides a compound of Formula (IIa) or pharmaceutically acceptable salt thereof:
Figure imgf000005_0002
wherein: n, R2, R3, and R4 are as defined above in Formula (II); Z1, Z2, Z3, Z4 and Z5 are independently selected from N and CR5; wherein R5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O- aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0011] In some embodiments, the present disclosure provides a compound of Formula (IIb) or pharmaceutically acceptable salt thereof:
Figure imgf000006_0001
wherein: n, R2, R3, and R4 are as defined above in Formula (II); R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0012] In some embodiments, the present disclosure provides a compound of Formula (IIc) or pharmaceutically acceptable salt thereof:
Figure imgf000006_0002
wherein: n, R2, R3, and R4 are as defined above in Formula (II); R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0013] In some embodiments, the present disclosure provides a compound of Formula (III) or pharmaceutically acceptable salt thereof:
Figure imgf000007_0001
wherein: n is 0 or 1; Y is a bond or CR2R3; R1 is selected from the group consisting of H, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. [0014] In some embodiments, the present disclosure provides a compound of Formula (IV) or pharmaceutically acceptable salt thereof:
Figure imgf000007_0002
wherein: n is 0 or 1; p is 0, 1, 2, 3, or 4; q is each independently 0, 1, or 2; X is O, S(O)2, NR12, or CHR12; R11 is each independently H, F, alkyl, or oxo; or two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl, heteroaryl, or heterocyclyl ring; or two non-adjacent R11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring; R12 is selected from the group consisting of alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and –(CH2)– heteroaryl; or R11 and R12 taken together with the carbon and/or nitrogen atoms to which they are attached form an aryl or heteroaryl ring; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. [0015] In some embodiments, the present disclosure provides therapeutic methods comprising use of the compounds disclosed herein (i.e., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (II), Formula (IIa), Formula (IIb), Formula (IIc), Formula (III), and Formula (IV)) in treating patients suffering from aberrant cell proliferative disorders, β-amyloid protein aggregation, polyglutamine protein aggregation, neurodegeneration, stroke, psychiatric disorders, depression, autoimmune disease, chemotherapy-induced neuropathy, Charcot-Marie-Tooth disease, idiopathic pulmonary fibrosis, erectile dysfunction, hypertension, muscular dystrophy, and/or cardiac diseases or disorders. Proliferative disorders include, but are not limited to, malignant gliomas, breast cancer, basal cell carcinoma, medulloblastomas, neuroectodermal tumors, and ependymomas. Cardiac diseases or disorders that can be treated with the compounds of the present disclosure include, but art not limited to, coronary heart disease, cardiomyopathy, endocarditis, congenital cardiovascular defects, congestive heart failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, myocardial infarction, congestive heart failure, long QT syndrome, atrial arrhythmia, ventricular arrhythmia, diastolic heart failure, systolic heart failure, cardiac valve disease, cardiac valve calcification, left ventricular non- compaction, ventricular septal defect, and ischemia. DEFINITIONS [0016] While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter. [0017] The term “a” or “an” refers to one or more of that entity; for example, “an HDAC6 inhibitor” refers to one or more HDAC6 inhibitors or at least one HDAC6 inhibitor. As such, the terms “a” (or “an”), “one or more” and “at least one” are used interchangeably herein. In addition, reference to “an inhibitor” by the indefinite article “a” or “an” does not exclude the possibility that more than one of the inhibitors is present, unless the context clearly requires that there is one and only one of the inhibitors. [0018] The term “pharmaceutically acceptable salts” include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc. Those skilled in the art will further recognize that acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. [0019] “Alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a C1-C10 alkyl, an alkyl comprising up to 6 carbon atoms is a C1-C6 alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl. A C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and C1 alkyl (i.e., methyl). A C1-C6 alkyl includes all moieties described above for C1-C5 alkyls but also includes C6 alkyls. A C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and C1-C6 alkyls, but also includes C7, C8, C9 and C10 alkyls. Similarly, a C1-C12 alkyl includes all the foregoing moieties, but also includes C11 and C12 alkyls. Non-limiting examples of C1-C12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t- butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted. [0020] “Alkylene” or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms. Non-limiting examples of C1-C12 alkylene include methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted. [0021] “Alkenyl” or “alkenyl group” refers to a straight or branched hydrocarbon chain having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included. An alkenyl group comprising up to 12 carbon atoms is a C2-C12 alkenyl, an alkenyl comprising up to 10 carbon atoms is a C2-C10 alkenyl, an alkenyl group comprising up to 6 carbon atoms is a C2-C6 alkenyl and an alkenyl comprising up to 5 carbon atoms is a C2-C5 alkenyl. A C2-C5 alkenyl includes C5 alkenyls, C4 alkenyls, C3 alkenyls, and C2 alkenyls. A C2-C6 alkenyl includes all moieties described above for C2-C5 alkenyls but also includes C6 alkenyls. A C2-C10 alkenyl includes all moieties described above for C2-C5 alkenyls and C2-C6 alkenyls, but also includes C7, C8, C9 and C10 alkenyls. Similarly, a C2- C12 alkenyl includes all the foregoing moieties, but also includes C11 and C12 alkenyls. Non- limiting examples of C2-C12 alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso- propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3- pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2- heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4- octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6- decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9- dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted. [0022] “Alkenylene” or “alkenylene chain” refers to an unsaturated, straight or branched divalent hydrocarbon chain radical having one or more olefins and from two to twelve carbon atoms. Non- limiting examples of C2-C12 alkenylene include ethenylene, propenylene, n-butenylene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted. [0023] “Alkynyl” or “alkynyl group” refers to a straight or branched hydrocarbon chain having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included. An alkynyl group comprising up to 12 carbon atoms is a C2-C12 alkynyl, an alkynyl comprising up to 10 carbon atoms is a C2-C10 alkynyl, an alkynyl group comprising up to 6 carbon atoms is a C2-C6 alkynyl and an alkynyl comprising up to 5 carbon atoms is a C2-C5 alkynyl. A C2-C5 alkynyl includes C5 alkynyls, C4 alkynyls, C3 alkynyls, and C2 alkynyls. A C2-C6 alkynyl includes all moieties described above for C2-C5 alkynyls but also includes C6 alkynyls. A C2-C10 alkynyl includes all moieties described above for C2-C5 alkynyls and C2-C6 alkynyls, but also includes C7, C8, C9 and C10 alkynyls. Similarly, a C2- C12 alkynyl includes all the foregoing moieties, but also includes C11 and C12 alkynyls. Non- limiting examples of C2-C12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted. [0024] “Alkynylene” or “alkynylene chain” refers to an unsaturated, straight or branched divalent hydrocarbon chain radical having one or more alkynes and from two to twelve carbon atoms. Non- limiting examples of C2-C12 alkynylene include ethynylene, propynylene, n-butynylene, and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to a radical group (e.g., those described herein) through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through any two carbons within the chain having a suitable valency. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted. [0025] “Alkoxy” refers to a group of the formula -ORa where Ra is an alkyl, alkenyl or alknyl as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted. [0026] “Aryl” refers to a hydrocarbon ring system comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring, and which is attached to the rest of the molecule by a single bond. For purposes of this disclosure, the aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems. Aryls include, but are not limited to, aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the “aryl” can be optionally substituted. [0027] “Carbocyclyl,” “carbocyclic ring” or “carbocycle” refers to a rings structure, wherein the atoms which form the ring are each carbon, and which is attached to the rest of the molecule by a single bond. Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring. Carbocyclic rings include aryls and cycloalkyl, cycloalkenyl, and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted. [0028] “Carbocyclylalkyl” refers to a radical of the formula -Rb-Rd where Rb is an alkylene, alkenylene, or alkynylene group as defined above and Rd is a carbocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a carbocyclylalkyl group can be optionally substituted. [0029] “Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon consisting solely of carbon and hydrogen atoms, which can include fused or bridged ring systems, having from three to twenty carbon atoms (e.g., having from three to ten carbon atoms) and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted. [0030] “Cycloalkenyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkenyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like. Polycyclic cycloalkenyls include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted. [0031] “Cycloalkynyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkynyl include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted. [0032] “Haloalkyl” refers to an alkyl, as defined above, that is substituted by one or more halo radicals, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted. [0033] “Heterocyclyl,” “heterocyclic ring” or “heterocycle” refers to a stable saturated, unsaturated, or aromatic 3- to 20-membered ring which consists of two to nineteen carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and which is attached to the rest of the molecule by a single bond. Heterocyclycl or heterocyclic rings include heteroaryls, heterocyclylalkyls, heterocyclylalkenyls, and hetercyclylalkynyls. Unless stated otherwise specifically in the specification, the heterocyclyl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl can be partially or fully saturated. Examples of such heterocyclyl include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, a heterocyclyl group can be optionally substituted. [0034] “Heteroaryl” refers to a 5- to 20-membered ring system comprising hydrogen atoms, one to nineteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, at least one aromatic ring, and which is attached to the rest of the molecule by a single bond. For purposes of this disclosure, the heteroaryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl can be optionally oxidized; the nitrogen atom can be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group can be optionally substituted. [0035] “Heterocyclylalkyl” refers to a radical of the formula -Rb-Re where Rb is an alkylene, alkenylene, or alkynylene group as defined above and Re is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkyl group can be optionally substituted. [0036] The term “substituted” used herein means any of the groups described herein (e.g., alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, heterocyclyl, and/or heteroaryl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple- bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with -NRgRh, -NRgC(=O)Rh, -NRgC(=O)NRgRh, -NRgC(=O)ORh, -NRgSO2Rh, -OC(=O)NRgRh, - ORg, -SRg, -SORg, -SO2Rg, -OSO2Rg, -SO2ORg, =NSO2Rg, and -SO2NRgRh. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRh, -CH2SO2Rg, -CH2SO2NRgRh. In the foregoing, Rg and Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N- heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents. [0037] As used herein, the symbol “
Figure imgf000016_0001
” (hereinafter can be referred to as “a point of attachment bond”) denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond. For example, “ ” indicates
Figure imgf000016_0002
that the chemical entity “XY” is bonded to another chemical entity via the point of attachment bond. Furthermore, the specific point of attachment to the non-depicted chemical entity can be specified by inference. For example, the compound CH3-R3, wherein R3 is H or “ X
Figure imgf000016_0003
” infers that when R3 is “XY”, the point of attachment bond is the same bond as the bond by which R3 is depicted as being bonded to CH3. DETAILED DESCRIPTION [0038] Histone deacetylases (“HDAC”) are a class of enzymes with deacetylase activity with a broad range of genomic and non-genomic substrates. There are eleven Zinc-dependent HDAC enzymes classified based on sequence identity and catalytic activity (Haberland et al., 2009). [0039] Histone deacetylase inhibitors have been described as a therapeutic agents in oncology (Yoon and Eom, 2016), neurodegeneration (Butler et al., 2010) autoimmune disease (Choi et al., 2018), chemotherapy-induced peripheral neuropathy (Krukowski et al., 2017) and cardiac indications (Zhang et al., 2002). Given the role of nuclear HDACs on regulating gene transcription, inhibition of these class of targets is known to have pleiotropic effects in various cell types; most notably resulting in cell toxicities. Therefore, limiting the toxicity of pan-HDAC inhibitors has been a major obstacle in wide-spread utilization for this class of compounds. In addition, significant adverse effects of pan-HDAC inhibitors (e.g. SAHA and Panabinostat) has been observed in the clinic including fatigue, nausea, diarrhea and thrombocytopenia (Subramanian et al., 2010). [0040] In the cardiac-indication space, most studies have utilized pan-HDAC inhibitors (e.g. SAHA, TSA and Givinostat) for the treatment of pressure-overload rodent models including transverse aortic constriction (TAC) (Cao et al., 2011), hypertension in Dahl salt-sensitive rats (Jeong et al., 2018) and myocardial infarction (Nagata et al., 2019) . In addition, HDAC6-selective inhibitors have been used to ameliorate the effects of pressure overload in rodent models (Demos- Davies et al., 2014) and provide protection against proteotoxicity in a transgenic cardiomyopathy mouse model (McLendon et al., 2014). [0041] HDAC6 belongs to the class IIb enzyme and contains two catalytic domains, a ubiquitin binding domain and a cytoplasmic retention domain (Haberland et al., 2009). HDAC6 is predominately a cytoplasmic enzyme and its best-characterized substrates include tubulin, HSP90 and cortactin (Brindisi et al., 2019). [0042] Pharmacological inhibition of HDAC6 blocks its deacetylase activity, thus resulting in hyperacetylation of its substrates, most notably tubulin (Hubbert et al., 2002). [0043] HDAC6-selective inhibitors are known to have reduced cytotoxicity due to the cytoplasmic nature of HDAC6 substrates and reduced effects on nuclear targets (including H3K9 and c-MYC) and on global transcription (Nebbioso et al., 2017). [0044] Hydroxamic acids are zinc chelators and have been used extensively in the development of pan- and HDAC-selective inhibitors. However, most hydroxamic-acid based HDAC inhibitors either lack the desired selectivity or show poor bioavailability with a poor pharmacokinetic profile (Butler et al., 2010; Santo et al., 2012). [0045] The present disclosure provide hydroxamic acid compounds that, in some embodiments, selectively inhibit HDAC6. Compounds of Formulas (I)-(III) [0046] In one aspect, the present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof:
Figure imgf000017_0001
wherein: n is 0 or 1; X is O, NR4, or CR4R4'; Y is a bond, CR2R3 or S(O)2; R1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are each independently selected from the group consisting of H, alkyl, –CO2–alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, –C(O)NH(OH), –CH3, morpholine, and –C(O)N-cyclopropyl. [0047] In one aspect, the present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof:
Figure imgf000018_0001
wherein: n is 0 or 1; X is O, NR4, or CR4R4'; Y is a bond, CR2R3 or S(O)2; R1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are each independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and – (CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more halogen, haloalkyl, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, – C(O)NH(OH), and –CH3. [0048] In some embodiments, a compound of Formula (I) or a pharmaceutically acceptable salt thereof is provided:
Figure imgf000019_0001
wherein: n is 0 or 1; X is NR4 or CR4R4'; Y is CR2R3 or S(O)2; R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl, or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl, each of which is optionally substituted; and R4 and R4' are independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and – (CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl, each of which is optionally substituted; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3 and –CH3. [0049] In some embodiments of Formula (I), n is 1. In some embodiments, n is 0. [0050] In some embodiments of Formula (I), X is NR4 or CR4R4'. In some embodiments, X is NR4 or O. In some embodiments, X is NR4. In some embodiments, X is CR4R4'. In some embodiments, X is O. [0051] In some embodiments of Formula (I), X is NR4, and R4 is H. [0052] In some embodiments of Formula (I), Y is a bond or CR2R3. In some embodiments, Y is S(O)2 or CR2R3. In some embodiments, Y is a bond. In some embodiments, Y is CR2R3. In some embodiments,Y is S(O)2. [0053] In some embodiments of Formula (I), X is NR4 and Y is CR2R3. In some embodiments, X is NR4 and Y is S(O)2. In some embodiments, X is NR4 and Y is a bond. In some embodiments, X is CR4R4' and Y is CR2R3. In some embodiments, X is CR4R4' and Y is a bond. In some embodiments, X is O and Y is CR2R3. In some embodiments, X is O and Y is a bond. [0054] In some embodiments of Formula (I), R1 is selected from the group consisting of amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R1 is selected from the group consisting of H, cyclopropyl, phenyl, 6-membered heterocyclyl, 8-10 membered fused bicyclic heterocyclyl and 11-13 membered fused tricyclic heterocyclyl, wherein each heterocyclyl contains 1-3 heteroatoms selected from the group consisting of N, O, and S(O)w (wherein w is 0, 1, or 2). In some embodiments, each cyclopropyl, phenyl, and heterocyclyl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, –C(O)NH(OH),–CH3, morpholine, and –C(O)N-cyclopropyl. In some embodiments, R1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. In some embodiments, R1 is pyridinyl. In some embodiments, R1 is phenyl. In some embodiments, R1 is H. In some embodiments, R1 is cyclopropyl. In some embodiments, R1 is selected from the group consisting of pyridinyl, hydrogen, cyclopropyl, and phenyl. [0055] In some embodiments of Formula (I), X is NR4, Y is CR2R3, and R1 is aryl or heteroaryl. In some embodiments, X is NR4, Y is CR2R3, and R1 is aryl. In some embodiments, X is NR4, Y is CR2R3, and R1 is heteroaryl. In some embodiments, n is 0. In some embodiments, n is 1. [0056] In some embodiments of Formula (I), X is NR4, Y is a bond, and R1 is H. In some embodiments, X is CR4R4', Y is a bond, and R1 is H. In some embodiments, X is O, Y is CR2R3, and R1 is H. In some embodiments, n is 0. In some embodiments, n is 1. [0057] In some embodiments of Formula (I), R1 and R2 taken together with the carbon atom to which they are attached form a C3-12 carbocyclyl. In some embodiments, the C3-12 carbocyclyl is a propyl ring. In some embodiments, the C3-12 carbocyclyl is a cyclobutyl ring. In another embodiment, the C3-12 carbocyclyl is an indane ring. In some embodiments of Formula (I), R1 and R2 taken together with the carbon atom to which they are attached form a C3-12 heterocyclyl. In some embodiments, the C3-12 heterocyclyl is an oxetanyl ring. [0058] In some embodiments of Formula (I), R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). In some embodiments, R3 is C1-6 alkyl optionally substituted with alkoxy. In some embodiments, R3 is C1-6 alkyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, or cyclohexyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form an azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, or tetrahydropyranyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form an oxetanyl, cyclopropyl, cyclobutyl, cyclopentyl, pyrrolidinyl, and piperidinyl, each of which is optionally substituted with one or more substituents selected from the group consisting of fluoro, -OCH3, -CH3 and oxo. [0059] In some embodiments of Formula (I), R2 is H and R3 is C3-6 cycloalkyl. In some embodiments, R2 is H and R3 is cyclopropyl. In some embodiments, R2 and R3 are C1-6 alkyl. In some embodiments, R2 and R3 are methyl. [0060] In some embodiments of Formula (I), R1 is C3-6 cycloalkyl or aryl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl or C1-5 alkyl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl or C1-5 alkyl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl. In some embodiments, the aryl is phenyl and C3-6 cycloalkyl is cyclopropyl. [0061] In some embodiments of Formula (I), R4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)–heterocyclyl. In some embodiments, R4 is H or alkyl. In some embodiments, R4 is H. In some embodiments, R4 is –(CH2)–heterocyclyl. In some embodiments, R4 is –(CH2)–oxetane. In some embodiments, R4 is alkyl. In some embodiments, the alkyl is C1-5 alkyl. In some embodiments, R4 is methyl. In some embodiments, R4 is ethyl. In some embodiments, R4 is isopropyl. In some embodiments, R4 is –C(O)(CH3). [0062] In some embodiments of Formula (I), R4 and R4' are each H. In some embodiments, R4 and R4' are each alkyl. In some embodiments, R4 and R4' are each methyl. In some embodiments, R4 and R4' taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. In some embodiments, R4 and R4' taken together with the carbon atom to which they are attached form a cyclopropyl. [0063] In some embodiments, the compound of Formula (I) is selected from the group consisting of:
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
; or a pharmaceutically acceptable salt thereof. [0064] In some embodiments, the present disclosure provides a compound of Formula (Ia) or pharmaceutically acceptable salt thereof:
Figure imgf000027_0002
wherein: n, X, and Y are as defined above for Formula (I); and Z1, Z2, Z3, Z4 and Z5 are independently selected from N and CR5; wherein R5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0065] In some embodiments of Formula (Ia), Z1, Z2, Z3, Z4 and Z5 are CR5. In some embodiments, Z1 is N and Z2, Z3, Z4 and Z5 are CR5. In some embodiments, Z2 is N and Z1, Z3, Z4 and Z5 are CR5. In some embodiments, Z3 is N and Z1, Z2, Z4 and Z5 are CR5. In some embodiments, one of Z1, Z2, Z3, Z4 and Z5 is N. In some embodiments, two of Z1, Z2, Z3, Z4 and Z5 are N. In some embodiments, Z1 and Z5 are each N. [0066] In some embodiments of Formula (Ia), R5 is independently selected from H, halogen, alkyl, alkoxy, and haloalkyl. In some embodiments, R5 is independently selected from H and halogen. In some embodiments, R5 is independently selected from H and fluoro. [0067] In some embodiments, the present disclosure provides a compound of Formula (Ib) or pharmaceutically acceptable salt thereof:
Figure imgf000028_0001
wherein: n, X, and Y are as defined above for Formula (I); and R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0068] In some embodiments of Formula (Ib), R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. In some embodiments, R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and -O-haloalkyl. In some embodiments, R6, R7 R8, R9, and R10 are independently selected from the group consisting of H and halogen. In some embodiments, R6 and R10 are halogen and R7 R8, and R9 are H. In some embodiments, R6 and R10 are fluoro and R7 R8, and R9 are H. [0069] In some embodiments, the present disclosure provides a compound of Formula (Ic) or pharmaceutically acceptable salt thereof:
Figure imgf000029_0001
wherein: n, X, and Y are as defined above for Formula (I); and R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, hydroxyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0070] In some embodiments of the compound of Formula (Ic), R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0071] In some embodiments of Formula (Ic), R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. In some embodiments, R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and - O-haloalkyl. In some embodiments, R6, R7 R8, and R9 are independently selected from the group consisting of H and halogen. In some embodiments, R6 is halogen and R7 R8, and R9 are H. In some embodiments, R6 is fluoro and R7 R8, and R9 are H. [0072] In some embodiments of Formulas (I)-(Ic), each optionally substituted alkyl is independently an optionally substituted C1-6 alkyl. In further embodiments, the C1-6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert- butyl, amyl, and isoamyl. In some embodiments, the C1-6 alkyl is Me or Et. In some embodiments, the C1-6 alkyl is a C1-6 haloalkyl. In further embodiments, the C1-6 haloalkyl is selected from the group consisting of –CF3, –CHF2, –CH2F, and –CHBr2. In some embodiments, the C1-6 haloalkyl is CF3. In some embodiments, the C1-6 haloalkyl is CHF2. [0073] In some embodiments of Formulas (I)-(Ic), each optionally substituted carbocyclyl is independently an optionally substituted C3-12 cycloalkyl. In some embodiments, the carbocyclyl is a C3-6 cycloalkyl. In some embodiments, the cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. [0074] In some embodiments of Formulas (I)-(Ic), each optionally substituted heterocyclyl is independently an optionally substituted 3-12 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heterocyclyl is independently an optionally substituted 3-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S. In further embodiments, the heterocycloalkyl is an optionally substituted 5-membered or 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N, O, and S. In some embodiments, the heterocyclyl is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl. [0075] In some embodiments of Formulas (I)-(Ic), each optionally substituted aryl is independently a C6-12 aryl. In further embodiments, the C6-12 aryl is an optionally substituted phenyl. [0076] In some embodiments of Formulas (I)-(Ic), each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1 heteroatom independently selected from N, O, and S. In further embodiments, each optionally substituted heteroaryl is an optionally substituted 5-membered or 6-membered heteroaryl having 1 heteroatom independently from N, O, and S. In some embodiments, each heteroaryl is independently selected from the group consisting of tetrazole, oxadiazole, thiadiazole, imidazole, pyrazole, thiazole, or oxazole, each of which is optionally substituted. In some embodiments, the heteroaryl is tetrazole. In some embodiments, the heteroaryl is oxadiazole. [0077] In one aspect, the present disclosure provides a compound of Formula (II) or pharmaceutically acceptable salt thereof:
Figure imgf000031_0001
wherein: n is 0 or 1; X is NR4 or CR4R4'; R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl, or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and –(CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. [0078] In some embodiments of Formula (II), n is 1. In some embodiments, n is 0. [0079] In some embodiments of Formula (II), X is NR4. In some embodiments, X is CR4R4'. [0080] In some embodiments of Formula (II), R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. In some embodiments, R1 is pyridinyl. In some embodiments, R1 is phenyl. [0081] In some embodiments of Formula (II), X is NR4 and R1 is aryl or heteroaryl. In some embodiments, X is NR4 and R1 is aryl. In some embodiments, X is NR4 and R1 is heteroaryl. In some embodiments, X is NR4 and R1 is carbocyclyl. In some embodiments, X is NR4 and R1 is heterocycloalkyl. In some embodiments, n is 0. In some embodiments, n is 1. [0082] In some embodiments of Formula (II), R1 and R2 taken together with the carbon atom to which they are attached form a C3-12 carbocyclyl. In some embodiments, the C3-12 carbocyclyl is a propyl ring. In some embodiments, the C3-12 carbocyclyl is a cyclobutyl ring. In another embodiment, the C3-12 carbocyclyl is an indane ring. [0083] In some embodiments of Formula (II), R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, or cyclohexyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, or tetrahydropyranyl. [0084] In some embodiments of Formula (II), R2 is H and R3 is C3-6 cycloalkyl. In some embodiments, R2 is H and R3 is cyclopropyl. In some embodiments, R2 and R3 are C1-6 alkyl. In some embodiments, R2 and R3 are methyl. [0085] In some embodiments of Formula (II), R1 is C3-6 cycloalkyl or aryl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl or C1-5 alkyl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl or C1-5 alkyl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl. In some embodiments, the aryl is phenyl and C3-6 cycloalkyl is cyclopropyl. [0086] In some embodiments of Formula (II), R4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)–heterocyclyl. In some embodiments, R4 is H or alkyl. In some embodiments, R4 is H. In some embodiments, R4 is –(CH2)–heterocyclyl. In some embodiments, R4 is –(CH2)–oxetane. In some embodiments, R4 is alkyl. In some embodiments, the alkyl is C1-5 alkyl. In some embodiments, R4 is methyl. In some embodiments, R4 is ethyl. In some embodiments, R4 is isopropyl. [0087] In some embodiments of Formula (II), R4 and R4' are each H. In some embodiments, R4 and R4' are each alkyl. In some embodiments, R4 and R4' are each methyl. In some embodiments, R4 and R4' taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. In some embodiments, R4 and R4' taken together with the carbon atom to which they are attached form a cyclopropyl. [0088] In some embodiments of Formula (II), each optionally substituted alkyl is independently an optionally substituted C1-6 alkyl. In further embodiments, the C1-6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, amyl, and isoamyl. In some embodiments, the C1-6 alkyl is Me or Et. In some embodiments, the C1-6 alkyl is a C1-6 haloalkyl. In further embodiments, the C1-6 haloalkyl is selected from the group consisting of –CF3, –CHF2, –CH2F, and –CHBr2. In some embodiments, the C1-6 haloalkyl is CF3. In some embodiments, the C1-6 haloalkyl is CHF2. [0089] In some embodiments of Formula (II), each optionally substituted carbocyclyl is independently an optionally substituted C3-12 cycloalkyl. In some embodiments, the carbocyclyl is a C3-6 cycloalkyl. In some embodiments, the cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. [0090] In some embodiments of Formula (II), each optionally substituted heterocyclyl is independently an optionally substituted 3-12 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heterocyclyl is independently an optionally substituted 3-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S. In further embodiments, the heterocycloalkyl is an optionally substituted 5-membered or 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N, O, and S. In some embodiments, the heterocyclyl is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl. [0091] In some embodiments of Formula (II), each optionally substituted aryl is independently a C6-12 aryl. In further embodiments, the C6-12 aryl is an optionally substituted phenyl. [0092] In some embodiments of Formula (II), each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1 heteroatom independently selected from N, O, and S. In further embodiments, each optionally substituted heteroaryl is an optionally substituted 5-membered or 6-membered heteroaryl having 1 heteroatom independently from N, O, and S. In some embodiments, each heteroaryl is independently selected from the group consisting of tetrazole, oxadiazole, thiadiazole, imidazole, pyrazole, thiazole, or oxazole, each of which is optionally substituted. In some embodiments, the heteroaryl is tetrazole. In some embodiments, the heteroaryl is oxadiazole. [0093] In some embodiments, the present disclosure provides a compound selected from the group consisting of:
Figure imgf000035_0001
Figure imgf000036_0001
pharmaceutically acceptable salt thereof. [0094] In some embodiments, the present disclosure provides a compound of Formula (IIa) or pharmaceutically acceptable salt thereof:
Figure imgf000036_0002
wherein: n, R2, R3, and R4 are as defined above in Formula (II); and Z1, Z2, Z3, Z4 and Z5 are independently selected from N and CR5; wherein R5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0095] In some embodiments of Formula (IIa), Z1, Z2, Z3, Z4 and Z5 are CR5. In some embodiments, Z1 is N and Z2, Z3, Z4 and Z5 are CR5. In some embodiments, Z2 is N and Z1, Z3, Z4 and Z5 are CR5. In some embodiments, Z3 is N and Z1, Z2, Z4 and Z5 are CR5. In some embodiments, one of Z1, Z2, Z3, Z4 and Z5 is N. In some embodiments, two of Z1, Z2, Z3, Z4 and Z5 are N. In some embodiments, Z1 and Z5 are each N. [0096] In some embodiments of Formula (IIa), R5 is independently selected from H, halogen, alkyl, alkoxy, and haloalkyl. In some embodiments, R5 is independently selected from H and halogen. In some embodiments, R5 is independently selected from H and fluoro. [0097] In some embodiments, the present disclosure provides a compound of Formula (IIb) or pharmaceutically acceptable salt thereof:
Figure imgf000037_0001
wherein: n, R2, R3, and R4 are as defined above in Formula (II); and R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [0098] In some embodiments of Formula (IIb), R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. In some embodiments, R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and -O-haloalkyl. In some embodiments, R6, R7 R8, R9, and R10 are independently selected from the group consisting of H and halogen. In some embodiments, R6 and R10 are halogen and R7 R8, and R9 are H. In some embodiments, R6 and R10 are fluoro and R7 R8, and R9 are H. [0099] In some embodiments, the present disclosure provides a compound of Formula (IIc) or pharmaceutically acceptable salt thereof:
Figure imgf000038_0001
wherein: n, R2, R3, and R4 are as defined above in Formula (II); and R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. [00100] In some embodiments of Formula (IIc), R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, –CO2H, –CO2–alkyl, -O-alkyl, -O-haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. In some embodiments, R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, -O-alkyl, and -O-haloalkyl. In some embodiments, R6, R7 R8, and R9 are independently selected from the group consisting of H and halogen. In some embodiments, R6 is halogen and R7 R8, and R9 are H. In some embodiments, R6 is fluoro and R7 R8, and R9 are H. [00101] In another aspect, the present disclosure provides a compound of Formula (III) or pharmaceutically acceptable salt thereof:
Figure imgf000038_0002
wherein: n is 0 or 1; Y is a bond or CR2R3; R1 is selected from the group consisting of H, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 when present taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisiting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. [00102] In some embodiments of Formula (III), n is 1. In some embodiments, n is 0. [00103] In some embodiments of Formula (III), Y is a bond or CR2R3. In some embodiments, Y is S(O)2 or CR2R3. In some embodiments, Y is a bond. In some embodiments, Y is CR2R3. In some embodiments,some embodiments, Y is S(O)2. [00104] In some embodiments of Formula (III), R1 is selected from the group consisting of amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl. In some embodiments, R1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. In some embodiments, R1 is pyridinyl. In some embodiments, R1 is phenyl. [00105] In some embodiments of Formula (III), Y is CR2R3 and R1 is aryl or heteroaryl. In some embodiments, Y is CR2R3 and R1 is aryl. In some embodiments, Y is CR2R3 and R1 is heteroaryl. In some embodiments, n is 0. In some embodiments, n is 1. [00106] In some embodiments of Formula (III), Y is a bond and R1 is H. In some embodiments, Y is a bond and R1 is H. In some embodiments, Y is CR2R3 and R1 is H. In some embodiments, n is 0. In some embodiments, n is 1. [00107] In some embodiments of Formula (III), R1 and R2 taken together with the carbon atom to which they are attached form a C3-12 carbocyclyl. In some embodiments, the C3-12 carbocyclyl is a propyl ring. In some embodiments, the C3-12 carbocyclyl is a cyclobutyl ring. In another embodiment, the C3-12 carbocyclyl is an indane ring. [00108] In some embodiments of Formula (III), R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, or cyclohexyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. In some embodiments, R2 and R3 taken together with the carbon atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, or tetrahydropyranyl. [00109] In some embodiments of Formula (III), R2 is H and R3 is C3-6 cycloalkyl. In some embodiments, R2 is H and R3 is cyclopropyl. In some embodiments, R2 and R3 are C1-6 alkyl. In some embodiments, R2 and R3 are methyl. [00110] In some embodiments of Formula (III), R1 is C3-6 cycloalkyl or aryl, R2 is H, and R3 is C3- 6 cycloalkyl or aryl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl or C1-5 alkyl. In some embodiments, R1 is aryl, R2 is H, and R3 is C3-6 cycloalkyl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl or C1-5 alkyl. In some embodiments, R1 is C3-6 cycloalkyl, R2 is H, and R3 is C3-6 cycloalkyl. In some embodiments, the aryl is phenyl and C3-6 cycloalkyl is cyclopropyl. [00111] In some embodiments of Formula (III), each optionally substituted alkyl is independently an optionally substituted C1-6 alkyl. In further embodiments, the C1-6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, amyl, and isoamyl. In some embodiments, the C1-6 alkyl is Me or Et. In some embodiments, the C1-6 alkyl is a C1-6 haloalkyl. In further embodiments, the C1-6 haloalkyl is selected from the group consisting of –CF3, –CHF2, –CH2F, and –CHBr2. In some embodiments, the C1-6 haloalkyl is CF3. In some specific embodiments, the C1-6 haloalkyl is CHF2. [00112] In some embodiments of Formula (III), each optionally substituted carbocyclyl is independently an optionally substituted C3-12 cycloalkyl. In some embodiments, the carbocyclyl is a C3-6 cycloalkyl. In some embodiments, the cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. [00113] In some embodiments of Formula (III), each optionally substituted heterocyclyl is independently an optionally substituted 3-12 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heterocyclyl is independently an optionally substituted 3-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, and S. In further embodiments, the heterocycloalkyl is an optionally substituted 5-membered or 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N, O, and S. In some embodiments, the heterocyclyl is selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl. [00114] In some embodiments of Formula (III), each optionally substituted aryl is independently a C6-12 aryl. In further embodiments, the C6-12 aryl is an optionally substituted phenyl. [00115] In some embodiments of Formula (III), each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 3 heteroatoms independently selected from N, O, and S. In still some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 2 heteroatoms independently selected from N, O, and S. In some embodiments, each optionally substituted heteroaryl is independently a 5-12 membered heteroaryl having 1 heteroatom independently selected from N, O, and S. In further embodiments, each optionally substituted heteroaryl is an optionally substituted 5-membered or 6-membered heteroaryl having 1 heteroatom independently from N, O, and S. In some embodiments, each heteroaryl is independently selected from the group consisting of tetrazole, oxadiazole, thiadiazole, imidazole, pyrazole, thiazole, or oxazole, each of which is optionally substituted. In some embodiments, the heteroaryl is tetrazole. In some embodiments, the heteroaryl is oxadiazole. [00116] In some embodiments, the compounds of Formula (III) are selected from the group consisting of:
Figure imgf000042_0001
or a pharmaceutically acceptable salt thereof. Compounds of Formula (IV) [00117] In some embodiments, the present disclosure provides a compound of Formula (IV) or a pharmaceutically acceptable salt thereof:
Figure imgf000042_0002
wherein: n is 0 or 1; p is 0, 1, 2, 3, or 4; q is each independently 0, 1, or 2; X is O, S(O)2, NR12, or CHR12; R11 is each independently H, F, alkyl, or oxo; or two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl, heteroaryl, or heterocyclyl ring; or two non-adjacent R11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring; R12 is selected from the group consisting of alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and –(CH2)– heteroaryl; or R11 and R12 taken together with the carbon and/or nitrogen atoms to which they are attached form an aryl, heteroaryl ring, or heterocyclyl ring; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. [00118] In some embodiments of Formula (IV), n is 1. In some embodiments, n is 0. [00119] In some embodiments of Formula (IV), q is 2. In some embodiments of Formula (IV), q is 1. In some embodiments, q is 0. [00120] In some embodiments of Formula (IV), X is S(O)2, NR12, or CHR12. In some embodiments, X is NR12 or CHR12. In some embodiments, X is O. In some embodiments, X is S(O)2. In some embodiments, X is NR12. In some embodiments, X is CHR12. [00121] In some embodiments of Formula (IV), R11 is oxo, alkyl, or -O-alkyl. In some embodiments, R11 is oxo or alkyl. In some embodiments, R11 is oxo. [00122] In some embodiments of Formula (IV), two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring. In some embodiments, two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl ring. In some embodiments, the aryl ring is a phenyl ring. In some embodiments, two adjacent R11 taken together with the carbon atoms to which they are attached form a heteroaryl ring or a heterocyclyl ring. In some embodiments, the heteroaryl ring or a heterocyclyl ring is a pyridinyl ring or a pyrimidinyl ring. In some embodiments, the heteroaryl ring is a pyridinyl ring. [00123] In some embodiments of Formula (IV), two non-adjacent R11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring (i.e., a bridged ring). [00124] In some embodiments of Formula (IV), R12 is H, alkyl, or aryl. In some embodiments, R12 is H, Me, or Ph. In some embodiments, R12 is Me. In some embodiments, R12 is H. In some embodiments, R12 is Ph. [00125] In some embodiments of Formula (I), R11 and R12 taken together with the carbon and/or nitrogen atoms to which they are attached form an aryl, heteroaryl ring, or heterocyclyl ring. In some embodiments, aryl is phenyl. In some embodiments, heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, heterocyclyl is a 3- to 8-membered heterocyclyl having 1, 2, or 3 heteroatoms selected from the group of N, S, and O. In some embodiments, the heterocyclyl ring is
Figure imgf000044_0001
or
Figure imgf000044_0002
. [00126] In some embodiments of Formula (IV), p is 1, 2, or, 3, or 4. In some embodiments, p is 1, 2, or 3. In some embodiments, 2, 3, or 4. In some embodiments, p is 4. In some embodiments, p is 3. In some embodiments, p is 2. In some embodiments, p is 1. In some embodiments, p is 0. [00127] In some embodiments of Formulas (IV), when X is CHR12, an R11 and an R12 taken together with the carbon atoms to which they are attached form an aryl ring. In some embodiments, the aryl ring is a phenyl ring. [00128] In some embodiments of Formula (IV), when X is NR12, an R11 and an R12 taken together with the carbon and nitrogen atoms to which they are attached form a heterocyclyl ring or a heteroaryl ring. In some embodiments, the heteroaryl ring is a pyridinyl ring. [00129] In some embodiments of Formula (IV), when p is 4, two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl ring and two adjacent R11 taken together with the carbon atoms to which they are attached form a heterocyclyl ring. In some embodiments, the aryl ring is a phenyl ring. In some embodiments, the heterocyclyl ring is
Figure imgf000045_0001
or
Figure imgf000045_0002
. In some embodiments, n is 1 and q is 0. [00130] In some embodiments, the compound of Formula (IV) is selected from the group consisting of:
Figure imgf000045_0003
or a pharmaceutically acceptable salt thereof. [00131] In some embodiments of Formula (IV), p is 0, 1, 2, or 3. In some embodiments, p is 0, 1, or 2. In some embodiments, p is 0 or 1. In a specific embodiment, m is p. In another specific embodiment, p is 1. In yet another specific embodiment, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. [00132] In some embodiments, the present disclosure provides a compound of Table 1. Table 1. Examples of Compounds of the Present Disclosure.
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000047_0001
Figure imgf000047_0002
Figure imgf000048_0001
Figure imgf000048_0002
Figure imgf000049_0001
Figure imgf000049_0002
Figure imgf000050_0001
Figure imgf000050_0002
Figure imgf000051_0002
Figure imgf000051_0001
Pharmaceutical Compositions [00133] In various embodiments of the present disclosure, pharmaceutical compositions comprising one or more compounds disclosed herein, or a pharmaceutically acceptable solvate, hydrate, tautomer, N-oxide, or salt thereof, and a pharmaceutically acceptable excipient or adjuvant is provided. The pharmaceutically acceptable excipients and adjuvants are added to the composition or formulation for a variety of purposes. In some embodiments, a pharmaceutical compositions comprising one or more compounds disclosed herein, or a pharmaceutically acceptable solvate, hydrate, tautomer, N-oxide, or salt thereof, further comprise a pharmaceutically acceptable carrier. In some embodiments, a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent. In some embodiments, suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone. EXAMPLES [00134] The invention is further illustrated by the following examples. The examples below are non-limiting and merely representative of various aspects of the invention. Solid and dotted wedges within the structures herein disclosed illustrate relative stereochemistry, with absolute stereochemistry depicted only when specifically stated or delineated. [00135] General Methods [00136] All reagents, for which the synthesis is not described in the experimental part, are either commercially available, or are known compounds or may be formed from known compounds by known methods by a person skilled in the art. [00137] The compounds and intermediates produced according to the methods of the present disclosure may require purification. Purification of organic compounds is well known to a person skilled in the art and there may be several ways of purifying the same compound. In some cases, no purification may be necessary. In some cases, the compounds may be purified by crystallization. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compounds may be purified by chromatography, particularly flash column chromatography, using e.g. prepacked silica gel cartridges, e.g. RediSep®Rf and eluents such as gradients of 0-100% ethyl acetate in hexanes or 0-100% of 10% MeOH in CH2Cl2 [00138] Purification methods as described herein may provide compounds of the present disclosure which possess a sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present disclosure which is sufficiently basic, a trifluoroacetate or formate salt, or, in the case of a compound of the present disclosure which is sufficiently acidic, an ammonium salt. A salt of this type can either be transformed into its free base or free acid form, respectively, by various methods known to a person skilled in the art, or be used as salts in subsequent biological assays. It is to be understood that the specific form of a compound of the present disclosure as isolated and as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity. [00139] All commercially available starting materials and reagents were used as is. 1H Nuclear magnetic resonance (NMR) spectroscopy was carried out using a Bruker Avance III instrument operating at 400MHz using the stated solvent at around room temperature unless otherwise stated. In all cases, NMR data were consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet; br, broad. Preparative HPLC purification was performed by reverse phase HPLC using Agilent Technologies 1200 Infinity Series or an equivalent HPLC system such as Teledyne ISCO CombiFlash Rf. [00140] Chemical names were generated using the ChemDraw naming software (Version 17.0.0.206) by PerkinElmer Informatics, Inc. In some cases, generally accepted names of commercially available reagents were used in place of names generated by the naming software. [00141] The following abbreviations are used in the examples, while other abbreviations have their customary meaning in the art: BOC: tert-butoxycarbonyl protecting group DMAP: Dimethylaminopyridine DIPEA: Diisopropylethylamine EDCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride EtOH: Ethanol EtOC(O)Cl: Ethyl chloroformate EtOAc: Ethyl acetate h: hour(s) HCl: Hydrochloric acid HOBt: Hydroxybenzotriazole KOtBu: Potassium t-butoxide L: Liter LCMS: liquid chromatography – mass spectrometry M: Molar MeOH: Methanol min: Minute(s) µL: Microliter mL: Millliliter N : Normal N2: Nitrogen n-BuLi n-butyl lithium NMR: nuclear magnetic resonance spectroscopy ppm: parts per million PCC: Pyridinium chlorochromate PPTS: Pyridinium p-toluenesulfonate rt: Room temperature Rt: Retention time sat.: Saturated Sphos: 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl TEA: Triethylamine THF: Tetrahydrofuran TMS-Cl: Trimethylsilyl chloride [00142] Analytical LC-MS Methods [00143] Column: Eclipse Plus C184.6 x 3.5 µm; eluent A: 0.1% TFA in H2O; eluent B: 0.1% TFA in CH3CN; gradient: 20-100% over 4 minutes; flow: 1.5mL/min; injection volume1-5 µL; temperature: 23 °C; UV scan:220 and 250 nm; signal settings- scan positive mode. [00144] Analytical HPLC Methods [00145] Column: Eclipse Plus C184.6 x 110 mm; eluent A: 0.1% TFA in H2O; eluent B: 0.1% TFA in CH3CN; gradient: 10-100% eluent B over 10 minutes; flow: 1 mL/min; injection volume 1-5 µL; temperature: 23 °C; UV scan: 220, 254 and 280 nm (method 1); 20-100% eluent B over 10 minutes; flow: 1 mL/min; injection volume 1-5 µL; temperature: 23 °C; UV scan:220, 254 and 280 nm (method 2). [00146] Preparative HPLC [00147] Instrument: Agilent Technologies 1200 Infinity Series Column: Gemini 5 µm NX- C18 110 Å, 250 x 21.2 mm; eluent A: 0.1% TFA in H2O , eluent B: 0.1% TFA in CH3CN; gradient:10-100%; flow: 20 mL/min; injection volume 0.5 – 2 mL; temperature: 23 °C; UV scan: 254 and 220 nm. Synthesis of Compounds [00148] Example 1 [00149] Preparation of 5-Fluoro-N-hydroxynicotinamide (1)
Figure imgf000055_0001
[00150] To a cold solution of the commercially available methyl 5-fluoronicotinate (100 mg, 0.64 mmol) in methanol-THF (4 mL, 1:1) in an ice bath, was added aqueous 50% NH2OH (1.28 g, 19.2 mmol) and KOH (362 mg, 6.4 mmol). The reaction mixture was stirred and allowed to warm up to ambient temperature. Monitored by LCMS. After the reaction was completed, 1 N HCl was added carefully until pH 6-7 followed by addition of ethyl acetate. The organic layer was washed with water, dried (Na2SO4), filtered and concentrated. The resulting white solid was triturated in ethyl acetate/hexane, and filtered to afford the title compound, 50 mg (49.7%). Analysis of 5-fluoro-N-hydroxynicotinamide: [00151] 1H NMR (400MHz, CD3OD-d4) δ 8.78 (s, 1 H), 8.66 (d, J=2.69 Hz, 1 H), 7.98 (br d, J=9.05 Hz, 1 H), 4.64 (s, 1 H). [00152] LC-MS: tR (min) 1.21 (20-100% ACN with 0.1 %TFA 4 min), m/z [M+H]+ C6H5FN2O2 requires: 156.0, found 157.1 [00153] HPLC tR (min) 2.70, 98% (20-100% ACN with 0.1 %TFA 10 min.) [00154] Example 2 [00155] Preparation of 6-methyl-N-hydroxynicotinamide (2)
Figure imgf000055_0002
[00156] Following the same experimental procedure as described in Example 1, methyl 6- methylnicotinate was converted to the title compound by employing the commercially available methyl 6-methyl-N-nicotinate instead. [00157] Analysis of 6-methyl-N-hydroxynicotinamide: [00158] 1H NMR (400MHz, DMSO-d6) δ 11.32 (br s, 1 H) 9.15 (br s, 1 H) 8.79 (d, J=1.71 Hz, 1 H) 7.99 (dd, J=8.07, 2.45 Hz, 1 H) 7.35 (d, J=8.07 Hz, 1 H), 3.30 (s, 3 H). [00159] LC-MS: tR (min) 1.36 (20-100% ACN with 0.1 %TFA 4 min), m/z [M+H]+ C7H8N2O2 requires: 152.1, found 153.1 [00160] HPLC tR (min) 1.21, 100% (20-100% ACN with 0.1 %TFA 10 min.) [00161] Example 3 [00162] Preparation of 5-Fluoro-6-methy-N-hydroxynicotinamide (I-1)
Figure imgf000056_0001
[00163] Step 1: Methyl 5-fluoro-6-methylnicotinate [00164] The commercially available methyl 6-bromo 5-fluoronicotinate (360 mg, 1.54 mmol) was mixed with trimethyl-1,3,5,2,4,6-trioxatriborinane (966 mg, 7.69 mmol), K2CO3 (319 mg, 2.31 mmol), and Pd(Ph3P)4 (196 mg, 0.169 mmol) in 1,4-dioxane (5 mL). The mixture was sparged with N2 and stirred at 110 o C in a sealed tube under N2 atmosphere for 18 h. After cooled, the reaction was added ethyl acetate and washed with water. The organic layer was dried (Na2SO4) and filtered through Celite. Solvent was evaporated and the resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 1:1) to afford the title compound, 198 mg (76%). LC-MS: m/z [M+H]+ 170.1. [00165] Step 2: 5-Fluoro-6-methy-N-hydroxynicotinamide [00166] Following the same experimental procedure as described in Example 1, methyl 5- fluoronicotinate (20 mg) from above Step 1 was converted to the title compound as a white solid, 8 mg (40%). [00167] Analysis of 5-fluoro-6-methy-N-hydroxynicotinamide: [00168] 1H NMR (400MHz, CD3OD-d4) δ 8.65 (s, 1 H), 7.88 (d, J=9.78 Hz, 1 H), 4.64 (s, 2 H), 2.57 (d, J=2.93 Hz, 3 H). [00169] LC-MS: tR (min) 1.26 (20-100% ACN with 0.1 %TFA 4 min), m/z [M+H]+ C7H7FN2O2 requires: 170.1, found 171.1 [00170] HPLC tR (min) 3.14, 98% (20-100% ACN with 0.1 %TFA 10 min.) [00171] Example 4 [00172] Preparation of 6-amino-5-fluoro-N-hydroxynicotinamide (I-2)
Figure imgf000057_0001
[00173] Step 1: Tert-butyl-(3-fluoro-5-(hydroxycarbamoy)pyridine-2-yl)carbamate [00174] Methyl 6-bromo 5-fluoronicotinate (300 mg, 1.28 mmol) was mixed with tert-butyl carbamate (150 mg, 1.28 mmol), sodium tert-butoxide (123 mg, 1.28 mmol), palladium acetate (7.20 mg, 0.032 mmol) and Xantphos (37.1 mg, 0.064 mmol) in 1,4-dioxane in an oven-dried sealed tube. After evacuated and refilled with N2 (X3), the mixture was stirred and heated at 75 o C for 5 h. After cooled, the reaction was added ethyl acetate and washed with water. The organic layer was dried (Na2SO4), concentrated and purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 5:1) to afford a white solid as the title compound, 250 mg (72.1%). LC-MS: m/z [2M+Na]+ 563.5 [00175] Step 2: Methyl 6-amino-5-fluoronicotinate hydrochloride [00176] Tert-butyl-(3-fluoro-5-(hydroxycarbamoy)pyridine-2-yl)carbamate obtained from above Step 1 was treated with 4 N HCl in methanol (5 ml) at ambient temperature for 18 h. Solvent was evaporated and a white solid was obtained, 150 mg (65%) as the title compound. LC-MS: m/z [M+H]+ 171.1 [00177] Step 3: 6-Amino-5-fluoro-N-hydroxynicotinamide [00178] Following the same experimental procedure as described in Example 1, methyl 6- amino-5-fluoronicotinate hydrochloride from above Step 2 which was first treated with saturated NaHCO3 and extracted with ethyl acetate/MeOH was then converted to the title compound. [00179] Analysis of 6-amino-5-fluoro-N-hydroxynicotinamide: [00180] 1H NMR (400MHz, METHANOL-d4) δ 8.21 (s, 1 H) 7.66 (d, J=9.78 Hz, 1 H). [00181] LC-MS: tR (min) 1.36 (20-100% ACN with 0.1 %TFA 4 min), m/z [M+H]+ C6H6FN3O2 requires: 171.1, found: 172.1. [00182] HPLC tR (min) 2.36, 96% (20-100% ACN with 0.1 %TFA 10 min.) [00183] Example 5 [00184] Preparation of 5-fluoro-6-methoxyl-N-hydroxynicotinamide (I-3)
Figure imgf000058_0001
[00185] Step 1: Methyl 5-fluoro-methoxynicotinate [00186] The commercially available 5-bromo-2,3-difluoropyridine (520 mg, 2.7 mmol) in a vial was added palladium acetate (12 mg, 2.7 mmol), Xantphos (62 mg, 2.7 mmol), methanol (1.1 mL, 27 mmol) and triethylamine (20 mL). The reaction mixture was sparged with a CO balloon for 1 minute, sealed and heated at 65 °C under CO atmosphere. After 17 h, full consumption of the starting material was observed by TLC. The mixture was washed with water, extracted with ethyl acetate, and concentrated. The resulting residue was purified by chromatography (Silica gel, ethyl acetate/hexane, 0-5%) to afford the title compound as a white solid, 91.7 mg (18%). LC-MS: m/z [M+H]+ 186.0 [00187] Step 2: 5-Fluoro-N-hydroxy-6-methoxynicotinamide [00188] Following the same experimental procedure as described in Example 1, methyl 6- methoxy-5-fluoronicotinate (31 mg, 0.17 mmol) from above Step 1 was converted to the title compound as a tan solid, 24.4 mg (79%). [00189] Analysis of 5-fluoro-N-hydroxy-6-methoxynicotinamide: [00190] 1H NMR (400 MHz, METHANOL-d4) δ 8.35 (s, 1 H) 7.80 (dd, J=10.76, 1.47 Hz, 1 H) 4.05 (s, 3 H). [00191] LC-MS: m/z [M+H]+ C7H7FN2O3 requires: 186.1, found: 187.0 [00192] HPLC tR (min) 3.92, 100% (20-100% ACN with 0.1 %TFA 10 min.) [00193] Example 6 [00194] Preparation of 5-fluoro-N-hydroxy-6-(((1- phenylcycloproyl)amino)methyl)nicotinamide (I-4)
Figure imgf000059_0001
[00195] Step 1: Methyl 6-(bromomethyl)-5-fluoronicotinate [00196] To a solution of methyl 5-fluoro-6-methylnicotinate (195 mg, 1.15 mmol) in CCl4 was added NBS (328 mg, 1.84 mmol) and AIBN (38 mg, 231 mmol). The reaction mixture was stirred and heated at 75 o C for 48 h. After cooled, the reaction mixture was evaporated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 0:1) to afford the title compound as a white solid, 131 mg (46%). LC-MS: m/z [M+H]+ 249.0 [00197] Step 2: Methyl 5-fluoro-6-(((1-phenylcyclopropyl)amino)methyl)nicotinate [00198] Methyl 6-(bromomethyl)-5-fluoronicotinate from above Step 2 (80 mg, 0.323 mmol) was mixed with 1-phenylcyclopropan-1-amine hydrochloride (54.8 mg, 0.323 mmol) and K2CO3 (89.1 mg, 0.323 mmol) in acetonitrile (3 mL). The reaction was stirred and heated under a N2 atmosphere at 77 o C for 18 h. After cooled and filtered via Celite, the mixture was concentrated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 1:1) to afford the title compound as an oil, 60 mg (62%). LC-MS: m/z [M+H]+ 301.3 [00199] Step 3: 5-Fluoro-N-hydroxy-6-(((1-phenylcycloproyl)amino)methyl)nicotinamide [00200] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-(((1-phenylcyclopropyl)amino)methyl)nicotinate from above Step 2 was converted to the title compound. LC-MS: m/z [M+H]+ 302.3 [00201] Analysis of 5-fluoro-N-hydroxy-6-(((1- phenylcycloproyl)amino)methyl)nicotinamide: [00202] 1H NMR (400 MHz, METHANOL-d4) δ 8.69 (s, 1 H), 7.81 (d, J=10.03 Hz, 1 H), 7.42 (d, J=7.83 Hz, 2 H), 7.31 (t, J=7.58 Hz, 2 H), 7.19 - 7.24 (m, 1 H), 4.64 (s, 1 H), 3.94 (s, 2 H), 1.05 - 1.11 (m, 2 H), 0.96 - 1.04 (m, 2 H). [00203] LC-MS: tR (min) 1.94 (20-100% ACN with 0.1 %TFA 4 min), m/z [M+H]+ C16H16FN3O2 requires: 301.3, found: 302.3 [00204] HPLC tR (min) 4.16, 99% (20-100% ACN with 0.1 %TFA 10 min.) [00205] Example 7 [00206] Preparation of 6-((2,3-dihydro-1H-inden-2-yl)amino)-5-fluoro-N- hydroxynicotinamide (I-5)
Figure imgf000060_0001
[00207] Step 1: Methyl 6-((2.3-dihydro-1H-inden-2-yl)amino-5-fluoronicotinate [00208] To a solution of methyl 5-fluoro-6-bromonicotinate (100 mg, 0.47 mmol) in NMP (2 mL) was added 2,3-dihydro-1H-inden-2-amine (62.6 mg, 0.47 mmol) and K2CO3 (195 mg, 1.41 mmol) in a vial. The reaction mixture was stirred and heated at 120 o C under N2 for 18 h. After cooled and diluted with ethyl acetate, the organic layer was washed with water. Dried (Na2SO4), filtered and concentrated, the resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 0:1) to afford the title compound as a brown oil, 38 mg (31%). LC- MS: m/z [M+H]+ 287.3 [00209] Step 2: 6-((2,3-Dihydro-1H-inden-2-yl)amino)-5-fluoro-N-hydroxynicotinamide [00210] Following the same experimental procedure as described in Example 1, methyl 6- ((2.3-dihydro-1H-inden-2-yl)amino-5-fluoronicotinate from above Step 1 was converted to the title compound. [00211] Analysis of 6-((2,3-dihydro-1H-inden-2-yl)amino)-5-fluoro-N- hydroxynicotinamide [00212] 1H NMR (400 MHz, DMSO-d6) δ 11.0 (br, s, 1 H), 8.98 (s, 1 H), 8.32 (s, 1 H), 7.63 (d, J=12.2 Hz, 1 H), 7.45 (br, d, J=6.60 Hz, 1 H), 7.26-7.19 (m, 2 H), 7.18-7.11 (m, 2 H), 4.84- 4.75 (m, 1 H), 3.27 (dd, J=15.9, 7.58 HZ, 2 H), 2.96 (dd, J=15.9, 7.09 Hz, 2 H). [00213] LC-MS: m/z [M+H]+ C15H13FN3O2 requires: 287.3, found: 288.3 [00214] HPLC tR (min) 5.16, 99% (20-100% ACN with 0.1 %TFA 10 min.) [00215] Example 8 [00216] Preparation of 5-fluoro-N-hydroxy-6-((1-phenylcyclopropyl)amino)nicotinamide (I-6)
Figure imgf000061_0001
[00217] Step 1: Methyl 5-fluoro-6-((1-phenylcyclopropyl)amino)nicotinate [00218] The title compound was synthesized by following the same experimental procedure as described in Step 1 of Example 7 employing methyl 5-fluoro-6-bromonicotinate and 1- phenylcyclopropan-1-amine hydrochloride instead. LC-MS: m/z [M+H]+ 287.3 [00219] Step 2: 5-Fluoro-N-hydroxy-6-((1-phenylcyclopropyl)amino)nicotinamide [00220] Following the same experimental procedure as describe in Example 1, methyl 5- fluoro-6-((1-phenylcyclopropyl)amino)nicotinate from above Step 1 was converted to the title compound as a solid. [00221] Analysis of 5-Fluoro-N-hydroxy-6-((1-phenylcyclopropyl)amino)nicotinamide [00222] 1H NMR (400 MHz, METHANOL-d4) δ 8.18 (s, 1 H), 7.63 (dd, J=11.9, 1.59 Hz, 1 H), 7.27-7.18 (m, 4 H), 7.15-7.11 (m 1 H), 5.03-493 (m, 1 H), 1.42-1.38 (m, 2 H), 1.36-1.32 (m, 2 H). [00223] LC-MS: tR (min) 1.90 (20-100% ACN with 0.1 %TFA 4 min) m/z [M+H]+ C15H14FN3O2 found: 288.3 [00224] HPLC tR (min) , % (20-100% ACN with 0.1 %TFA 10 min.) [00225] Example 9 [00226] Preparation of 5-fluoro-N-hydroxy-6-(4-(2-methoxyphenyl)piperazin-1- yl)nicotinamide (IV-1)
Figure imgf000061_0002
[00227] Step 1: Methyl 5-fluoro-6-(4-(2-methyoxyphenyl)piperazin-1-yl)nicotinate [00228] The title compound was synthesized by following the same experimental procedure as described in Step 1, Example 7 employing methyl 5-fluoro-6-bromonicotinate and 1-(2- methoxyphenyl)piperazine instead. LC-MS: m/z [M+H]+ 346.3 [00229] Step 2: 5-Fluoro-N-hydroxy-6-(4-(2-methoxyphenyl)piperazin-1-yl)nicotinamide [00230] Following the same experimental procedure as describe in Example 1, methyl 5- fluoro-6-(4-(2-methyoxyphenyl)piperazin-1-yl)nicotinate from above Step 1 was converted to the title compound. [00231] Analysis of 5-fluoro-N-hydroxy-6-(4-(2-methoxyphenyl)piperazin-1- yl)nicotinamide [00232] 1H NMR (400 MHz, METHANOL-d4) δ 8.40 (s, 1 H), 7.76 (d, J=14.7 Hz, 1 H), 7.01-6.87 (m, 4 H), 3.81 (s, 3 H), 3.67 (br, d, J=4.65 Hz, 4 H), 3.12-3.12 (m, 4 H). [00233] LC-MS: m/z [M+H]+ C17H19FN4O2 requires: 346.4, found: 347.2 [00234] HPLC tR (min) 4.50, 98% (20-100% ACN with 0.1 %TFA 10 min.) [00235] Example 10 [00236] Preparation of (R)-5-fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide (I-7A)
Figure imgf000062_0001
[00237] Step 1: Methyl (R)-5-fluoro-6-((1-phenylethyl)amino)nicotinate [00238] The title compound was synthesized by following the same experimental procedure as described in Step 1 of Example 7 employing methyl 5-fluoro-6-bromonicotinate and the commercially available (R)-1-phenylethan-1-amine instead. LC-MS: m/z [M+H]+ 302.3 [00239] Step 2: (R)-5-Fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide [00240] Following the same experimental procedure as described in Example 1, methyl (R)-5-fluoro-6-((1-phenylethyl)amino)nicotinate from above Step 1 was converted to the title compound. [00241] Analysis of (R)-5-fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide [00242] 1H NMR (400 MHz, METHANOL-d4) δ 8.19 (s, 1 H), 7.57 (s, 1 H), 7.57 (dd, J=11.9, 1.35 Hz, 1 H), 7.39 (d, J=7.83 Hz, 2 H), 7.30 (t, J=7.70 Hz, 2 H), 7.23-7.18 (m, 1 H), 5.34 (q, J=7.01 Hz, 1 H), 1.58 (d, J=7.09 Hz, 3 H). [00243] LC-MS: tR (min) 1.86 (20-100% ACN with 0.1 %TFA 4 min) m/z [M+H]+ C14H13FN3O2 requires: 275.3, found: 276.1 [00244] HPLC tR (min) 4.06, 99% (20-100% ACN with 0.1 %TFA 10 min.) [00245] Example 11 [00246] Preparation of (S)-5-fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide (I-7B)
Figure imgf000063_0001
[00247] Step 1: Methyl (S)-5-fluoro-6-((1-phenylethyl)amino)nicotinate [00248] The title compound was synthesized by following the same experimental procedure as described in Step 1 of Example 7 employing methyl 5-fluoro-6-bromonicotinate and (S)-1- phenylethan-1-amine instead. LC-MS: m/z [M+H]+ 302.3 [00249] Step 2: (S)-5-Fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide [00250] Following the same experimental procedure as described in Example 1, methyl (S)-5-fluoro-6-((1-phenylethyl)amino)nicotinate from above Step 1 was converted to the title compound. [00251] Analysis of (S)-5-fluoro-N-hydroxy-6-((1-phenylethyl)amino)nicotinamide: [00252] 1H NMR (400 MHz, METHANOL-d4) δ 8.19 (s, 1 H), 7.59 (s, 1 H), 7.56 (s, 1 H), 7.42-7.36 (m, 2 H), 7.30 (t, J=7.70 Hz, 2 H), 7.23-7.18 (m, 1 H), 5.34 (q, J=7.01 Hz, 1 H), 1.58 (d, J=7.09 Hz, 3 H). [00253] LC-MS: tR (min) 1.86 (20-100% ACN with 0.1 %TFA 4 min), m/z [M+H]+ C14H13FN3O2 requires: 275.3, found: 276.1 [00254] HPLC tR (min) 4.06, 97% (20-100% ACN with 0.1 %TFA 10 min.) [00255] Example 12 [00256] Preparation of (S )-6-((Cyclopropyl(phenyl)methyl)amino-5-fluoro-N- hydroxynicotinamide (I-8B)
Figure imgf000064_0001
[00257] Step 1: (S,E)-N-(Cyclopropylmethylene)-2methylpropane-sulfinamide [00258] To a solution of cyclopropylcarboxaldehyde (5.33 mL, 71.3 mmol) in THF (150 mL) was added (S )-(-)2-methyl-2-propanesulfonamide (8.65 g. 71.3 mmol), and tetraisopropyl orthotitanate (41.8 mL, 143 mmol). The mixture was stirred at ambient temperature for 18 h. After the completion of reaction, the mixture was poured into brine and the slurry was filtered through Celite. The filtrate was extracted with ethyl acetate, and the organic layer was dried (Na2O4) and concentrated. The crude title compound, 12.4 g (100%) was taken to the next step without purification. LC-MS: m/z [M+H]+ 174.2 [00259] Step 2: (S)-N-((S)-Cyclopropyl(phenyl)methyl)-2-methylpropane-2-sulfonamide [00260] To a solution of (S,E)-N-(cyclopropylmethylene)-2methylpropane-sulfinamide from above Step 1 (12.4 g, 71.6 mmol) in THF (25 mL) was added phenyl magnesium bromide (1.0 N, 71.6 mL) dropwise at ambient temperature. The mixture was then stirred at 50 to 60 o C for 2 h. After the completion of reaction, the reaction mixture was quenched with saturated ammonium chloride followed by addition of water. Filtered, the sold was washed with ethyl ester and the filtrate was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate) to afford the title compound, 5.0 g (28%). LC- MS: m/z [M+H]+ 252.3 [00261] Step 3: (S)-Cyclopropyl(phenyl)methanamine hydrochloride [00262] (S)-N-((S)-Cyclopropyl(phenyl)methyl)-2-methylpropane-2-sulfonamide was converted to the title compound by treating with 4 N HCl in methanol from 0 o C to ambient temperature for 18 h. Ethyl acetate was added to the mixture and a white solid was formed as the title compound (85%). LC-MS: m/z [M+H]+ 148.2 [00263] Step 4: Methyl (S )-6-((cyclopropyl(phenyl)methyl)amino)-5-fluoronicotinate [00264] The commercially available methyl 5-bromo-3-fluoronicotinate (50 mg, 0.214 mmol) was mixed with (S)-cyclopropyl(phenyl)methanamine hydrochloride (59 mg, 0.320 mmol) and diisopropylethylamine (166 mg, 1.28 mmol) in DMSO (2 mL). The mixture was stirred and heated under microwave at 100 o C for 1 h. After cooled, the reaction was added water and extracted with ethyl acetate. The organic layers were dried (Na2SO4), filtered and concentrated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 1:1) to afford the title compound, 10 mg (15.5%). LC-MS: m/z [M+H]+ 301.3 [00265] Step 5: (S )-6-((Cyclopropyl(phenyl)methyl)amino-5-fluoro-N- hydroxynicotinamide [00266] Following the same experimental procedure as described in Example 1, methyl (S )-6-((cyclopropyl(phenyl)methyl)amino)-5-fluoronicotinate from above Step 4 was converted to the title compound. [00267] Analysis of (S )-6-((cyclopropyl(phenyl)methyl)amino-5-fluoro-N- hydroxynicotinamide: [00268] 1H NMR (400 MHz, METHANOL-d4) δ 8.16 (s, 1 H), 7.58 (d, J=1.71 Hz, 1 H), 7.49-7.41 (m, 2 H), 7.36-7.27 (m, 2 H), 7.24-7.18 (m, 1 H), 4.59-4.55 (m, 1 H), 1.40-1.30 (m, 1 H), 0.66-0.60 (m, 2 H), 0.40-0.30 (m, 2 H). [00269] LC-MS: tR (min) 3.67 (20-100% ACN with 0.1 %TFA 6 min), m/z [M+H]+ C16H16FN3O2 requires: 301.3, found: 302.1 [00270] HPLC tR (min) 4.09, 94% (20-100% ACN with 0.1 %TFA 10 min.) [00271] Example 13 [00272] Preparation of (R)-6-((cyclopropyl(pyridine-2-yl)methyl)amino)-5-fluoro-N- hydroxynicotinamide (I-9A)
Figure imgf000065_0001
[00273] The title compound was synthesized by following the same experimental procedure as described in Example 12 employing 5-bromo-2,3-difluoropyridine and (R)- cyclopropyl(pyridine-2-yl)methanamine instead. [00274] Analysis of (R)-6-((cyclopropyl(pyridine-2-yl)methyl)amino)-5-fluoro-N- hydroxynicotinamide: [00275] 1H NMR (400 MHz, METHANOL-d4) δ 8.49 (d, J=4.65 Hz, 1 H), 8.14 (s, 1 H), 7.80 (t, J=7.83 Hz, 1 H), 7.51-7.61 (m, 2 H), 7.33 - 7.27 (m, 1 H), 4.60 - 4.65 (m, 1H), 0.72 - 0.62 (m, 1 H), 0.59 – 0.49 (m, 3 H). [00276] LC-MS: tR (min) 1.38 (20-100% ACN with 0.1 %TFA 6 min), m/z [M+H]+ C14H16FN4O2 requires: 302.3, found: 303.1 [00277] HPLC tR (min) 3.38, 98% (20-100% ACN with 0.1 %TFA 10 min.) [00278] Example 14 [00279] Preparation of (S)-6-((cyclopropyl(pyridine-2-yl)methyl)amino)-5-fluoro-N- hydroxynicotinamide (I-9B)
Figure imgf000066_0001
[00280] The title compound was synthesized by following the same experimental procedure as described in Example 12 employing 5-bromo-2,3-difluoropyridine and (S)- cyclopropyl(pyridine-2-yl)methanamine instead. [00281] Analysis of (S)-6-((cyclopropyl(pyridine-2-yl)methyl)amino)-5-fluoro-N- hydroxynicotinamide: [00282] 1H NMR (400 MHz, METHANOL-d4) δ 8.49 (d, J=4.65 Hz, 1 H), 8.14 (s, 1 H), 7.80 (t, J=7.83 Hz, 1 H), 7.51-7.61 (m, 2 H), 7.33 - 7.27 (m, 1 H), 4.60 - 4.65 (m, 1H), 0.72 - 0.62 (m, 1 H), 0.59 – 0.49 (m, 3 H). [00283] LC-MS: tR (min) 1.41 (20-100% ACN with 0.1 %TFA 6 min), m/z [M+H]+ C14H16FN4O3 requires: 302.3, found: 303.1 [00284] HPLC tR (min) 3.38, 98% (20-100% ACN with 0.1 %TFA 10 min.) [00285] Example 15 [00286] Preparation of 5-fluoro-N-hydroxy-6-(phenylsulfonamido)nicotinamide (I-10)
Figure imgf000066_0002
[00287] Step 1: Methyl 5-fluoro-6-(phenylsulfonamido)nicotinate [00288] The commercially available methyl 6-bromo 5-fluoronicotinate (100 mg, 0.427 mmol) was mixed with benzenesulfonamide (67.2 mg, 0.427 mmol), sodium tert-butoxide (41.1 mg, 0.427 mmol), palladium acetate (2.4 mg, 0.0107 mmol) and Xantphos (12.4 mg, 0.0214 mmol) in 1,4-dioxane under N2 atomasphere in an oven-dried sealed tube, the reaction mixture was stirred and heated at 120 o C for 1 h under microwave. After cooled, the reaction was added saturated NaHCO3, and extracted with ethyl ester (X3). The combined organic layers were dried (Na2SO4), filtered, and concentrated. The resulting residue was purified by chromatography (Silica gel, DCM/15%MeOH in DCM, 1:0 to 0:1) to afford the title compound as a white solid, 45 mg (34%). LC-MS: m/z [M+H]+ 311.3 [00289] Step 2: 5-Fluoro-N-hydroxy-6-(phenylsulfonamido)nicotinamide [00290] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-(phenyl-sulfonamido)nicotinate from above Step 1 was converted to the title compound. [00291] Analysis of 5-fluoro-N-hydroxy-6-(phenylsulfonamido)nicotinamide [00292] 1H NMR (400 MHz, METHANOL-d4) δ 8.33 (s, 1 H), 8.10 (d, J=7.34 Hz, 2 H), 7.83 (s, 1 H), 7.80 (s, 1 H), 7.66 – 7.52 (m, 3 H). [00293] LC-MS: tR (min) 2.81 (20-100% ACN with 0.1 %TFA 6 min), m/z [M+H]+ C12H10FSN3O4 requires: 311.1, found: 312.0 [00294] HPLC tR (min) 4.66, 93% (20-100% ACN with 0.1 %TFA 10 min.) [00295] Example 16 [00296] Preparation of 5-fluoro-N-hydroxy-6-morpholinonicotinamide (IV-2)
Figure imgf000067_0001
[00297] The title compound was synthesized by following the same experimental procedure as described in Example 7 employing methyl 5-fluoro-6-bromonicotinate and morpholine instead. [00298] Analysis of 5-fluoro-N-hydroxy-6-morpholinonicotinamide: [00299] 1H NMR (400 MHz, DMSO-d4) δ 8.35 (s, 1 H), 7.68 (d, J=14.4 Hz, 1 H), 3.674- 3.69 (m, 4 H), 3.44-3.39 (m, 4 H). [00300] LC-MS: m/z [M+H]+ C10H12FN3O3 requires: 241.2, found: 242.1 [00301] HPLC tR (min) 5.56, 99% (20-100% ACN with 0.1 %TFA 10 min.) [00302] Example 17 [00303] Preparation of 5-fluoro-N-hydroxy-6-((4-phenylpropan-2-yl)amino)nicotinamide (I-11)
Figure imgf000068_0001
[00304] Step 1: 5-Bromo-3-fluoro-N-(2-phenylpropan-2-yl)pyridine-2-amine [00305] To a solution of the 5-bromo-2,3-difluoropyridine (50 mg, 0.26 mmol) in DMSO (1.0 mL) was added 2-phenylpropan-2-amine (52 mg, 0.39 mmol) and DIPEA (0.23 mL, 1.30 mmol). The mixture was stirred and heated at 120 o C for 15 h. After cooled, the reaction was added water and extracted with ethyl acetate. The combined organic layer was dried (Na2SO4), filtered and concentrated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 0:1 to 9:1) to afford the title compound as a colorless oil, 25.8 mg (32.4%). LC-MS: m/z [M+H]+ 310.1 [00306] Step 2: Methyl 5-fluoro-6-((2-phenylpropan-2-yl)amino)nicotinate [00307] 5-Bromo-3-fluoro-N-(2-phenylpropan-2-yl)pyridine-2-amine from above Step 1 was mixed with palladium acetate (0.8 mg, 0.0003 mmol), Xantphos (3.9 mg, 0.007 mmol), methanol and triethylamine (0.5 mL). The mixture was sparged with CO for 1 min, stirred and heated at 65 o C under CO atmosphere. Monitored by LCMS, additional palladium acetate (0.80 mg), Xantphos (3.9 mg), methanol (0.2 mL) and triethyl amine (0.2 mL) were added. After the reaction was completed, the mixture was added water/Brine and washed with ethyl acetate. The organic layer was dried (Na2SO4), filtered, and concentrated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 4:1) to afford the title compound as a white solid, 13.5 mg (56.1%). LC-MS: m/z [M+H]+ 289.1 [00308] Step 3: 5-Fluoro-N-hydroxy-6-((4-phenylpropan-2-yl)amino)nicotinamide [00309] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-((2-phenylpropan-2-yl)amino)nicotinate from above Step 2 was converted to the title compound. [00310] Analysis of 5-Fluoro-N-hydroxy-6-((4-phenylpropan-2-yl)amino)nicotinamide: [00311] 1H NMR (400 MHz, METHANOL-d4) δ 8.00 (s, 1 H), 7.54 (d. J=12.2 Hz, 1 H), 7.40 (d, J=8.07 Hz, 2 H), 7.25 (t, J=7.58 Hz, 2 H), 7.17-7.12 (m, 1 H), 1.80 (s, 6 H). [00312] LC-MS: m/z [M+H]+ C15H16FN3O2, requires: 289.3, found, 290.1 [00313] HPLC tR (min) 5.14, 99% (20-100% ACN with 0.1 %TFA 10 min.) [00314] Example 18 [00315] Preparation of 5-fluoro-N-hydroxy-6-(4-phenylpiperidin-1-yl)nicotinamide (IV-3)
Figure imgf000069_0001
[00316] The title compound was synthesized by following the same experimental procedure as described in Example 7 employing methyl 5-fluoro-6-bromonicotinate and 4-phenylpiperidine instead. [00317] Analysis of 5-fluoro-N-hydroxy-6-(4-phenylpiperidin-1-yl)nicotinamide: [00318] 1H NMR (400 MHz, DMSO-d4) δ 8.37 (s, 1 H), 7.71 (d, J=14.7 Hz, 1 H), 7.33- 7.18 (m, 5 H), 4.25 (br, d, J=13.0 Hz, 2 H), 3.02 (br, t, J=11.9 Hz, 2 H), 2.85-2.76 (m, 1 H), 1.86 (br, d, J=11.4 Hz, 2 H), 1.72 (qd, J=12.5, 3.30 Hz, 2 H). [00319] LC-MS: m/z [M+H]+ C17H18FN3O2, requires: 315.3, found: 316.1 [00320] HPLC tR (min) 5.92, 99% (20-100% ACN with 0.1 %TFA 10 min.) [00321] Example 19 [00322] Preparation of 6-(3,4-dihydroisoquinolin-2(1H)-yl-5-fluoro-N- hydroxynicotinamide (IV-4)
Figure imgf000069_0002
[00323] Step 1: Methyl 6-(3,4-dihydroisoquinolin-2(1H)-yl-5-fluoronicotinate [00324] To a solution of methyl 6-bromo-5-fluoropyridine-3-carboxylate (0.15 g, 0.64 mmol) in DMF was added 1,2,3,4-tetrahydroisoquinoline (0.17 g, 1.28 mmol) and DMAP (2.0 mg). The mixture was stirred and heated at 80 o C under microwave for 3 h. After cooled, the reaction was added saturated ammonium chloride and extracted with ethyl acetate. The organic layer was dried (Na2SO4), filtered and concentrated. The resulting residue was purified by chromatography (Silica gel, hexane/ethyl acetate, 1:0 to 0:1) to afford the title compound as an oil, 160 mg (87.2%). [00325] Step 2: 6-(3,4-Dihydroisoquinolin-2(1H)-yl-5-fluoro-N-hydroxynicotinamide: [00326] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-bromonicotinate and 1,2,3,4-tetrahydroisoquinoline was converted to the title compound. [00327] Analysis of 6-(3,4-dihydroisoquinolin-2(1H)-yl-5-fluoro-N-hydroxynicotinamide: [00328] 1H NMR (400 MHz, DMSO-d4) δ 8.38 (s, 1 H), 7.73 (d, J=14.7 Hz, 1 H), 7.24- 7.16 (m, 4 H), 4.71 (s, 2 H), 3.81 (t, J=5.75 Hz, 2 H), 2.93 (t, J=5.75 Hz, 2 H). [00329] LC-MS: m/z [M+H]+ C15H14FN3O2 requires: 287.3, found: 288.1 [00330] HPLC tR (min) 5.30, 97% (20-100% ACN with 0.1 %TFA 10 min.) [00331] Example 20 [00332] Preparation of (S )-6-(1-phenylpropyl)amino-5-fluoro-N-hydroxynicotinamide (I-12B)
Figure imgf000070_0001
[00333] The title compound was synthesized by following the same experimental procedure as described in Example 11 employing methyl 5-fluoro-6-bromonicotinate and (S)-1- phenylpropyl-1-amine instead. [00334] Analysis of (S )-6-(1-phenylpropyl)amino-5-fluoro-N-hydroxynicotinamide: [00335] 1H NMR (400 MHz, DMSO-d4) δ 8.19 (s, 1 H), 7.56 (br, d, J=12.2 Hz, 1 H), 7.41- 7.36 (m, 2 H), 7.30 (t, J=7.58 Hz, 2 H), 7.23-7.18 (m, 1 H), 5.10 (t, J=7.46 Hz, 1 H), 2.00-1.86 (m, 2 H), 1.01-0.91 (m, 3 H). [00336] LC-MS: m/z [M+H]+ C15H16FN3O2 requires: 289.3, found: 290.2 [00337] HPLC tR (min) 5.08, 95% (20-100% ACN with 0.1 %TFA 10 min.) [00338] Example 21 [00339] Preparation of (R)-6-((cyclopropyl(phenyl)methyl)amino-5-fluoro-N- hydroxynicotinamide (I-8A)
Figure imgf000071_0001
[00340] The title compound was synthesized by following the same experimental procedure as described in Example 11 employing methyl (R)-5-fluoro-6-((1-phenylethyl)amino)nicotinate instead. [00341] Analysis of (R)-6-((cyclopropyl(phenyl)methyl)amino-5-fluoro-N- hydroxynicotinamide: [00342] 1H NMR (400 MHz, DMSO-d4) δ 8.16 (s, 1 H), 7.57 (br, d, J=12.2 Hz, 1 H), 7.44 (br, d, J=7.34 Hz, 2 H), 7.30 (t, J=7.46 Hz, 2 H), 7.24-7.18 (m, 1 H), 4.66-4.55 (m, 2 H), 1.41-1.25 (m, 2 H), 0.67-0.58 (M, 2 H), 0.44 (br, s, 2 H). [00343] LC-MS: m/z [M+H]+ C16H16FN3O2 requires: 301.3, found: 302.1 [00344] HPLC tR (min) 4.03, 96% (20-100% ACN with 0.1 %TFA 10 min.) [00345] Example 22 [00346] Preparation of 6-((methyl(1-phenylcyclopropyl)amino)methyl-5-fluoro-N- hydroxynicotinamide (I-13)
Figure imgf000071_0002
[00347] Step 1: Methyl 5-fluoro-6-((methyl(1-phenylcyclopropyl)amino)methyl)nicotinate [00348] Methyl 5-fluoro-6-(((1-phenylcyclopropyl)amino)methyl)nicotinate (36 mg, 0.12 mmol) was dissolved in acetonitrile/water (10:1) followed by the addition of 37% Formaldehyde (19.5 mg, 0.24 mmol), NaCNBH3 (15.1 mg, 0.24 mmol) and 1 drop of acetic acid. The reaction mixture was stirred at ambient temperature for 15 min. Quenched with water, the mixture was extracted with ethyl acetate. The organic layer was dried (Na2SO4), concentrated and purified by chromatography (Silica gel, hexane/EtOAc, 1:0 to 1:1) to afford the title compound, 20 mg (53.1%). LC-MS: m/z [M+H]+ 315.1 [00349] Step 2: 6-((Methyl(1-phenylcyclopropyl)amino)methyl-5-fluoro-N- hydroxynicotinamide [00350] Following the same experimental procedure as described in Example 1, methyl 5- fluoro-6-((methyl(1-phenylcyclopropyl)amino)methyl)nicotinate was converted to the title compound. [00351] Analysis of 6-((methyl(1-phenylcyclopropyl)amino)methyl-5-fluoro-N- hydroxynicotinamide [00352] 1H NMR (400 MHz, DMSO-d4) δ 8.68 (s, 1 H), 7.89 (d, J=10.0 Hz, 1 H), 7.47- 7.29 (m, 5 H), 4.54 (br, s, 1 H), 3.83 (s, 2 H), 2.19 (3, 3 H), 1.12-1.06 (m, 2 H), 0.95-0.83 (m, 2 H). [00353] Analysis of 6-((Methyl(1-phenylcyclopropyl)amino)methyl-5-fluoro-N- hydroxynicotinamide: [00354] LC-MS: m/z [M+H]+ C17H18FN3O2 requires: 315.3, found: 316.1 [00355] HPLC tR (min)4.12, 100% (20-100% ACN with 0.1 %TFA 10 min.) [00356] Example 23 [00357] Preparation of 6-(((oxetan-3-yl-methyl)(1-phenylcyclopropyl)amino)methyl)-5- fluoro-N-hydroxynicotinamide (I-14)
Figure imgf000072_0001
[00358] Following the same experimental procedure as described in Example above, the title compound was prepared by the reductivamination between methyl 5-fluoro-6-(((1- phenylcyclopropyl)amino)methyl)nicotinate and oxetane-3-carbaldehyde, and followed by the hydroxamic acid formation. [00359] Analysis of 6-(((oxetan-3-yl-methyl)(1-phenylcyclopropyl)amino)methyl)-5- fluoro-N-hydroxynicotinamide: [00360] 1H NMR (400 MHz, DMSO-d4) δ 8.71 (s, 1 H), 7.89 (d, J=9.90 Hz, 1 H), 7.49 (d, J=6.85 Hz, 2 H), 7.41-7.28 (m, 3 H), 4.63 (t, J=6.73 Hz, 2 H),4.54 (s, 1 H), 4.15-4.09 (m, 2 H), 3.96 (s, 2 H), 3.23-316 (m, 1 H), 2.87 (d, J=8.31, 2 H), 0.78-0.82 (m, 4 H). [00361] LC-MS: m/z [M+H]+ C20H22FN3O3 requires: 371.4, found: 372.1 [00362] HPLC tR (min) 4.77, 100% (20-100% ACN with 0.1 %TFA 10 min.) [00363] Example 24 [00364] Preparation of 6-(dicyclopropylamino)-5-fluoro-N-hydroxynicotinamide (I-15)
Figure imgf000073_0001
[00365] The title compound was prepared by following the same experimental procedure as described in Example 7 employing methyl 5-fluoro-6-bromonicotinate and 1,1- dicyclopropylmethyl amine instead. [00366] Analysis of 6-(dicyclopropylamino)-5-fluoro-N-hydroxynicotinamide: [00367] 1H NMR (400 MHz, DMSO-d4) δ 8.18 (s, 1 H), 7.55 (d, J= 11.5 Hz, 1 H), 3.39- 3.35 (m, 1 H), 1.19-1.08 (m, 2H), 0.60-0.55 (m, 2H), 0.54-0.50 (m, 6 H). [00368] LC-MS: m/z [M+H]+ C13H16FN3O2 requires: 265.3, found: 266.1 [00369] HPLC tR (min) 3.37, 97% (20-100% ACN with 0.1 %TFA 10 min.) [00370] Example 25 [00371] Preparation of 6-(dimethylamino)-5-fluoro-N-hydroxynicotinamide (I-16)
Figure imgf000073_0002
[00372] Step 1: methyl 6-(dimethylamino)-5-fluoronicotinate [00373] The title compound was synthesized by following the same experimental procedure as described in Step 1, Example 7 employing methyl 5-fluoro-6-bromonicotinate and dimethylamine instead. [00374] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.57 (t, J=1.59 Hz, 1 H) 7.68 (dd, J=14.55, 1.83 Hz, 1 H) 3.87 (s, 3 H) 3.22 (d, J=2.69 Hz, 6 H) LC-MS: m/z [M+H]+ 199.3 [00375] Step 2: 6-(dimethylamino)-5-fluoro-N-hydroxynicotinamide [00376] Following the same experimental procedure as describe in Example 1, methyl 6- (dimethylamino)-5-fluoronicotinate from above Step 1 was converted to the title compound. [00377] Analysis of 6-(dimethylamino)-5-fluoro-N-hydroxynicotinamide [00378] 1H NMR (400 MHz, DMSO-d6) δ ppm 11.05 (br s, 1 H) 8.97 (s, 1 H) 8.35 (s, 1 H) 7.68 (br d, J=15.41 Hz, 1 H) 3.09 - 3.14 (m, 6 H) [00379] LC-MS: m/z [M+H]+ C8H11FN3O2 requires: 200.2, found: 200.1 [00380] HPLC tR (min) 5.23, 99% (10-100% ACN with 0.1 %TFA 10 min.) [00381] Example 26 [00382] Preparation of 6-(1,1-dioxidothiomorpholino)-5-fluoro-N-hydroxynicotinamide (IV-5)
Figure imgf000074_0001
[00383] Step 1: methyl 6-(1,1-dioxidothiomorpholino)-5-fluoronicotinate [00384] The title compound was synthesized by following the same experimental procedure as described in Step 1, Example 7 employing methyl 5-fluoro-6-bromonicotinate and 1,1- dioxidothiomorpholine instead. [00385] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.63 (s, 1 H) 7.85 (dd, J=13.82, 1.59 Hz, 1 H) 4.20 - 4.28 (m, 4 H) 3.91 (s, 3 H) 3.07 - 3.22 (m, 4 H) [00386] LC-MS: m/z [M+H]+ 289.1 [00387] Step 2: 6-(dimethylamino)-5-fluoro-N-hydroxynicotinamide [00388] Following the same experimental procedure as describe in Example 1, methyl 6- (1,1-dioxidothiomorpholino)-5-fluoronicotinate from above Step 1 was converted to the title compound. [00389] Analysis of 6-(1,1-dioxidothiomorpholino)-5-fluoro-N-hydroxynicotinamide [00390] 1H NMR (400 MHz, DMSO-d6)δ ppm 11.20 (br s, 1 H) 9.10 (br s, 1 H) 8.43 (s, 1 H) 7.83 (d, J=14.43 Hz, 1 H) 4.04 (br s, 4 H) 3.25 (br s, 4 H) [00391] LC-MS: m/z [M+H]+ C10H12FN3O4S requires: 290.2, found: 290.0 [00392] HPLC tR (min) 3.94, 98% (10-100% ACN with 0.1 %TFA 10 min.) [00393] Example 27 [00394] Preparation of 5-fluoro-N-hydroxy-6-(4-methylpiperazin-1-yl)nicotinamide (IV-6)
Figure imgf000075_0001
[00395] Step 1: methyl 5-fluoro-6-(4-methylpiperazin-1-yl)nicotinate [00396] The title compound was synthesized by following the same experimental procedure as described in Step 1, Example 7 employing methyl 5-fluoro-6-bromonicotinate and N- methylpiperazine instead. [00397] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.59 (s, 1 H) 7.74 (d, J=1.22 Hz, 1 H) 4.37 (s, 1 H) 3.88 (s, 3 H) 3.71 - 3.80 (m, 4 H) 2.50 - 2.55 (m, 4 H) 2.34 (s, 3 H) [00398] LC-MS: m/z [M+H]+ 254.3 [00399] Step 2: 6-(dimethylamino)-5-fluoro-N-hydroxynicotinamide [00400] Following the same experimental procedure as describe in Example 1, methyl 5- fluoro-6-(4-methylpiperazin-1-yl)nicotinate from above Step 1 was converted to the title compound. [00401] Analysis of 5-fluoro-N-hydroxy-6-(4-methylpiperazin-1-yl)nicotinamide [00402] 1H NMR (400 MHz, DMSO-d6) δ ppm 11.07 (s, 1 H) 9.03 (s, 1 H) 8.38 (s, 1 H) 7.74 (d, J=14.67 Hz, 1 H) 3.51 - 3.58 (m, 4 H) 2.40 - 2.45 (m, 4 H) 2.21 (s, 3 H) [00403] LC-MS: m/z [M+H]+ C11H15FN4O2 requires: 255.3, found: 255.1 [00404] HPLC tR (min) 1.46, 99% (10-100% ACN with 0.1 %TFA 10 min.) [00405] Example 28 [00406] Preparation of 5-chloro-N-hydroxy-6-morpholinonicotinamide (3)
Figure imgf000075_0002
[00407] Step 1: methyl 5-chloro-6-morpholinonicotinate [00408] To a 10 mL microwave vial were added methyl 5,6-dichloropyridine-3-carboxylate (100 mg, 0.485 mmol) and morpholine (1 mL, 23.9 mmol). The resulting mixture was stirred at MW (100 °C) for 2 h, then cooled to rt. The crude was mixed with silica gel, the volatiles were evaporated, and then purified by ISCO using EtOAc-Hexanes (0-20%) to provide the product as a white solid (35 mg, 28%). LC-MS: m/z [M+H]+ 257.1. [00409] Step 2: 5-chloro-N-hydroxy-6-morpholinonicotinamide [00410] Following the same experimental procedure as described in Example 1, methyl 5- chloro-6-morpholinonicotinate (35 mg, 0.14 mmol) from above Step 1 was converted to the title compound as a tan solid, 20 mg (57%). [00411] Analysis of 5-chloro-N-hydroxy-6-morpholinonicotinamide: [00412] 1H NMR (400 MHz, DMSO-d6) δ 11.23 (br, s, 1 H), 9.12 (s, 1 H), 8.56 (m, 1 H), 8.06 (m, 1 H), 3.73 (m, 4 H), 3.39 (m, 4 H). [00413] LC-MS: m/z [M+H]+ C10H12ClN3O3 requires: 257.1, found: 258.1 [00414] HPLC tR (min) 4.52, 100% (20-100% ACN with 0.1 %TFA 10 min.) [00415] Example 29 [00416] Preparation of 6-(benzhydrylamino)-5-fluoro-N-hydroxynicotinamide (I-17)
Figure imgf000076_0001
[00417] The title compound was synthesized by following the same experimental procedure as described in Example 12 employing 6-bromo-5-fluoropyridine-3-carboxylate and diphenylmethanamine instead. [00418] Analysis of 6-(benzhydrylamino)-5-fluoro-N-hydroxynicotinamide: [00419] 1H NMR (400 MHz, DMSO-d6) δ 10.97 (br, s, 1 H), 8.93 (s, 1 H), 8.22 (s, 1 H), 7.91 (m, 1 H), 87.66 (m, 1 H), 3.39-7.21 (m, 11 H), 6.59 (d, J=8.8 Hz, 1 H). [00420] LC-MS: m/z [M+H]+ C19H16FN3O2 requires: 337.1, found: 338.1 [00421] HPLC tR (min) 5.49, 100% (20-100% ACN with 0.1 %TFA 10 min.) [00422] Example 30 [00423] Preparation of 5-fluoro-N-hydroxy-6-((2-methyl-1H-benzo[d]imidazol-1- yl)methyl)nicotinamide (4)
Figure imgf000077_0001
[00424] Step 1: methyl 5-bromo-3-fluoropicolinate [00425] To a solution of 5-bromo-3-fluoropyridine-2-carboxylic acid in MeOH (40 mL) was added SOCl2 (2 mL) at rt slowly. The resulting mixture was stirred at 60 o C overnight. The volatiles were evaporated, the product was obtained as a white solid. (2.24 g, 100%). 1H NMR (400 MHz, DMSO-d6) δ 8.71 (m, 1 H), 8.44-8.41 (m, 1 H), 3.90 (s, 1 H); LC-MS: m/z [M+H]+ 233.9, 235.9. [00426] Step 2: (5-bromo-3-fluoropyridin-2-yl)methanol [00427] Methyl 5-bromo-3-fluoropyridine-2-carboxylate (1.2 g, 5.13 mmol) was dissolved in dry methanol (30 mL), sodium borohydride (813 mg, 15.4 mmol) was slowly added in an ice bath. The ice bath was removed after complete addition, the mixture was warmed to room temperature and stirred overnight, LC-MS showed complete conversion; then 1 N HCl was added to adjust PH 1, again was added saturated sodium bicarbonate solution to adjust PH 10, and then extracted with ethyl acetate, the organic phase was dried over anhydrous magnesium sulfate and filtered, concentrated under reduced pressure to give the crude, which was purified by ISCO column using EtOAc-Hexanes (0-40%) to afford the product as a white solid (800 mg, 76%).1H NMR (400 MHz, CDCl3) δ 8.49 (m, 1 H), 7.61-7.59 (m, 1 H), 4.80-4.79 (m, 2 H), 3.51 (t, J = 5.2 Hz, 1 H); LC-MS: m/z [M+H]+ 205.9, 207.9. [00428] Step 3: 5-bromo-2-(bromomethyl)-3-fluoropyridine [00429] To a stirred solution of (5-bromo-3-fluoropyridin-2-yl)methanol (0.25 g, 1.21 mmol) and triphenyl phosphine (0.51 g, 1.94 mmol) dichloromethane (10 mL) was added, a solution of CBr4 (0.644 g, 1.94 mmol) in DCM (5 mL) at 0° C dropwise, and allowed to stir at room temperature overnight. The reaction mixture was quenched with sat. NaHCO3, and extracted with dichloromethane twice. The combined organic layers were washed with brine, dried over sodium sulfate, concentrated and crude was purified by silica gel column chromatography using ethyl acetate/hexanes (0- 15%) as eluent to provide the product as a white solid (240 mg, 74%). 1H NMR (400 MHz, CDCl3) δ 8.49 (m, 1 H), 7.64-7.61 (m, 1 H), 4.57 (s, 2 H); LC-MS: m/z [M+H]+ 269.9, 271.9. [00430] Step 4: 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-2-methyl-1H- benzo[d]imidazole [00431] To a solution of 2-methyl-1H-1,3-benzodiazole (153 mg, 1.16 mmol) in dry DMF (3 mL) was added 60% NaH (46 mg, 1.16 mmol) at 0 o C, then the mixture was stirred at 0 o C for 20 min. A solution of 5-bromo-2-(bromomethyl)-3-fluoropyridine (240 mg, 1.0 mmol) in dry DMF (2 mL) was dropwise added. Th resulting mixture was stirred at 0 o C for 20 min and then rt overnight. The mixture was carefully quenched with water at 0 o C, diluted and worked up with EtOAc-water. The combined organic layers were dried over MgSO4, then residue DMF was removed under lyophilization. The crude was evaporated and subjected to ISCO purification using EtOAc-Hexanes (0-100%) to provide the product as a white solid (190 mg, 66%). LC-MS: m/z [M+H]+ 319.1, 321.1. [00432] Step 5: methyl 5-fluoro-6-((2-methyl-1H-benzo[d]imidazol-1-yl)methyl)nicotinate [00433] The title compound was synthesized by following the same experimental procedure as described in Example 17 (step 2) employing 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-2- methyl-1H-benzo[d]imidazole instead. LC-MS: m/z [M+H]+ 300.1. [00434] Step 6: 5-fluoro-N-hydroxy-6-((2-methyl-1H-benzo[d]imidazol-1- yl)methyl)nicotinamide [00435] The title compound was synthesized by following the same experimental procedure as described in Example 17 employing methyl 5-fluoro-6-((2-methyl-1H-benzo[d]imidazol-1- yl)methyl)nicotinate instead. [00436] Analysis of 5-fluoro-N-hydroxy-6-((2-methyl-1H-benzo[d]imidazol-1- yl)methyl)nicotinamide: [00437] 1H NMR (400 MHz, DMSO-d6) δ 11.35 (br, s, 1 H), 9.25 (s, 1 H), 8.59 (s, 1 H), 8.01 (m, 1 H), 7.51 (m, 1 H), 7.39 (m, 1 H), 7.13 (m, 2 H), 5.68 (s, 2 H). [00438] LC-MS: m/z [M+H]+ C15H13FN4O2 requires: 300.1, found: 301.1 [00439] HPLC tR (min) 1.65, 98% (10-100% ACN with 0.1 %TFA 10 min.) [00440] Example 31 [00441] Preparation of 5-fluoro-N-hydroxy-6-((3-oxo-2,3-dihydro-4H- benzo[b][1,4]oxazin-4-yl)methyl)nicotinamide (IV-7)
Figure imgf000079_0001
[00442] The title compound was synthesized by following the same experimental procedure as described in Example 30 employing 2H-benzo[b][1,4]oxazin-3(4H)-one instead. [00443] Analysis of 5-fluoro-N-hydroxy-6-((3-oxo-2,3-dihydro-4H-benzo[b][1,4]oxazin- 4-yl)methyl)nicotinamide: [00444] 1H NMR (400 MHz, DMSO-d6) δ 11.39 (br, s, 1 H), 9.28 (s, 1 H), 8.59 (s, 1 H), 7.98 (m, 1 H), 7.04-6.96 (m, 4 H), 5.34 (s, 2 H), 4.72 (s, 2 H). [00445] LC-MS: m/z [M+H]+ C15H12FN3O4 requires: 317.1, found: 318.1 [00446] HPLC tR (min) 4.76, 99% (10-100% ACN with 0.1 %TFA 10 min.) [00447] Example 32 [00448] Preparation of 6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-5-fluoro-N- hydroxynicotinamide (IV-8)
Figure imgf000079_0002
[00449] The title compound was synthesized by following the same experimental procedure as described in Example 30 employing 1,2,3,4-tetrahydroisoquinoline instead. [00450] Analysis of 6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-5-fluoro-N- hydroxynicotinamide: [00451] 1H NMR (400 MHz, DMSO-d6) δ 11.45 (br, s, 1 H), 9.41 (s, 1 H), 8.74 (s, 1 H), 7.97 (m, 1 H), 7.08-6.99 (m, 4 H), 3.86 (s, 2 H), 3.62 (s, 2 H), 2.77 (m, 4 H). [00452] LC-MS: m/z [M+H]+ C16H16FN3O2 requires: 301.1, found: 302.1 [00453] HPLC tR (min) 4.63, 97% (10-100% ACN with 0.1 %TFA 10 min.) [00454] Example 33 [00455] Preparation of 5-fluoro-N-hydroxy-6-((1-(pyridin-2- yl)cyclopropyl)amino)nicotinamide (I-18)
Figure imgf000080_0001
[00456] Step 1: 1-(pyridin-2-yl)cyclopropan-1-amine [00457] To an oven-dried 200 mL round-bottom flask containing a 1.5-inch egg-shaped stirbar under N2 atmosphere was added pyridine-2-carbonitrile (2.08 g, 20 mmol), followed by THF (80 mL). To the pale yellow solution was added titanium tetraisopropoxide (7.1 mL, 24 mmol, 1.2 equiv) all at once, yielding no visible changes. Ethylmagnesium bromide (3M in ether, 16.7 mL, 50 mmol, 2.5 equiv) was added dropwise over the course of 10 minutes with vigorous stirring, immediately yielding a viscous black opaque suspension (caution: exothermic, gas evolution). After stirring for 90 minutes at room temperature, the black suspension was cooled to 0 °C in an ice bath. Then, BF3.OEt2 (4.9 mL, 40 mmol, 2 equiv) was added dropwise over the course of 5 minutes (caution: exothermic, gas evolution). The ice bath was removed and the viscous black suspension was allowed to warm to room temperature overnight. The following day, the reaction was quenched by adding 1M NaOH (100 mL, 5 equiv) in small portions at first, followed by ethyl acetate (50 mL), and then stirred vigorously at room temperature for 2 hours to yield a biphasic mixture of a top orange organic layer and a bottom black aqueous emulsion. This biphasic mixture was filtered directly through water-wetted celite, washed once with water (50 mL) and once with ethyl acetate (50 mL). The filtrate was collected and the layers separated. The aqueous layer was extracted twice more with ethyl acetate (50 mL). The combined organic layers were washed twice with water (50 mL) and once with brine (25 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product was purified by column chromatography (Silica gel, 0 – 10% methanol in DCM with 1% NH4OH) to afford the title compound as a brown oil, 346 mg (13%). LC-MS: m/z [M+H]+ 135.1.
Figure imgf000081_0001
[00458] Step 2: 5-bromo-3-fluoro-N-(1-(pyridin-2-yl)cyclopropyl)pyridin-2-amine [00459] To a vial was added 1-(pyridin-2-yl)cyclopropan-1-amine (171 mg, 1.27 mmol), DMSO (3 mL), DIPEA (1.1 mL, 6.4 mmol, 5 equiv), and 5-bromo-2,3-difluoropyridine (0.26 mL, 1.9 mmol, 1.5 equiv). The biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic. The following day, LCMS analysis of the dark brown mixture reveals full conversion of the amine partner. The reaction was worked up by pouring into water (50 mL) and extracting three times with EtOAc (30 mL each). The combined organic layers were washed twice with water and once with brine, then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product, a brown oil, was dry-loaded onto silica gel and purified by column chromatography (Silica gel, 0 – 50% EtOAc/hexanes) to afford the title compound as a yellow oil that solidifies into a beige solid at room temperature, 185.3 mg (47%). LC-MS: m/z [M+H]+ 308.1, 310.1 (1:1 ratio).
Figure imgf000081_0002
[00460] Step 3: methyl 5-fluoro-6-((1-(pyridin-2-yl)cyclopropyl)amino)nicotinate [00461] To a vial was added 5-bromo-3-fluoro-N-(1-(pyridin-2-yl)cyclopropyl)pyridin-2- amine (85.0 mg, 0.28 mmol), followed by palladium diacetate (1.2 mg, 5 μmol, 0.02 equiv) and Xantphos (6.4 mg, 11 μmol, 0.04 equiv). Then, triethylamine (2 mL) and methanol (0.5 mL) were added, yielding a dark yellow heterogeneous suspension. The reaction mixture was sparged with a CO balloon for 1 minute, then the reaction mixture was heated to 70 °C overnight under a static CO atmosphere (CO balloon). The following day, LCMS analysis of the gray heterogeneous mixture reveals complete conversion of the bromide starting material. The reaction was worked up by dry-loading onto silica gel directly: the reaction was diluted with ethyl acetate (5 mL), silica gel (2 g) was added, and all volatiles were removed by rotary evaporation. The material was purified by column chromatography (Silica gel, 0 – 50% EtOAc/hexanes) to afford the title compound as a colorless oil, 51.7 mg (65%). LC-MS: m/z [M+H]+ 288.1.
Figure imgf000082_0001
[00462] Step 4: 5-fluoro-N-hydroxy-6-((1-(pyridin-2-yl)cyclopropyl)amino)nicotinamide [00463] To a vial was added methyl 5-fluoro-6-((1-(pyridin-2- yl)cyclopropyl)amino)nicotinate (28.3 mg, 0.098 mmol), followed by methanol (1 mL) and THF (1 mL). The colorless homogeneous solution was cooled to 0 °C in an ice bath. Then, 50% aqueous hydroxylamine (0.18 mL, 3.0 mmol, 30 equiv) was added all at once. Lastly, one pellet of KOH (55 mg, 1.0 mmol, 10 equiv) was added. The vial was capped, and the ice bath was removed. The reaction was allowed to warm to room temperature with vigorous stirring. After 1 hour, the reaction was quenched by addition of 1M HCl (3 mL, 30 equiv). The pH was tested via colorimetric strip and found to be pH 5-6. The reaction was poured into 50 mL half-saturated aqueous NaHCO3, then extracted three times with EtOAc (30 mL). The combined organic layers were washed once with half-saturated NaHCO3 (50 mL), once with brine (30 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation to afford the title compound as a pale yellow oil, 26.9 mg (95%) of high analytical purity. [00464] Analysis of 5-fluoro-N-hydroxy-6-((1-(pyridin-2- yl)cyclopropyl)amino)nicotinamide: [00465] 1H NMR (400 MHz, d6-DMSO), δ ppm 10.98 (br s, 1 H) 8.94 (br s, 1 H) 8.43 (d, J=4.16 Hz, 1 H) 8.17 (s, 1 H) 8.09 (s, 1 H) 7.67 (d, J=11.98 Hz, 1 H) 7.59 (t, J=7.59 Hz, 1 H) 7.24 (d, J=7.83 Hz, 1 H) 7.11 (dd, J=6.48, 5.26 Hz, 1 H) 1.51 - 1.64 (m, 2 H) 1.24 (br d, J=2.69 Hz, 2 H). [00466] LC-MS: m/z [M+H]+ C14H13FN4O2 requires: 288.1, found: 289.1. [00467] HPLC tR (min) 1.41, 97.8% (10-100% MeCN / H2O with 0.1% TFA, 10 min) [00468] Example 34 [00469] Preparation of 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5-fluoro-N- hydroxynicotinamide (I-19)
Figure imgf000083_0001
[00470] Step 1: 1-(2,6-difluorophenyl)cyclopropan-1-amine [00471] To an oven-dried 200 mL round-bottom flask containing a 1.5-inch egg-shaped stirbar under N2 atmosphere was added 2,6-difluorobenzonitrile (2.78 g, 20 mmol), followed by methyl tert-butyl ether (MTBE) (100 mL). The pale yellow solution was cooled to –78 °C. Titanium tetraisopropoxide (7.3 mL, 24 mmol, 1.2 equiv) was added all at once, yielding no visible changes. Ethylmagnesium bromide (3M in ether, 16.7 mL, 50 mmol, 2.5 equiv) was added dropwise over the course of 5 minutes with vigorous stirring, yielding a pale yellow homogeneous solution (caution: potential for exotherm and gas evolution). No gas evolution was observed in this case. The dry ice bath was left to expire slowly over the course of 4 hours with vigorous stirring (1500 RPM) of the solution. Upon warming to room temperature, a viscous opaque brown solution is formed. This solution was cooled to 0 °C in an ice bath. Then, BF3.OEt2 (4.9 mL, 40 mmol, 2 equiv) was added dropwise over the course of 5 minutes (caution: exothermic, gas evolution). The ice bath was removed and the opaque brown suspension was allowed to warm to room temperature overnight. The following day, the reaction was quenched by adding 1M NaOH (100 mL, 5 equiv) in small portions at first, followed by ethyl acetate (50 mL), and then stirred vigorously at room temperature for 2 hours to yield a biphasic mixture of a top colorless organic layer and a bottom dark blue aqueous emulsion. This biphasic mixture was filtered directly through water-wetted celite, washed once with water (50 mL) and once with ethyl acetate (50 mL). The filtrate was collected and the layers separated. The aqueous layer was extracted twice more with ethyl acetate (50 mL). The combined organic layers were washed twice with water (50 mL) and once with brine (25 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product was purified by column chromatography (Silica gel, 0 – 50% ethyl acetate in hexanes) to afford the title compound as a pale yellow oil, 1.66 g (49%). LC-MS: m/z [M+H]+ 170.1.
Figure imgf000084_0001
[00472] Step 2: 5-bromo-N-(1-(2,6-difluorophenyl)cyclopropyl)-3-fluoropyridin-2-amine [00473] To a vial was added 1-(2,6-difluorophenyl)cyclopropan-1-amine (304 mg, 1.80 mmol), DMSO (3 mL), DIPEA (1.57 mL, 9.0 mmol, 5 equiv), and 5-bromo-2,3-difluoropyridine (0.29 mL, 2.2 mmol, 1.2 equiv). The biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic. The following day, LCMS analysis of the dark brown mixture reveals full conversion of the amine partner. The reaction was worked up by pouring into water (50 mL) and extracting three times with EtOAc (30 mL each). The combined organic layers were washed twice with water and once with brine, then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product, a brown oil, was dry-loaded onto silica gel and purified by column chromatography (Silica gel, 0 – 25% EtOAc/hexanes) to afford the title compound as a pale yellow oil, 400.5 mg (65%). LC-MS: does not ionize.1H NMR (CDCl3): δ ppm 8.00 (s, 1 H) 7.22 (dd, J=10.15, 1.83 Hz, 1 H) 7.10 - 7.19 (m, 1 H) 6.81 (t, J=8.07 Hz, 2 H) 5.53 (br s, 1 H) 1.31 (s, 4 H).
Figure imgf000085_0001
[00474] Step 3: methyl 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5-fluoronicotinate [00475] To a vial was added 5-bromo-N-(1-(2,6-difluorophenyl)cyclopropyl)-3- fluoropyridin-2-amine (110 mg, 0.32 mmol), followed by palladium diacetate (1.4 mg, 6 μmol, 0.02 equiv) and Xantphos (7.4 mg, 13 μmol, 0.04 equiv). Then, triethylamine (2 mL) and methanol (0.5 mL) were added, yielding a pale yellow heterogeneous suspension. The reaction mixture was sparged with a CO balloon for 1 minute, then the reaction mixture was heated to 70 °C overnight under a static CO atmosphere (CO balloon). The following day, LCMS analysis of the gray heterogeneous mixture reveals complete conversion of the bromide starting material. The reaction was worked up by dry-loading onto silica gel directly: the reaction was diluted with ethyl acetate (5 mL), silica gel (2 g) was added, and all volatiles were removed by rotary evaporation. The material was purified by column chromatography (Silica gel, 0 – 40% EtOAc/hexanes) to afford the title compound as a colorless oil, 73.6 mg (72%). LC-MS: m/z [M+H]+ 323.1.
Figure imgf000085_0002
[00476] Step 4: 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5-fluoro-N- hydroxynicotinamide [00477] To a vial was added methyl 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5- fluoronicotinate (30.5 mg, 0.095 mmol), followed by methanol (1 mL) and THF (1 mL). The colorless homogeneous solution was cooled to 0 °C in an ice bath. Then, 50% aqueous hydroxylamine (0.17 mL, 2.8 mmol, 30 equiv) was added all at once. Lastly, one pellet of KOH (53 mg, 0.95 mmol, 10 equiv) was added. The vial was capped, and the ice bath was removed. The reaction was allowed to warm to room temperature with vigorous stirring. After 1 hour, the reaction was quenched by addition of 1M HCl (3 mL, 30 equiv). The pH was tested via colorimetric strip and found to be pH 5-6. The reaction was poured into 50 mL half-saturated aqueous NaHCO3, then extracted three times with EtOAc (30 mL). The combined organic layers were washed once with half-saturated NaHCO3 (50 mL), once with brine (30 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation to afford the title compound as a pale yellow oil, 37.6 mg (117%) of high analytical purity except for trace residual dichloromethane. [00478] Analysis of 6-((1-(2,6-difluorophenyl)cyclopropyl)amino)-5-fluoro-N- hydroxynicotinamide: [00479] 1H NMR (400 MHz, d6-DMSO), δ ppm 10.9 (br s, 1 H) 8.91 (br s, 1 H) 8.23 (s, 1 H) 7.82 (s, 1 H) 7.56 (d, J=12.23 Hz, 1 H) 7.28 (quin, J=7.40 Hz, 1 H) 6.97 (t, J=8.31 Hz, 2 H) 1.26 - 1.35 (m, 2 H) 1.14 - 1.23 (m, 2 H). [00480] LC-MS: m/z [M+H]+ C15H12F3N3O2 requires: 323.1, found: 324.1. [00481] HPLC tR (min) 5.03, 95.5% (10-100% MeCN / H2O with 0.1% TFA, 10 min) [00482] Example 35 [00483] Preparation of 5-fluoro-N-hydroxy-6-((1-(pyridin-3- yl)cyclopropyl)amino)nicotinamide (I-20)
Figure imgf000086_0001
[00484] Step 1: 1-(pyridin-3-yl)cyclopropan-1-amine [00485] To an oven-dried 200 mL round-bottom flask containing a 1.5-inch egg-shaped stirbar under N2 atmosphere was added pyridine-3-carbonitrile (2.08 g, 20 mmol), followed by methyl tert-butyl ether (MTBE) (100 mL). The colorless homogeneous solution was cooled to – 78 °C. Ethylmagnesium bromide (3M in ether, 16.7 mL, 50 mmol, 2.5 equiv) was added dropwise over the course of 5 minutes with vigorous stirring (caution: potential for exotherm and gas evolution). Titanium tetraisopropoxide (7.3 mL, 24 mmol, 1.2 equiv) was added dropwise over 5 minutes. No gas evolution was observed in this case. A bright orange solution was formed. The dry ice bath was removed after the addition of the above reagents. Upon warming to room temperature, a viscous opaque brown suspension is formed. After stirring at room temperature for 3 hours, the suspension was cooled to 0 °C in an ice bath. Then, BF3.OEt2 (4.9 mL, 40 mmol, 2 equiv) was added dropwise over the course of 5 minutes (caution: exothermic, gas evolution). The ice bath was removed and the opaque brown suspension was allowed to warm to room temperature overnight. The following day, the reaction was quenched by adding 1M NaOH (100 mL, 5 equiv) in small portions at first, followed by ethyl acetate (50 mL), and then stirred vigorously at room temperature for 2 hours to yield a biphasic mixture of a top pale yellow organic layer and a bottom yellow aqueous emulsion. This biphasic mixture was filtered directly through water-wetted celite, washed once with water (50 mL) and once with ethyl acetate (50 mL). The filtrate was collected and the layers separated. The aqueous layer was extracted twice more with ethyl acetate (50 mL). The combined organic layers were washed twice with water (50 mL) and once with brine (25 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product was purified by column chromatography (Silica gel, 0 – 10% methanol in DCM with 1% NH4OH) to afford the title compound as an orange oil, 822 mg (31%). LC-MS: m/z [M+H]+ 135.2.
Figure imgf000087_0001
[00486] Step 2: 5-bromo-3-fluoro-N-(1-(pyridin-3-yl)cyclopropyl)pyridin-2-amine [00487] To a vial was added 1-(pyridin-3-yl)cyclopropan-1-amine (134 mg, 1.0 mmol), DMSO (3 mL), DIPEA (0.87 mL, 5 mmol, 5 equiv), and 5-bromo-2,3-difluoropyridine (0.20 mL, 1.5 mmol, 1.5 equiv). The biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic. The following day, LCMS analysis of the dark brown mixture reveals full conversion of the amine partner. The reaction was worked up by pouring into water (50 mL) and extracting three times with EtOAc (30 mL each). The combined organic layers were washed twice with water and once with brine, then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product, a brown oil, was dry-loaded onto silica gel and purified by column chromatography (Silica gel, 0 – 100% EtOAc/hexanes) to afford the title compound as a pale orange oil, 127 mg (41%). LC-MS: m/z [M+H]+ 308.1, 310.1 (1:1 ratio).
Figure imgf000088_0001
[00488] Step 3: methyl 5-fluoro-6-((1-(pyridin-3-yl)cyclopropyl)amino)nicotinate [00489] To a vial was added 5-bromo-3-fluoro-N-(1-(pyridin-3-yl)cyclopropyl)pyridin-2- amine (44.6 mg, 0.15 mmol), followed by palladium diacetate (0.6 mg, 3 μmol, 0.02 equiv) and Xantphos (3.3 mg, 6 μmol, 0.04 equiv). Then, triethylamine (2 mL) and methanol (0.5 mL) were added, yielding a pale yellow heterogeneous suspension. The reaction mixture was sparged with a CO balloon for 1 minute, then the reaction mixture was heated to 70 °C overnight under a static CO atmosphere (CO balloon). The following day, LCMS analysis of the gray heterogeneous mixture reveals complete conversion of the bromide starting material. The reaction was worked up by dry-loading onto silica gel directly: the reaction was diluted with ethyl acetate (5 mL), silica gel (2 g) was added, and all volatiles were removed by rotary evaporation. The material was purified by column chromatography (Silica gel, 0 – 100% EtOAc/hexanes) to afford the title compound as a pale yellow waxy solid, 35.8 mg (86%). LC-MS: m/z [M+H]+ 288.1.
Figure imgf000088_0002
[00490] Step 4: 5-fluoro-N-hydroxy-6-((1-(pyridin-3-yl)cyclopropyl)amino)nicotinamide [00491] To a vial was added methyl 5-fluoro-6-((1-(pyridin-3- yl)cyclopropyl)amino)nicotinate (35.8 mg, 0.13 mmol), followed by methanol (1 mL) and THF (1 mL). The colorless homogeneous solution was cooled to 0 °C in an ice bath. Then, 50% aqueous hydroxylamine (0.23 mL, 3.7 mmol, 30 equiv) was added all at once. Lastly, one pellet of KOH (70 mg, 1.3 mmol, 10 equiv) was added. The vial was capped, and the ice bath was removed. The reaction was allowed to warm to room temperature with vigorous stirring. After 1 hour, the reaction was quenched by addition of 1M HCl (3 mL, 30 equiv). The pH was tested via colorimetric strip and found to be pH 5-6. The reaction was poured into 50 mL half-saturated aqueous NaHCO3, then extracted three times with EtOAc (30 mL). The combined organic layers were washed once with half-saturated NaHCO3 (50 mL), once with brine (30 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation to afford the title compound as a white powder, 25.3 mg (70%) of high analytical purity. [00492] 1H NMR (400 MHz, d6-DMSO), δ ppm 11.01 (br s, 1 H) 8.99 (br s, 1 H) 8.40 (br s, 1 H) 8.33 (br d, J=3.42 Hz, 1 H) 8.10 - 8.27 (two overlapping br s, 2 H) 7.65 (br d, J=12.47 Hz, 1 H) 7.54 (br d, J=7.34 Hz, 1 H) 7.23 - 7.30 (m, 1 H) 1.36 (br s, 2 H) 1.28 (br s, 2 H). [00493] LC-MS: m/z [M+H]+ C14H13FN4O2 requires: 288.1, found: 289.1. [00494] HPLC tR (min) 1.49, 76.7% with protonation state shoulder artifact at 1.65, 20.4%. Sum of both peaks is 97.1%. (10-100% MeCN / H2O with 0.1% TFA, 10 min) [00495] Example 36 [00496] Preparation of 5-fluoro-N-hydroxy-6-((2-(pyridin-2-yl)propan-2- yl)amino)nicotinamide (I-21)
Figure imgf000089_0001
[00497] Step 1: 2-(pyridin-2-yl)propan-2-amine [00498] To a vial containing pyridine-2-carbonitrile (521 mg, 5.0 mmol) was added toluene (6 mL). The pale orange-brown homogeneous solution was cooled to 0 °C in an ice bath. Methylmagnesium bromide (1.4 M in 3:1 toluene : THF, 8.9 mL, 12.5 mmol, 2.5 equiv) was added dropwise with vigorous stirring over 5 minutes. The resulting brown opaque solution was heated to 70 °C overnight under N2 atmosphere (balloon). The following day, LCMS analysis indicated complete conversion. The black heterogeneous mixture was worked up by cooling to 0 °C in an ice bath, then adding 1M HCl (20 mL) (caution: exothermic, gas evolution). The lower brown aqueous layer was separated from the top clear toluene layer. The aqueous layer was basified (pH > 10) using 1M NaOH (30 mL), then extracted three times with EtOAc (30 mL each). The combined organic layers were washed with water, then brine, then dried over MgSO4 and filtered and concentrated by rotary evaporation to provide the title compound as a brown oil, 485 mg (71%), which was taken forward without further purification. LC-MS: m/z [M+H]+ 137.1.
Figure imgf000090_0001
[00499] Step 2: 5-bromo-3-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)pyridin-2-amine [00500] To a vial was added 2-(pyridin-2-yl)propan-2-amine (144 mg, 1.06 mmol), DMSO (2 mL), DIPEA (0.92 mL, 5.3 mmol, 5 equiv), and 5-bromo-2,3-difluoropyridine (0.21 mL, 1.6 mmol, 1.5 equiv). The biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic. The following day, LCMS analysis of the dark brown mixture reveals full conversion of the amine partner. The reaction was worked up by pouring into water (50 mL) and extracting three times with EtOAc (30 mL each). The combined organic layers were washed twice with water and once with brine, then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product, a brown oil, was dry-loaded onto silica gel and purified by column chromatography (Silica gel, 0 – 25% EtOAc/hexanes) to afford the title compound as a yellow oil, 199.5 mg (61%). LC-MS: m/z [M+H]+ 310.1, 312.1 (1:1 ratio).
Figure imgf000090_0002
[00501] Step 3: methyl 5-fluoro-6-((2-(pyridin-2-yl)propan-2-yl)amino)nicotinate [00502] To a vial was added the oil 5-bromo-3-fluoro-N-(2-(pyridin-2-yl)propan-2- yl)pyridin-2-amine (63.4 mg, 0.20 mmol), followed by palladium diacetate (1 mg, 4 μmol, 0.02 equiv) and Xantphos (4.7 mg, 8 μmol, 0.04 equiv). Then, triethylamine (2 mL) and methanol (0.5 mL) were added, yielding a pale yellow heterogeneous suspension. The reaction mixture was sparged with a CO balloon for 1 minute, then the reaction mixture was heated to 70 °C overnight under a static CO atmosphere (CO balloon). The following day, LCMS analysis of the gray heterogeneous mixture reveals complete conversion of the bromide starting material. The reaction was worked up by dry-loading onto silica gel directly: the reaction was diluted with ethyl acetate (5 mL), silica gel (2 g) was added, and all volatiles were removed by rotary evaporation. The material was purified by column chromatography (Silica gel, 0 – 30% EtOAc/hexanes) to afford the title compound as a colorless oil, 44.1 mg (75%). LC-MS: m/z [M+H]+ 290.1.
Figure imgf000091_0001
[00503] Step 4: 5-fluoro-N-hydroxy-6-((2-(pyridin-2-yl)propan-2-yl)amino)nicotinamide [00504] To a vial was added methyl 5-fluoro-6-((2-(pyridin-2-yl)propan-2- yl)amino)nicotinate (44.1 mg, 0.15 mmol), followed by methanol (1 mL) and THF (1 mL). The colorless homogeneous solution was cooled to 0 °C in an ice bath. Then, 50% aqueous hydroxylamine (0.28 mL, 4.5 mmol, 30 equiv) was added all at once. Lastly, one pellet of KOH (85 mg, 1.5 mmol, 10 equiv) was added. The vial was capped, and the ice bath was removed. The reaction was allowed to warm to room temperature with vigorous stirring. After 1 hour, the reaction was quenched by addition of 1M HCl (3 mL, 20 equiv). The pH was tested via colorimetric strip and found to be pH 5-6. The reaction was poured into 50 mL half-saturated aqueous NaHCO3, then extracted three times with EtOAc (30 mL). The combined organic layers were washed once with half-saturated NaHCO3 (50 mL), once with brine (30 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation to afford the title compound as a solid yellow powder, 37.7 mg (85%) of high analytical purity. [00505] Analysis of 5-fluoro-N-hydroxy-6-((2-(pyridin-2-yl)propan-2- yl)amino)nicotinamide: [00506] 1H NMR (400 MHz, d6-DMSO), δ ppm 10.92 (br s, 1 H) 8.91 (s, 1 H) 8.51 (d, J=4.65 Hz, 1 H) 8.06 (s, 1 H) 7.71 (t, J=7.83 Hz, 1 H) 7.63 (br d, J=12.47 Hz, 1 H) 7.39 - 7.49 (m, 2 H) 7.22 (dd, J=6.85, 5.38 Hz, 1 H) 1.76 (s, 6 H). [00507] LC-MS: m/z [M+H]+ C14H15FN4O2 requires: 290.1, found: 291.1. [00508] HPLC tR (min) 3.67, 98.8% (10-100% MeCN / H2O with 0.1% TFA, 10 min) [00509] Example 37 [00510] Preparation of 5-fluoro-N-hydroxy-6-(methyl(1- phenylcyclopropyl)amino)nicotinamide (I-22)
Figure imgf000092_0001
[00511] Step 1: 5-bromo-3-fluoro-N-(1-phenylcyclopropyl)pyridin-2-amine [00512] To a vial was added 1-phenylcyclopropan-1-amine (244 mg, 1.83 mmol), DMSO (3 mL), DIPEA (1.7 mL, 10 mmol, 5 equiv), and 5-bromo-2,3-difluoropyridine (0.40 mL, 3.0 mmol, 1.5 equiv). The biphasic homogeneous mixture was heated to 120 °C overnight under N2 atmosphere (balloon). Upon reaching 120 °C, the reaction becomes monophasic. The following day, LCMS analysis of the dark orange mixture reveals full conversion of the amine partner. The reaction was worked up by pouring into water (50 mL) and extracting three times with EtOAc (30 mL each). The combined organic layers were washed twice with water and once with brine, then dried over MgSO4, filtered and concentrated by rotary evaporation. The crude product, an orange oil, was dry-loaded onto silica gel and purified by column chromatography (Silica gel, 0 – 20% EtOAc/hexanes) to afford the title compound as a grainy oil, which was triturated from hexanes (2 mL) at room temperature to yield a crystalline white solid, 208.1 mg (34%). LC-MS: m/z [M+H]+ 307.2, 309.2 (1:1 ratio).
Figure imgf000092_0002
[00513] Step 2: 5-bromo-3-fluoro-N-methyl-N-(1-phenylcyclopropyl)pyridin-2-amine [00514] To a vial was added 5-bromo-3-fluoro-N-(1-phenylcyclopropyl)pyridin-2-amine (59.4 mg, 0.19 mmol) dissolved in THF (1 mL). The reaction was cooled to 0 °C in an ice bath. Sodium hydride (60 wt% in mineral oil, 40 mg, 1 mmol, 5 equiv) was added all at once, and the reaction was allowed to warm to room temperature for 10 minutes with vigorous stirring open to air (caution: gas evolution), yielding a beige suspension. Then, iodomethane (62 μL, 1 mmol, 5 equiv) was added all at once. The reaction was left to stir at room temperature for 2 hours, after which point TLC and LCMS analysis indicate complete, clean conversion. The reaction was worked up by pouring into water (50 mL), and then extracted three times with EtOAc (30 mL). The combined organic layers were washed with water (30 mL), then brine (30 mL), dried over MgSO4, filtered and concentrated by rotary evaporation to yield the title product as a brown oil of reasonable purity, which was taken forward to the next step without further purification. LC-MS: m/z [M+H]+ 321.2, 323.2 (1:1 ratio).
Figure imgf000093_0001
[00515] Step 3: methyl 5-fluoro-6-(methyl(1-phenylcyclopropyl)amino)nicotinate [00516] To a vial was added 5-bromo-3-fluoro-N-methyl-N-(1-phenylcyclopropyl)pyridin- 2-amine (69.5 mg, 0.22 mmol), followed by palladium diacetate (1 mg, 4 μmol, 0.02 equiv) and Xantphos (5.0 mg, 9 μmol, 0.04 equiv). Then, triethylamine (2 mL) and methanol (0.5 mL) were added, yielding an orange heterogeneous suspension. The reaction mixture was sparged with a CO balloon for 1 minute, then the reaction mixture was heated to 70 °C overnight under a static CO atmosphere (CO balloon). The following day, LCMS analysis of the gray heterogeneous mixture reveals complete conversion of the bromide starting material. The reaction was worked up by dry- loading onto silica gel directly: the reaction was diluted with ethyl acetate (5 mL), silica gel (2 g) was added, and all volatiles were removed by rotary evaporation. The material was purified by column chromatography (Silica gel, 0 – 15% EtOAc/hexanes) to afford the title compound as a colorless oil, 32.6 mg (50%). LC-MS: m/z [M+H]+ 301.1.
Figure imgf000093_0002
[00517] Step 4: methyl 5-fluoro-6-(methyl(1-phenylcyclopropyl)amino)nicotinate [00518] To a vial was added methyl 5-fluoro-6-((1-(pyridin-2- yl)cyclopropyl)amino)nicotinate (32.6 mg, 0.11 mmol), followed by methanol (1 mL) and THF (1 mL). The colorless homogeneous solution was cooled to 0 °C in an ice bath. Then, 50% aqueous hydroxylamine (0.20 mL, 3.3 mmol, 30 equiv) was added all at once. Lastly, one pellet of KOH (61 mg, 1.1 mmol, 10 equiv) was added. The vial was capped, and the ice bath was removed. The reaction was allowed to warm to room temperature with vigorous stirring. After 1 hour, the reaction was quenched by addition of 1M HCl (3 mL, 30 equiv). The pH was tested via colorimetric strip and found to be pH 5-6. The reaction was poured into 50 mL half-saturated aqueous NaHCO3, then extracted three times with EtOAc (30 mL). The combined organic layers were washed once with half-saturated NaHCO3 (50 mL), once with brine (30 mL), then dried over MgSO4, filtered and concentrated by rotary evaporation to afford the title compound as a pale yellow oil, 32.2 mg (98%) of high analytical purity. [00519] Analysis of methyl 5-fluoro-6-(methyl(1-phenylcyclopropyl)amino)nicotinate: [00520] 1H NMR (400 MHz, d6-DMSO), δ ppm 11.06 (br s, 1 H) 9.00 (br s, 1 H) 8.38 (s, 1 H) 7.66 (br d, J=13.69 Hz, 1 H) 7.27 - 7.34 (m, 2 H) 7.15 - 7.21 (m, 1 H) 7.08 (d, J=8.07 Hz, 2 H) 3.18 (s, 3 H) 1.38 (br d, J=6.85 Hz, 4 H). [00521] LC-MS: m/z [M+H]+ C16H16FN3O2 requires: 301.1, found: 302.1. [00522] HPLC tR (min) 5.47, 99.0% (10-100% MeCN / H2O with 0.1% TFA, 10 min)
Figure imgf000094_0001
[00523] A mixture of methyl 6-bromo-5-fluoropyridine-3-carboxylate (70 mg, 0.3 mmol), cyclopropylboronic acid (128 mg, 1.5 mmol), potassium carbonate (62.0 mg, 0.45 mmol) in 1,4- dioxane (1.5 mL) was flushed with nitrogen for 10 min. [1,1′- Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (43.8 mg, 0.06 mmol) was added and the mixture was flushed with nitrogen again for 5 min and heated in microwave at 110 °C for 4h. LCMS showed complete conversion. The mixture was partitioned in ethyl acetate and water. The layers were separated. The aqueous layer was extracted with ethyl acetate (2x) and the combined organic layers were filtered over a pad of celite. The filtrate was concentrated to half of the volume and washed with water (3x), brine and concentrated to give 169 mg crude volatile oil. This material was purified by column chromatography (4 g SiO2, 0-10% ethyl acetate in hexane). Fractions containing the desired product were combined and collected to 55.3 mg (95%) colorless oil. [00524] Methyl 6-cyclopropyl-5-fluoropyridine-3-carboxylate: [00525] LCMS m/z [M+H]+ C9H9FN2O2 requires: 195.07, found 195.1 [00526] 1H NMR (400 MHz, CDCl3) δ= 8.85 (s, 1 H), 7.85 (dd, J=9.90, 1.59 Hz, 1 H), 3.94 (s, 3 H), 2.35 - 2.45 (m, 1 H), 1.19 - 1.26 (m, 2 H), 1.09 - 1.15 (m, 2 H) ppm. [00527] A mixture of methyl 6-cyclopropyl-5-fluoropyridine-3-carboxylate (55.3 mg, 0.283 mmol), methanol (1 mL), and THF (1 mL) was cooled to 0 °C. Hydroxylamine (0.52 mL, 50 wt% in water, 8.5 mmol) was added in a dropwise fashion, potassium hydroxide (80 mg, 1.42 mmol) was added in one portion, then reaction was stirred warming to room temperature. After 10 min, reaction complete by LCMS. Reaction mixture was concentrated under reduced pressure to remove organic solvents. The crude mixture was then diluted with water and neutralized to pH 7 with 1 M HCl (aq). The product was extracted with EtOAc (3x), dried over Na2SO4, then concentrated to yield 39.1 mg (70%) product colorless solid. [00528] 6-cyclopropyl-5-fluoro-N-hydroxypyridine-3-carboxamide [00529] LCMS m/z [M+H]+ C9H9FN2O2 requires: 196.06, found 197.1 [00530] HPLC method 2 Rt (min) purity 3.5, 99% 1H NMR (400 MHz, CD3OD) δ= 8.57 (s, 1 H), 7.77 (d, J=10.27 Hz, 1 H), 2.31 - 2.46 (m, 1 H), 1.08 - 1.16 (m, 4 H) ppm. [00531] Example 38 [00532] Preparation of 5-fluoro-N-hydroxy-6-{[3-(pyridin-2-yl)oxetan-3-yl]oxy}pyridine- 3-carboxamide (III-2)
Figure imgf000095_0001
[00533] Step 1: 3-(pyridin-2-yl)oxetan-3-ol [00534] A solution of 2-bromopyridine (0.91 μL, 9.5 mmol) in 50 mL of THF was cooled to -78 °C and stirred for 30 min under nitrogen.1 equiv of n-BuLi (2.5 M solution in hexanes, 4.5 mL, 11.4 mmol) was slowly added over a period of 5 min. The solution was stirred for 2 hrs at - 78 °C after which oxetan-3-one (560 μL, 9.5 mmol) was added and the reaction solution was brought up to room temperature and stirred overnight under nitrogen. The reaction mixture was quenched with a saturated aqueous ammonium chloride solution and extracted with EtOAc. The organic layer was washed with brine and dried over MgSO4. The organic layer was evaporated to an oil on a rotary evaporator that was dried onto silica. The product was purified by column chromatography using a Hex:EtOAc gradient 0-55%. to afford the title compound as a colorless oil, 517 mg (35%). [00535] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.52 (br d, J=4.89 Hz, 1 H) 8.00 (d, J=7.83 Hz, 1 H) 7.89 (t, J=7.32 Hz, 1 H) 7.33 (t, J=6.05 Hz, 1 H) 6.03 (s, 1 H) 5.11 (d, J=7.09 Hz, 2 H) 4.74 (d, J=6.85 Hz, 2 H) [00536] Step 2: 5-bromo-3-fluoro-2-{[3-(pyridin-2-yl)oxetan-3-yl]oxy}pyridine [00537] 3-(pyridin-2-yl)oxetan-3-ol (200 mg, 1.32 mmol) was dissolved in THF (13 mL) under nitrogen and cooled in an ice-bath. NaH (60% in mineral oil, 80 mg) was added in portions and the mixture stirred for 30-45 min. Then, 5-bromo-2,3-difluoropyridine (385 mg, 1.98 mmol) was added dropwise and the mixture heated to 60 °C overnight. After completion, the reaction was cooled to room temperature and quenched with saturated ammonium chloride. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over MgSO4, filtered and concentrated. The product was purified by column chromatography using a Hex:EtOAc gradient 0-100% to afford the title compound as a colorless oil, 364 mg (85%). [00538] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.71 (d, J=5.09 Hz, 1 H) 7.69 - 7.73 (m, 1 H) 7.59 - 7.64 (m, 1 H) 7.56 (dd, J=9.05, 1.96 Hz, 1 H) 7.19 - 7.31 (m, 2 H) 5.22 (d, J=7.58 Hz, 2 H) 5.13 (d, J=7.34 Hz, 2 H) [00539] Step 3: methyl 5-fluoro-6-{[3-(pyridin-2-yl)oxetan-3-yl]oxy}pyridine-3- carboxylate [00540] A mixture of 5-bromo-3-fluoro-2-{[3-(pyridin-2-yl)oxetan-3-yl]oxy}pyridine (340 mg, 1.05 mmol), Palladium(II) acetate (9.47 mg, 0.0418 mmol) and Xantphos (48.4 mg, 0.0837 mmol) in MeOH (1.3 mL) and TEA (10 mL) was sparged with CO for 5-10 minutes and then heated to 72 °C overnight. After completion of reaction, the mixture was diluted with ethyl acetate and filtered through a pad of celite. The filtrate was washed with water followed by brine. The combined organic layers were dried over MgSO4, filtered and concentrated. The product was purified by column chromatography using a Hex:EtOAc gradient 0-100% to afford the title compound as a white solid, 268 mg (85%). [00541] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.71 (br d, J=4.65 Hz, 1 H) 8.32 (s, 1 H) 7.93 - 8.00 (m, 1 H) 7.61 (t, J=7.83 Hz, 1 H) 7.30 (d, J=8.07 Hz, 1 H) 7.18 - 7.24 (m, 1 H) 5.23 - 5.28 (m, 2 H) 5.17 (d, J=7.34 Hz, 2 H) 3.88 (s, 3 H) [00542] Step 4: 5-fluoro-N-hydroxy-6-{[3-(pyridin-2-yl)oxetan-3-yl]oxy}pyridine-3- carboxamide [00543] Methyl 5-fluoro-6-{[3-(pyridin-2-yl)oxetan-3-yl]oxy}pyridine-3-carboxylate (100 mg, 0.33 mmol) was dissolved in THF:MeOH (1:1, 3 mL) and cooled in an ice-bath with stirring. Hydroxylamine (50% solution in water, 0.3 mL, 9.89 mmol)) was added dropwise followed by KOH (94.2 mg, 1.65 mmol). The ice-bath was removed and the reaction stirred until complete consumption of starting material. After completion, the reaction mixture was concentrated, diluted with water and neutralized (pH=7) with 2N HCl. The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO4, filtered and concentrated to afford the title compound as a white solid, 99 mg (99%). 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.60 (br d, J=4.16 Hz, 1 H) 8.02 (s, 1 H) 7.90 (br d, J=11.00 Hz, 1 H) 7.71 - 7.81 (m, 1 H) 7.45 (d, J=7.83 Hz, 1 H) 7.27 - 7.35 (m, 1 H) 5.18 - 5.23 (m, 2 H) 5.13 (d, J=7.34 Hz, 2 H) [00544] LC-MS: tR (min) 4.20 (20-100% ACN with 0.1 %TFA 6 min), m/z [M+H]+ C14H12FN3O4 requires: 305.27; found 306.0 HPLC tR (min) 4.04, 100% (20-100% ACN with 0.1 %TFA 10 min.) [00545] Example 39 [00546] Synthesis of 5-fluoro-N-hydroxy-6-((1-(pyrimidin-2- yl)cyclopropyl)amino)nicotinamide (I-46)
Figure imgf000098_0001
[00547] 1-(pyrimidin-2-yl)cyclopropan-1-amine [00548] To a cooled (15 °C) light suspension of pyrimidine-2-carbonitrile (5.00 g, 47.6 mmol) in dry THF (120 mL, 0.2 M) was added Titanium isopropoxide (14.9 g, 42.3 mmol, 15.9 mL), followed by ethyl magnesium bromide (20.8 g, 97.5 mmol, 32.5 mL) dropwise within 15 min. Towards the end, the reaction was slightly exothermic, addition rate was decreased accordingly. (inner temp ca. 50 °C). After complete addition the mixture was stirred for 45 min until TLC indicated complete conversion of the starting material. The mixture was quenched with water (20 mL), stirred for 10 min, then added with 2N NaOH (75 mL) and stirred for 20 min. The fine suspension was filtered through a pad of celite (slow filtration). The pad of celite was washed with ethyl acetate. More water was added to the filtrate. The layers were separated. The aqueous layer was extracted with ethyl acetate (2x). The combined organics were washed with brine, dried (Na2SO4) and concentrated to give 615 mg (10%) of 1-(pyrimidin-2-yl)cyclopropan-1-amine. 1H NMR (400 MHz, CDCl3) δ= 8.62 (d, J=4.65 Hz, 2 H), 7.05 (t, J=4.89 Hz, 1 H), 2.05 (s, 2 H), 1.42 - 1.48 (m, 2 H), 1.20-1.24 (m, 2 H) ppm [00549] 5-bromo-3-fluoro-N-(1-(pyrimidin-2-yl)cyclopropyl)pyridin-2-amine A mixture of 1-(pyrimidin-2-yl)cyclopropan-1-amine (202 mg, 1.49 mmol), 5-bromo-2,3- difluoropyridine (522 mg, 2.69 mmol) and DIPEA (7.47 mmol, 966 mg, 1.3 mL) in DMSO (6 mL) was stirred at 110 °C for 40 hours. After completion of the reaction as indicated by TLC the mixture was poured into water (60 mL) and extracted with ethyl acetate (3x). The combined organics were washed with water (3x), brine and dried (Na2SO4) and concentrated to give 551 mg brown oil. The crude material was purified by column chromatography (24 g SiO2, 0-30% EA in hexane). Fractions containing the desired product were combined and concentrated to give 132 mg (29%) 5-bromo-3-fluoro-N-(1-(pyrimidin-2-yl)cyclopropyl)pyridin-2-amine as yellow solid. [00550] 1H NMR (400 MHz, CDCl3) δ= 8.56 (d, J=4.89 Hz, 2 H), 7.88 (s, 1 H), 7.28 - 7.37 (m, 1 H), 7.02 (t, J=4.89 Hz, 1 H), 5.63 (br s, 1 H), 1.77 - 1.86 (m, 2 H), 1.38 - 1.45 (m, 2 H) ppm. [00551] Methyl 5-fluoro-6-((1-(pyrimidin-2-yl)cyclopropyl)amino)nicotinate [00552] A mixture of 5-bromo-3-fluoro-N-[1-(pyrimidin-2-yl)cyclopropyl]pyridin-2-amine (112 mg, 0.362 mmol), Palladium(II) acetate (3.25 mg, 0.0145 mmol), Xantphos (16.8 mg, 0.029 mmol) in anhydrous triethylamine (3.62 mL, 0.1 M based on starting material) and anhydrous methanol (10.9 mmol, 1.07 mL, 30 equiv.) was flushed with CO (balloon) for 5 min with the needle being in the solution. After 5 min needle was taken out of the solution such that it hovered above the mixture and stirred at 70 °C. After 16 hours LCMS indicated complete conversion. The mixture was partitioned in water and ethyl acetate. The layers were separated and the aqueous was extracted with ethyl acetate (2x). The combined organics were washed with water (2x), brine, dried (Na2SO4) and concentrated to give 113 mg crude material. It was purified by column chromatography (4 g SiO2, 0-60% EA in hexane). Fractions containing the desired product were combined and concentrated to give 89.1 mg (85%) methyl 5-fluoro-6-((1-(pyrimidin-2- yl)cyclopropyl)amino)nicotinate as off-white solid. 1H NMR (400 MHz, CDCl3) δ= 8.55 (d, J=4.89 Hz, 2 H), 8.52 (s, 1 H), 7.68 - 7.76 (m, 1 H), 7.03 (t, J=4.89 Hz, 1 H), 5.99 (br s, 1 H), 3.85 (s, 3 H), 1.84-1.88 (m, 2 H), 1.42 - 1.51 (m, 2 H) ppm. [00553] 5-fluoro-N-hydroxy-6-((1-(pyrimidin-2-yl)cyclopropyl)amino)nicotinamide To a cooled solution (0 °C) of methyl 5-fluoro-6-{[1-(pyrimidin-2- yl)cyclopropyl]amino}pyridine-3-carboxylate (86 mg, 0.298 mmol) in methanol (2 mL) and THF (2 mL) was added dropwise NH2OH (591 mg, 50%w/w, 8.95 mmol, 547 uL) followed by KOH in one portion (124 mg, 2.21 mmol).5 min after complete addition the bath was removed, stirred at rt. After 15 min LCMS indicated complete conversion. The reaction mixture was concentrated under reduced pressure to remove organic solvents. The crude mixture was then diluted with water and neutralized to pH 7 by addition of 1 M HCl (aq). The product was extracted with EtOAc (3x), dried over Na2SO4 and concentrated to yield 52.1 mg (60%) 5- fluoro-N-hydroxy-6-((1-(pyrimidin-2-yl)cyclopropyl)amino)nicotinamide as pinkish solid. [00554] 1H NMR (400 MHz, MeOD ) δ= 8.60 (d, J=4.89 Hz, 2 H), 8.14 (s, 1 H), 7.58 - 7.69 (m, 1 H), 7.21 (t, J=4.89 Hz, 1 H), 1.78 - 1.86 (m, 2 H),1.40 - 1.47 (m, 2 H) ppm. LC-MS: tR (min) 1.10, m/z [M+H]+ C13H12FN5O2 require: 290.3, found 291.1 (20-100% ACN with 0.1 %TFA 6 min.) [00555] HPLC tR (min) 1.88, 99% (20-100% ACN with 0.1 %TFA 10 min.) [00556] Example 40 [00557] Preparation of N-cyclopropyl-1-((3-fluoro-5-(hydroxycarbamoyl)pyridin-2- yl)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (I-55) [00558]
Figure imgf000100_0001
[00559] Step 1: methyl 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3- b]pyridine-5-carboxylate [00560] To a solution of methyl 1H-pyrrolo[2,3-b]pyridine-5-carboxylate (170 mg, 0.97 mmol) in dry DMF (3 mL) was added 60% NaH (38 mg, 0.97 mmol) at 0 o C, then the mixture was stirred at 0 o C for 20 min. A solution of 5-bromo-2-(bromomethyl)-3-fluoropyridine (200 mg, 0.74 mmol) in dry DMF (2 mL) was dropwise added. The resulting mixture was stirred at 0 o C for 20 min and then rt overnight. The mixture was carefully quenched with water at 0 o C, diluted and worked up with EtOAc-water. The combined organic layers were dried over MgSO4, then residual DMF was removed under lyophilization. The crude was then subjected to ISCO purification using MeOH-DCM (0-10%) to provide the product as a white solid (230 mg, 85%). LC-MS: m/z [M+H]+ 364.0, 366.0. [00561] Step 2: 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-5- carboxylic acid [00562] To a 20 mL of vial with methyl 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-1H- pyrrolo[2,3-b]pyridine-5-carboxylate (230 mg, 0.63 mmol) were added LiOH.H2O (53 mg, 2.1 mmol) and THF-MeOH-H2O (v/v/v 1:1:1, 6 mL). The mixture was then stirred at 50 o C overnight. LC-MS showed completed conversion. The volatiles were evaporated. Then water (~ 10 mL) was added, and 1 N HCl (~ 2 mL) was added to adjust pH to 6. The white solid was filtered and washed with water (~ 20 mL) and EtOAc (~ 10 mL). (200 mg product obtained as a colorless solid after dried over lyophilization overnight). LC-MS: 350.1, 352.1. [00563] Step 3: 1-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-cyclopropyl-1H-pyrrolo[2,3- b]pyridine-5-carboxamide [00564] The crude acid from previous step (110 mg, 0.31 mmol) was dissolved in DMF (4 mL), then cyclopropanamine (21 mg, 0.37 mmol), EDCI (72 mg, 0.37 mmol), HOBt (51 mg, 0.37 mmol) and DIPEA (102 mg, 0.78 mmol) were added. The mixture was then allowed to stir at rt for 3 h, then poured into water (15 mL) and the product extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo to provide the crude, which was purified by ISCO using 10% MeOH in DCM : DCM (0-60%) as eluent to afford the product as a white solid. LC-MS: 389.1, 391.1.1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1 H), 7.38 (m, 1 H), 6.59 (m, 1 H), 4.99 (br s, 1 H), 2.27 (m, 1H), 1.70 (m, 2 H), 0.96 (m, 2 H), 0.74 (m, 2 H), 0.45 (m, 2 H). [00565] The last two steps followed the same experimental procedure as described in 5- fluoro-N-hydroxy-6-((2-methyl-1H-benzo[d]imidazol-1-yl)methyl)nicotinamide employing 1- ((5-bromo-3-fluoropyridin-2-yl)methyl)-N-cyclopropyl-1H-pyrrolo[2,3-b]pyridine-5- carboxamide instead. [00566] Analysis of N-cyclopropyl-1-((3-fluoro-5-(hydroxycarbamoyl)pyridin-2- yl)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide: [00567] 1H NMR (400 MHz, DMSO-d6) δ 11.41 (br s, 1 H), 9.33 (s, 1 H), 8.64 (s, 1 H), 8.56 (m, 1 H), 8.46 (m, 1 H), 8.41 (m, 1 H), 8.00 (m, 1 H), 7.67 (m, 1 H), 6.63 (m, 1 H), 5.75 (s, 2 H), 0.71 (m, 2 H), 0.58 (m, 2 H). [00568] LC-MS: m/z [M+H]+ C18H16FN5O3 requires: 369.3, found: 370.1 [00569] HPLC tR (min) 4.73, 100% (10-100% ACN with 0.1 %TFA 10 min.) [00570] Example 41 [00571] Preparation of 5-fluoro-6-{[1-(3-fluoropyridin-2-yl)cyclopropyl]amino}-N- hydroxypyridine-3-carboxamide (I-45)
Figure imgf000102_0001
[00572] Step 1: 5-bromo-3-fluoro-N-[1-(3-fluoropyridin-2-yl)cyclopropyl]pyridin-2-amine [00573] N-Ethyldiisopropylamine (0.42 mL, 2.46) was added to a mixture of 5-bromo-2,3- difluoropyridine (191 mg, .986 mmol) and 1-(3-fluoropyridin-2-yl)cyclopropan-1-amine (75 mg, 0.493 mmol) in anhydrous DMSO (2.5 mL) under nitrogen. The reaction mixture was stirred at 110 °C overnight. After completion of reaction, the mixture was cooled, diluted with water and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over MgSO4, filtered and concentrated. The product was purified by column chromatography using a Hex:EtOAc gradient 0-100% to afford the title compound as a yellow solid, 71 mg (44%). [00574] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.30 (br d, J=4.65 Hz, 1 H) 7.92 (s, 1 H) 7.21 - 7.32 (m, 3 H) 7.12 (dt, J=8.31, 4.16 Hz, 1 H) 5.66 (br s, 1 H) 1.68 - 1.74 (m, 2 H) 1.27 - 1.33 (m, 2 H) [00575] Step 2: methyl 5-fluoro-6-{[1-(3-fluoropyridin-2-yl)cyclopropyl]amino}pyridine- 3-carboxylate [00576] A mixture of 5-bromo-3-fluoro-N-[1-(3-fluoropyridin-2-yl)cyclopropyl]pyridin-2- amine (71 mg, 0.218 mmol), Palladium(II) acetate (1.97 mg, 0.0087 mmol) and Xantphos (10.1 mg, 0.0174 mmol) in MeOH (0.5 mL) and TEA (2 mL) was sparged with CO for 5-10 minutes and then heated to 72 °C overnight. After completion of reaction, the mixture was diluted with ethyl acetate and filtered through a pad of celite. The filtrate was washed with water followed by brine. The combined organic layers were dried over MgSO4, filtered and concentrated. The product was purified by column chromatography using a Hex:EtOAc gradient 0-100% to afford the title compound as a white solid, 49.2 mg (74%). [00577] 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.55 (s, 1 H) 8.28 - 8.33 (m, 1 H) 7.68 (dd, J=11.49, 0.73 Hz, 1 H) 7.28 (br d, J=2.45 Hz, 1 H) 7.12 (dt, J=8.25, 4.07 Hz, 1 H) 6.06 (br s, 1 H) 3.84 (s, 3 H) 1.71 - 1.82 (m, 2 H) 1.24 - 1.40 (m, 3 H) [00578] Step 3: 5-fluoro-6-{[1-(3-fluoropyridin-2-yl)cyclopropyl]amino}-N- hydroxypyridine-3-carboxamide [00579] methyl 5-fluoro-6-{[1-(3-fluoropyridin-2-yl)cyclopropyl]amino}pyridine-3- carboxylate (48 mg, 0.157 mmol) was dissolved in THF:MeOH (1:1, 1 mL) and cooled in an ice- bath with stirring. Hydroxylamine (50% solution in water, 0.15 mL, 4.72 mmol)) was added dropwise followed by KOH (45 mg, 0.786 mmol). The ice-bath was removed and the reaction stirred until complete consumption of starting material. After completion, the reaction mixture was concentrated, diluted with water and neutralized (pH=7) with 2N HCl. The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO4, filtered and concentrated to afford the title compound as a white solid, 48 mg (99%). [00580] 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.21 - 8.27 (m, 1 H) 8.14 (s, 1 H) 7.58 (br d, J=12.96 Hz, 1 H) 7.34 - 7.44 (m, 1 H) 7.17 - 7.24 (m, 1 H) 1.69 - 1.75 (m, 2 H) 1.27 - 1.32 (m, 3 H) [00581] LC-MS: tR (min) 4.20 (20-100% ACN with 0.1 %TFA 6 min), m/z [M+H]+ C14H12F2N4O2 requires: 306.27; found 307.0 [00582] HPLC tR (min) 3.29, 98.3% (20-100% ACN with 0.1 %TFA 10 min.) [00583] In the following example compound I-37 was synthesized by following the same experimental procedure as described in Example 12 with the listed aldehyde starting material for step 1, and the listed organometallic reagent precursors for step 2.
Figure imgf000103_0001
Figure imgf000104_0001
[00584] Examples 43-61 [00585] In the following examples the compounds were synthesized by following the same experimental procedure as described in Example 7 with the listed amine and methyl 5-fluoro-6- bromonicotinate starting material for step 1.
Figure imgf000104_0002
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
[00586] Examples 62-74 [00587] In the following examples (62-74), the compounds were synthesized by following the same experimental procedure as described in Example 30 with the listed amine and 5-bromo- 2-(bromomethyl)-3-fluoropyridine as the starting materials for step 4.
Figure imgf000108_0002
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
[00588] Examples 75-80: Characterization of Compounds
Figure imgf000111_0002
Figure imgf000112_0001
[00589] Example 81 [00590] Biochemical Assay The compounds disclosed herein were tested for potency against HDAC6 and selectivity against HDAC1 in a biochemical assay. A biochemical assay was adopted using a luminescent HDAC-Glo I/II assay (Promega) and measured the relative activity of HDAC6 and HDAC1 recombinant proteins. Compounds were first incubated in the presence of HDAC6 or HDAC1 separately, followed by addition of the luminescent substrate. The data was acquired using a plate reader and the biochemical IC50 were calculated from the data accordingly. Data is tabulated in Table 2. From these studies, it was determined that the compounds of the present disclosure are selective inhibitors of HDAC6 over HDAC1, providing selectivity ratios from about 5 to about 30,0000. Table 2. Evaluation of HDAC6 Activity and Selectivity for Disclosed Compounds.
Figure imgf000112_0002
Figure imgf000112_0003
Figure imgf000113_0001
Figure imgf000113_0002
Figure imgf000114_0002
Figure imgf000114_0003
[00591] Embodiments 1. A compound of Formula (I), or pharmaceutically acceptable salt thereof:
Figure imgf000114_0001
wherein n is 0 or 1; X is O, NR4, or CR4R4'; Y is a bond, CR2R3 or S(O)2; R1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are each independently selected from the group consisting of H, alkyl, –CO2– alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)– heterocyclyl, –(CH2)–aryl, and –(CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, –C(O)NH(OH),–CH3, morpholine, and –C(O)N-cyclopropyl . 2. The compound of embodiment 1, wherein n is 1. 3. The compound of embodiment 1, wherein n is 0. 4. The compound of any one of embodiments 1-3, wherein X is NR4 or CR4R4'. 5. The compound of any one of embodiments 1-4, wherein Y is CR2R3. 6. The compound of any one of embodiments 1-4, wherein X is NR4 and Y is S(O)2. 7. The compound of any one of embodiments 1-6, wherein R1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. 8. The compound of any one of embodiments 1-7, wherein R1 is pyridinyl. 9. The compound of any one of embodiments 1-6, wherein R1 is phenyl. 10. The compound of any one of embodiments 1-5, wherein X is CR4R4', Y is a bond, and R1 is H. 11. The compound of any one of embodiments 1-6, wherein R1 and R2 taken together with the carbon atom to which they are attached form a C3-12 carbocyclyl. 12. The compound of any one of embodiments 1-10, wherein R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). 13. The compound of any one of embodiments 1-10, wherein R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. 14. The compound of any one of embodiments 1-10, wherein R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. 15. The compound of any one of embodiments 1-10, wherein R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. 16. The compound of any one of embodiments 1-10, wherein R2 is H and R3 is C3-6 cycloalkyl. 17. The compound of any one of embodiments 1-10, wherein R2 is H and R3 is cyclopropyl. 18. The compound of any one of embodiments 1-10, wherein R2 and R3 are C1-6 alkyl. 19. The compound of any one of embodiments 1-10, wherein R2 and R3 are methyl. 20. The compound of any one of embodiments 1-10, wherein R1 is C3-6 cycloalkyl or aryl, R2 is H, and R3 is C3-6 cycloalkyl or aryl. 21. The compound of any one of embodiments 1-20, wherein R4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)– heterocyclyl. 22. The compound of any one of embodiments 1-21, wherein R4 is H. 23. The compound of any one of embodiments 1-21, wherein R4 is –(CH2)–heterocyclyl. 24. The compound of any one of embodiments 1-21, wherein R4 is –(CH2)–oxetane. 25. The compound of any one of embodiments 1-21, wherein R4 is alkyl. 26. The compound of any one of embodiments 1-21, wherein R4 is methyl. 27. The compound of any one of embodiments 1-21, wherein R4 and R4' are each H. 28. The compound of any one of embodiments 1-21, wherein R4 and R4' are each alkyl. 29. The compound of any one of embodiments 1-21, wherein R4 and R4' are each methyl. 30. The compound of any one of embodiments 1-21, wherein R4 and R4' taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. 31. The compound of any one of embodiments 1-21, wherein R4 and R4' taken together with the carbon atom to which they are attached form a cyclopropyl. 32. The compound of embodiment 1, wherein the compound is a compound of Formula (Ia):
Figure imgf000117_0001
Z1, Z2, Z3, Z4 and Z5 are independently selected from N and CR5; wherein R5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 33. The compound of embodiment 32, wherein X is NR4 or CR4R4'. 34. The compound of embodiment 32 or 33, wherein X is NR4 and Y is CR2R3. 35. The compound of any one of embodiments 32-33, wherein X is NR4 and Y is S(O)2. 36. The compound of embodiment 32, wherein Z1, Z2, Z3, Z4 and Z5 are CR5. 37. The compound of embodiment 32, wherein Z1 is N and Z2, Z3, Z4 and Z5 are CR5. 38. The compound of embodiment 32, wherein Z2 is N and Z1, Z3, Z4 and Z5 are CR5. 39. The compound of embodiment 32, wherein Z3 is N and Z1, Z2, Z4 and Z5 are CR5. 40. The compound of any one of embodiments 32-39, wherein n is 1. 41. The compound of any one of embodiments 32-39, wherein n is 0. 42. The compound of any one of embodiments 32-41, wherein R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). 43. The compound of any one of embodiments 32-41, wherein R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. 44. The compound of any one of embodiments 32-41, wherein R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. 45. The compound of any one of embodiments 32-41, wherein R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. 46. The compound of any one of embodiments 32-41, wherein R2 is H and R3 is C3-6 cycloalkyl. 47. The compound of any one of embodiments 32-41, wherein R2 is H and R3 is cyclopropyl. 48. The compound of any one of embodiments 32-41, wherein R2 and R3 are C1-6 alkyl. 49. The compound of any one of embodiments 32-41, wherein R2 and R3 are methyl. 50. The compound of any one of embodiments 32-49, wherein R4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)– heterocyclyl. 51. The compound of any one of embodiments 32-50, wherein R4 is H. 52. The compound of any one of embodiments 32-50, wherein R4 is –(CH2)–heterocyclyl. 53. The compound of any one of embodiments 32-50, wherein R4 is –(CH2)–oxetane. 54. The compound of any one of embodiments 32-50, wherein R4 is alkyl. 55. The compound of any one of embodiments 32-50, wherein R4 is methyl. 56. The compound of any one of embodiments 32-55, wherein R5 is independently selected from H and halogen. 57. The compound of any one of embodiments 32-55, wherein R5 is independently selected from H and fluoro. 58. The compound of any one of embodiments 32-35 and 40-57, wherein the compound is a compound of Formula (Ib):
Figure imgf000119_0001
wherein R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 59. The compound of embodiment 58, wherein X is NR4 or CR4R4'. 60. The compound of embodiment 58 or 59, wherein X is NR4. 61. The compound of any one of embodiments 58-60, wherein Y is CR2R3. 62. The compound of any one of embodiments 58-60, wherein Y is S(O)2. 63. The compound of any one of embodiments 58-62, wherein R6, R7 R8, R9, and R10 are independently selected from the group consisting of H and halogen. 64. The compound of any one of embodiments 58-62, wherein R6 and R10 are halogen and R7 R8, and R9 are H. 65. The compound of any one of embodiments 58-62, wherein R6 and R10 are fluoro and R7 R8, and R9 are H. 66. The compound of any one of embodiments 32-35 and 40-57, wherein the compound of Formula (I) is a compound of Formula (Ic):
Figure imgf000120_0001
wherein R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 67. The compound of embodiment 66, wherein X is NR4 or CR4R4'. 68. The compound of embodiment 66 or 67, wherein X is NR4. 69. The compound of any one of embodiments 66-68, wherein Y is CR2R3. 70. The compound of any one of embodiments 66-68, wherein Y is S(O)2. 71. The compound of embodiment 1, wherein the compound is selected from the group consisting of:
Figure imgf000120_0002
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
or a pharmaceutically acceptable salt thereof. 72. The compound of embodiment 1, wherein n is 0 or 1; X is NR4 or CR4R4'; Y is CR2R3 or S(O)2; R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl, or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and –(CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. 73. The compound of embodiment 72, wherein n is 1. 74. The compound of embodiment 72, wherein n is 0. 75. The compound of any one of embodiments 72-74, wherein X is NR4. 76. The compound of any one of embodiments 72-75, wherein Y is CR4R'. 77. The compound of any one of embodiments 72-76, wherein R1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. 78. The compound of any one of embodiments 72-77, wherein R1 is pyridinyl. 79. The compound of any one of embodiments 72-76, wherein R1 is phenyl. 80. The compound of any one of embodiments 72-79, wherein R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). 81. The compound of any one of embodiments 72-79, wherein R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. 82. The compound of any one of embodiments 72-79wherein R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. 83. The compound of any one of embodiments 72-79, wherein R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. 84. The compound of any one of embodiments 72-80, wherein R2 is H and R3 is C3-6 cycloalkyl. 85. The compound of any one of embodiments 72-80, wherein R2 is H and R3 is cyclopropyl. 86. The compound of any one of embodiments 72-80, wherein R2 and R3 are C1-6 alkyl. 87. The compound of any one of embodiments 72-80, wherein R2 and R3 are methyl. 88. The compound of any one of embodiments 72-87, wherein R4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)– heterocyclyl. 89. The compound of any one of embodiments 72-88, wherein R4 is H. 90. The compound of any one of embodiments 72-88, wherein R4 is –(CH2)–heterocyclyl. 91. The compound of any one of embodiments 72-88, wherein R4 is –(CH2)–oxetane. 92. The compound of any one of embodiments 72-88, wherein R4 is alkyl. 93. The compound of any one of embodiments 72-88, wherein R4 is methyl. 94. The compound of embodiment 1, wherein the compound is a compound of Formula (IIa):
Figure imgf000127_0001
wherein Z1, Z2, Z3, Z4 and Z5 are independently selected from N and CR5; wherein R5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 95. The compound of embodiment 94, wherein Z1, Z2, Z3, Z4 and Z5 are CR5. 96. The compound of embodiment 94, wherein Z1 is N and Z2, Z3, Z4 and Z5 are CR5. 97. The compound of embodiment 94, wherein Z2 is N and Z1, Z3, Z4 and Z5 are CR5. 98. The compound of embodiment 94, wherein Z3 is N and Z1, Z2, Z4 and Z5 are CR5. 99. The compound of any one of embodiments 94-98, wherein n is 1. 100. The compound of any one of embodiments 94-98, wherein n is 0. 101. The compound of any one of embodiments 94-100, wherein R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). 102. The compound of any one of embodiments 94-100, wherein R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. 103. The compound of any one of embodiments 94-100, wherein R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. 104. The compound of any one of embodiments 94-100, wherein R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. 105. The compound of any one of embodiments 94-100, wherein R2 is H and R3 is C3-6 cycloalkyl. 106. The compound of any one of embodiments 94-100, wherein R2 is H and R3 is cyclopropyl. 107. The compound of any one of embodiments 94-100, wherein R2 and R3 are C1-6 alkyl. 108. The compound of any one of embodiments 94-100, wherein R2 and R3 are methyl. 109. The compound of any one of embodiments 94-108, wherein R4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)– heterocyclyl. 110. The compound of any one of embodiments 94-109, wherein R4 is H. 111. The compound of any one of embodiments 94-109, wherein R4 is –(CH2)–heterocyclyl. 112. The compound of any one of embodiments 94-109, wherein R4 is –(CH2)–oxetane. 113. The compound of any one of embodiments 94-109, wherein R4 is alkyl. 114. The compound of any one of embodiments 94-109, wherein R4 is methyl. 115. The compound of any one of embodiments 94-114, wherein R5 is independently selected from H and halogen. 116. The compound of any one of embodiments 94-114, wherein R5 is independently selected from H and fluoro. 117. The compound of any one of embodiments 94 and 99-114, wherein the compound is a compound of Formula (IIb):
Figure imgf000129_0001
(IIb); wherein R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 118. The compound of embodiment 117, wherein R6, R7 R8, R9, and R10 are independently selected from the group consisting of H and halogen. 119. The compound of embodiment 117, wherein R6 and R10 are halogen and R7 R8, R9, and R10 are H. 120. The compound of embodiment 117, wherein R6 and R10 are fluoro and R7 R8, and R9 are H. 121. The compound of any one of embodiments 94 and 99-114, wherein the compound is a compound of Formula (IIc):
Figure imgf000129_0002
; wherein R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 122. The compound of embodiment 72, wherein the compound is selected from the group consisting of:
Figure imgf000130_0001
Figure imgf000131_0001
a pharmaceutically acceptable salt thereof. 123. The compound of embodiment 1, which is a compound of Formula (III), or pharmaceutically acceptable salt thereof:
Figure imgf000131_0002
wherein n is 0 or 1; Y is a bond or CR2R3; R1 is selected from the group consisting of H, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 when present taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. 124. The compound of embodiment 123, wherein Y is a bond. 125. The compound of embodiment 123, wherein Y is CR2CR3. 126. The compound of any one of embodiments 123-125, wherein n is 1. 127. The compound of any one of embodiments 123-125, wherein n is 0. 128. The compound of any one of embodiments 123-127, wherein R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl. 129. The compound of any one of embodiments 123-128, wherein R1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine. 130. The compound of any one of embodiments 123-128, wherein R1 is pyridinyl. 131. The compound of any one of embodiments 123-128, wherein R1 is phenyl. 132. The compound of any one of embodiments 123-127, wherein Y is a bond, and R1 is H. 133. The compound of any one of embodiments 123-124 or 126-127, wherein R1 and R2 taken together with the carbon atom to which they are attached form a C3-12 carbocyclyl. 134. The compound of any one of embodiments 123-132, wherein R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)– C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl). 135. The compound of any one of embodiments 123-132, wherein R2 and R3 taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl. 136. The compound of any one of embodiments 123-132, wherein R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl. 137. The compound of any one of embodiments 123-132, wherein R2 and R3 taken together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclyl. 138. The compound of any one of embodiments 123-132, wherein R2 is H and R3 is C3-6 cycloalkyl. 139. The compound of any one of embodiments 123-132, wherein R2 is H and R3 is cyclopropyl. 140. The compound of any one of embodiments 123-132, wherein R2 and R3 are C1-6 alkyl. 141. The compound of any one of embodiments 123-132, wherein R2 and R3 are methyl. 142. The compound of embodiment 123, wherein the compound is selected from the group consisting of:
Figure imgf000133_0001
Figure imgf000134_0002
, and
Figure imgf000134_0003
; or a pharmaceutically acceptable salt thereof. 143. A compound of Formula (IV), or pharmaceutically acceptable salt thereof:
Figure imgf000134_0001
wherein: n is 0 or 1; p is 0, 1, 2, 3, or 4; q is each independently 0, 1, or 2; X is O, S(O)2, NR12, or CHR12; R11 is each independently H, F, alkyl, or oxo; or two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl, heteroaryl, or heterocyclyl ring; or two non-adjacent R11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring; R12 is selected from the group consisting of alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and –(CH2)– heteroaryl; or R11 and R12 taken together with the carbon and/or nitrogen atoms to which they are attached form an aryl, heteroaryl ring, or heterocyclyl ring; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. 144. The compound of embodiment 143, wherein n is 1. 145. The compound of embodiment 143, wherein n is 0. 146. The compound of any one of embodiments 143-145, wherein q is 1. 147. The compound of any one of embodiments 143-145, wherein q is 0. 148. The compound of any one of embodiments 143-146, wherein X is O. 149. The compound of any one of embodiments 143-146, wherein X is S(O)2. 150. The compound of any one of embodiments 143-146, wherein X is NR12. 151. The compound of any of embodiments 143-146, wherein X is CHR12. 152. The compound of embodiment 150 or 151, wherein R12 is H, Me, or Ph. 153. The compound of any one of embodiments 143-152, wherein p is 4. 154. The compound of any one of embodiments 143-152, wherein p is 3. 155. The compound of any one of embodiments 143-152, wherein p is 2. 156. The compound of any one of embodiments 143-152, wherein p is 1. 157. The compound of any one of embodiments 143-152, wherein p is 0. 158. The compound of any one of embodiments 143-156, R11 is oxo. 159. The compound of any one of embodiments 143-155, wherein two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl ring. 160. The compound of embodiment 159, wherein the aryl ring is a phenyl ring. 161. The compound of any one of embodiments 143-155, wherein two adjacent R11 taken together with the carbon atoms to which they are attached form a heteroaryl ring or a heterocyclyl ring. 162. The compound of embodiment 161, wherein the heteroaryl ring is a pyridinyl ring. 163. The compound of embodiment 161, wherein the heterocyclyl ring is:
Figure imgf000136_0001
. 164. The compound of any one of embodiments 143-147 or 153-156, wherein when X is CHR12, an R11 and an R12 taken together with the carbon atoms to which they are attached form an aryl ring. 165. The compound of embodiment 164, wherein the aryl ring is a phenyl ring. 166. The compound of any one of embodiments 143-147 or 153-156, wherein when X is NR12, an R11 and an R12 taken together with the carbon and nitrogen atoms to which they are attached form a heteroaryl ring or a heterocyclyl ring. 167 The compound of embodiment 166, wherein the heteroaryl ring is a pyridinyl ring. 168. The compound of any one of embodiments 143-152, wherein when p is 4, two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl ring and two adjacent R11 taken together with the carbon atoms to which they are attached form a heterocyclyl ring. 169. The compound of embodiments 168, wherein the aryl ring is a phenyl ring. 170. The compound of embodiments 168 or 169, wherein the heterocyclyl ring is
Figure imgf000136_0002
171. The compound of embodiment 143, wherein the compound of Formula (IV) is selected from the group consisting of:
Figure imgf000137_0001
Figure imgf000137_0002
, and
Figure imgf000137_0003
or a pharmaceutically acceptable salt thereof. 172. A composition comprising a compound of any one of embodiments 1-171 and a pharmaceutically acceptable excipient. 173. A method of improving sarcomere quality or preventing sarcomere damage in cardiomyocytes, comprising contacting a cardiomyocyte with an effective amount of the compound of any one of embodiments 1-171 or the composition of embodiment 172, wherein the method induces an improvement in sarcomere quality. 174. The method of embodiment 173, wherein the improvement in sarcomere quality is measured using an artificial intelligence algorithm. 175. The method of embodiment 174, wherein the algorithm is trained to build neuronal net models to segregate classes of cells based on cardiomyocytes with sarcomere damage against cardiomyocytes with limited sarcomere damage. 176. A method of increasing tubulin acetylation in cardiomyocytes with an effective amount of the compound of any one of embodiments 1-171 or the composition of embodiment 172, wherein the method increases levels of tubulin acetylation in cardiomyocytes. 177. The method of any one of embodiments 173-176, wherein the cardiomyocyte is an in vivo cardiomyocyte. 178. A method of treating heart disease in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of embodiments 1-171 or the composition of embodiment 172 to the subject. 179. The method of embodiment 178, wherein the heart disease is dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), left ventricular non-compaction (LVNC), arrhythmogenic right ventricular cardiomyopathy (ARVC), or arrhythmogenic right ventricular dysplasia (ARVD). 180. The method of embodiment 178, wherein the heart disease is myocardial infarction. 181. The method of any one of embodiments 178-180, wherein the method causes at least one of the following effects in cardiomyocytes: increased tubulin acetylation, increased contractility, reduced sarcomere damage, increase in autophagy.

Claims

What is claimed: 1. A compound of Formula (I), or pharmaceutically acceptable salt thereof:
Figure imgf000139_0001
wherein n is 0 or 1; X is O, NR4, or CR4R4'; Y is a bond, CR2R3 or S(O)2; R1 is selected from the group consisting of H, amido, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl; or R1 and R2 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are each independently selected from the group consisting of H, alkyl, –CO2– alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)– heterocyclyl, –(CH2)–aryl, and –(CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, –C(O)NH(OH), –CH3, morpholine, and –C(O)N-cyclopropyl .
2. The compound of claim 1, wherein n is 1.
3. The compound of claim 1, wherein n is 0.
4. The compound of any one of claims 1-3, wherein X is NR4 or CR4R4'.
5. The compound of any one of claims 1-4, wherein Y is CR2R3.
6. The compound of any one of claims 1-5, wherein R1 is a heteroaryl selected from the group consisting of pyrimidinyl, pyridinyl, pyridazine, and pyrazine.
7. The compound of any one of claims 1-5, wherein R1 is phenyl.
8. The compound of any one of claims 1-7, wherein R2 and R3 are independently selected from the group consisting of H, F, C1-6 alkyl, C3-6 cycloalkyl, –(CH2)–C3-6 cycloalkyl, 4- to 6- membered heterocyclyl, and –(CH2)–(4- to 6-membered heterocyclyl).
9. The compound of any one of claims 1-7, wherein R2 and R3 taken together with the carbon atom to which they are attached form a cyclopropyl.
10. The compound of any one of claims 1-9, wherein R4 is selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, –(CH2)–carbocyclyl, and –(CH2)–heterocyclyl.
11. The compound of any one of claims 1-10, wherein R4 and R4' are each H.
12. The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
, and
Figure imgf000145_0002
; or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1, wherein n is 0 or 1; X is NR4 or CR4R4'; Y is CR2R3 or S(O)2; R1 is selected from the group consisting of carbocyclyl, heterocyclyl, aryl, and heteroaryl; R2 and R3 are independently selected from the group consisting of H, halogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, – (CH2)–aryl, and –(CH2)–heteroaryl, or R2 and R3 taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and R4 and R4' are independently selected from the group consisting of H, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and –(CH2)–heteroaryl; or R4 and R4' taken together with the carbon atom to which they are attached form a carbocyclyl or heterocyclyl; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3.
14. The compound of any one of claims 13, wherein Y is CR4R'.
15. The compound of claim 1, wherein the compound is a compound of Formula (IIa):
Figure imgf000146_0001
wherein Z1, Z2, Z3, Z4 and Z5 are independently selected from N and CR5; wherein R5 is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 16 The compound of any one of claims 15, wherein the compound is a compound of Formula (IIb):
Figure imgf000146_0002
wherein R6, R7 R8, R9, and R10 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 17. The compound of claim 16, wherein R6, R7 R8, R9, and R10 are independently selected from the group consisting of H and halogen. 18. The compound of any one of claims 15, wherein the compound is a compound of Formula (IIc):
Figure imgf000147_0002
wherein R6, R7 R8, and R9 are independently selected from the group consisting of H, halogen, alkyl, haloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –CO2H, –CO2–alkyl, -O-alkyl, -O- haloalkyl, -O-aryl, -O-heteroaryl, –SO2–alkyl, and –CN. 19. The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure imgf000147_0003
Figure imgf000147_0004
, and
Figure imgf000147_0005
or a pharmaceutically acceptable salt thereof. 20. A compound of Formula (IV), or pharmaceutically acceptable salt thereof:
Figure imgf000147_0001
wherein: n is 0 or 1; p is 0, 1, 2, 3, or 4; q is each independently 0, 1, or 2; X is O, S(O)2, NR12, or CHR12; R11 is each independently H, F, alkyl, or oxo; or two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl, heteroaryl, or heterocyclyl ring; or two non-adjacent R11 taken together with the atoms to which they are attached form a carbocyclyl or heterocyclyl ring; R12 is selected from the group consisting of alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, –(CH2)–carbocyclyl, –(CH2)–heterocyclyl, –(CH2)–aryl, and –(CH2)– heteroaryl; or R11 and R12 taken together with the carbon and/or nitrogen atoms to which they are attached form an aryl, heteroaryl ring, or heterocyclyl ring; and wherein each alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, alkoxy, –OCH3, –CO2CH3, and –CH3. 21. The compound of any one of claims 20, wherein q is 1. 22. The compound of claim 20 or 21, wherein two adjacent R11 taken together with the carbon atoms to which they are attached form an aryl ring. 23. The compound of claim 20, wherein the compound of Formula (IV) is selected from the group consisting of:
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000149_0002
, and
Figure imgf000149_0003
or a pharmaceutically acceptable salt thereof. 24. A composition comprising a compound of any one of claims 1-23 and a pharmaceutically acceptable excipient. 25. A method of improving sarcomere quality or preventing sarcomere damage in cardiomyocytes, comprising contacting a cardiomyocyte with an effective amount of the compound of any one of claims 1-23 or the composition of claim 24, wherein the method induces an improvement in sarcomere quality. 26. A method of increasing tubulin acetylation in cardiomyocytes with an effective amount of the compound of any one of claims 1-23 or the composition of claim 24, wherein the method increases levels of tubulin acetylation in cardiomyocytes. 27. A method of treating heart disease in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of claims 1-23 or the composition of claim 24 to the subject.
PCT/US2020/054134 2019-10-03 2020-10-02 5-fluoronicotinamide derivatives and uses thereof WO2021067859A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA3156303A CA3156303A1 (en) 2019-10-03 2020-10-02 5-fluoronicotinamide derivatives and uses thereof
JP2022520444A JP2022550576A (en) 2019-10-03 2020-10-02 5-fluoronicotinamide derivatives and uses thereof
EP20870779.4A EP4037670A4 (en) 2019-10-03 2020-10-02 5-fluoronicotinamide derivatives and uses thereof
US17/712,780 US20230123856A1 (en) 2019-10-03 2022-04-04 5-fluoronicotinamide derivatives and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962910278P 2019-10-03 2019-10-03
US62/910,278 2019-10-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/712,780 Continuation US20230123856A1 (en) 2019-10-03 2022-04-04 5-fluoronicotinamide derivatives and uses thereof

Publications (1)

Publication Number Publication Date
WO2021067859A1 true WO2021067859A1 (en) 2021-04-08

Family

ID=75338595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/054134 WO2021067859A1 (en) 2019-10-03 2020-10-02 5-fluoronicotinamide derivatives and uses thereof

Country Status (5)

Country Link
US (1) US20230123856A1 (en)
EP (1) EP4037670A4 (en)
JP (1) JP2022550576A (en)
CA (1) CA3156303A1 (en)
WO (1) WO2021067859A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226388A1 (en) 2021-04-23 2022-10-27 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
WO2022222856A1 (en) * 2021-04-22 2022-10-27 勤浩医药（苏州）有限公司 Benzo-condensed ring compound, pharmaceutical composition comprising same, preparation method therefor and use thereof
WO2022235842A1 (en) 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
EP4306106A1 (en) 2022-07-14 2024-01-17 Universidade de Aveiro Nitro-containing compounds, compositions and uses thereof
US11926622B2 (en) 2019-12-20 2024-03-12 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298924A1 (en) * 2005-05-05 2009-12-03 Chroma Therapeutics Ltd Hydroxamic acid derivatives as inhibitors of hdac enzymatic activity
US20110288117A1 (en) * 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2015042418A1 (en) * 2013-09-20 2015-03-26 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
US20180127356A1 (en) * 2016-11-10 2018-05-10 Acetylon Pharmaceuticals, Inc. Phenyl and pyridinyl hydroxamic acids
WO2018154118A2 (en) * 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
WO2019076986A1 (en) * 2017-10-17 2019-04-25 Centre National De La Recherche Scientifique 6-substituted 3-fluoro-2-pyridinaldoxime, 3-fluoro-2-pyridine hydroxamic acid, and 3-fluoro-2-pyridinamidoxime scaffolds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014264370B2 (en) * 2013-05-10 2017-12-14 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
EP3272742B1 (en) * 2015-03-18 2019-11-27 Guangdong Zhongsheng Pharmaceutical Co., Ltd Histone deacetylase inhibitor, and preparation method and use thereof
MA53430A (en) * 2018-08-24 2021-06-30 Xeniopro GmbH NEW COMPOUNDS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298924A1 (en) * 2005-05-05 2009-12-03 Chroma Therapeutics Ltd Hydroxamic acid derivatives as inhibitors of hdac enzymatic activity
US20110288117A1 (en) * 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2015042418A1 (en) * 2013-09-20 2015-03-26 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
US20180127356A1 (en) * 2016-11-10 2018-05-10 Acetylon Pharmaceuticals, Inc. Phenyl and pyridinyl hydroxamic acids
WO2018154118A2 (en) * 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
WO2019076986A1 (en) * 2017-10-17 2019-04-25 Centre National De La Recherche Scientifique 6-substituted 3-fluoro-2-pyridinaldoxime, 3-fluoro-2-pyridine hydroxamic acid, and 3-fluoro-2-pyridinamidoxime scaffolds

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
US11926622B2 (en) 2019-12-20 2024-03-12 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2022222856A1 (en) * 2021-04-22 2022-10-27 勤浩医药（苏州）有限公司 Benzo-condensed ring compound, pharmaceutical composition comprising same, preparation method therefor and use thereof
WO2022226388A1 (en) 2021-04-23 2022-10-27 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
WO2022235842A1 (en) 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
EP4306106A1 (en) 2022-07-14 2024-01-17 Universidade de Aveiro Nitro-containing compounds, compositions and uses thereof

Also Published As

Publication number Publication date
CA3156303A1 (en) 2021-04-08
EP4037670A4 (en) 2023-09-27
JP2022550576A (en) 2022-12-02
US20230123856A1 (en) 2023-04-20
EP4037670A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
WO2021067859A1 (en) 5-fluoronicotinamide derivatives and uses thereof
TWI830713B (en) Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7280881B2 (en) Cyclohexylate triazole azoles as LPA antagonists
EP3728216B1 (en) Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
AU2005240178B2 (en) Certain chemical entities, compositions, and methods
KR20200100719A (en) Cyclohexyl acid triazole azine as an LPA antagonist
EP3728209A1 (en) Cyclohexyl acid isoxazole azines as lpa antagonists
WO2019126099A1 (en) Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
MXPA06014562A (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors.
EP3137169A1 (en) Inhibitors of lysine specific demethylase-1
WO2021127643A1 (en) Fluoroalkyl-oxadiazoles and uses thereof
CN112041302A (en) Pyrazole O-linked carbamoylcyclohexanoic acids as LPA antagonists
JP2011507894A (en) Prolyl hydroxylase inhibitor
TWI280239B (en) Process for preparation of pyridine derivatives
CN112041029A (en) Cyclohexaneacetic acid pyrazolazoles as LPA antagonists
AU2015268494A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
US12110299B2 (en) Thiazole derivatives and pharmaceutically acceptable salts thereof
WO1997034873A1 (en) Aminopyridine derivatives
WO2001083479A2 (en) Process for the preparation of pyrazolopyridine derivatives
WO2024116207A1 (en) Adar1 inhibitors and methods of using the same
KR20200100723A (en) Cyclohexyl acid pyrazole azine as an LPA antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20870779

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3156303

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022520444

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020870779

Country of ref document: EP

Effective date: 20220503